II 

Calendar No. 452 

109TH CONGRESS 

2D SESSION S. 2560 

To reauthorize the Office of National Drug Control Policy. 

IN THE SENATE OF THE UNITED STATES 

APRIL 6, 2006 

Mr. SPECTER (for himself, Mr. BIDEN, Mr. HATCH, Mr. GRASSLEY, and Mr. 

LEVIN) introduced the following bill; which was read twice and referred 

to the Committee on the Judiciary 

MAY 25, 2006 

Reported by Mr. SPECTER, with an amendment 

[Strike out all after the enacting clause and insert the part printed in italic] 

A BILL 

To reauthorize the Office of National Drug Control Policy. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE, REFERENCE, AND TABLE OF 

4 CONTENTS. 

5 (a) SHORT TITLE.—This Act may be cited as the 

6 ‘‘Office of National Drug Control Policy Reauthorization 

7 Act of 2006’’. 


ccoleman on PROD1PC71 with BILLS
2 

•S 2560 RS

1 (b) AMENDMENT OF OFFICE OF NATIONAL DRUG

2 CONTROL POLICY REAUTHORIZATION ACT OF 1998.—Ex3 cept as otherwise expressly provided, whenever in this Act 

4 an amendment or repeal is expressed in terms of an 

5 amendment to, or repeal of, a section or other provision, 

6 the reference shall be considered to be made to a section 

7 or other provision of the Office of National Drug Control 

8 Policy Reauthorization Act of 1998 (Public Law 105–277; 

9 21 U.S.C. 1701 et seq.). 

10 (c) TABLE OF CONTENTS.—The table of contents for 

11 this Act is as follows: 

Sec. 1. Short title, reference, and table of contents. 

TITLE I—ORGANIZATION OF OFFICE OF NATIONAL DRUG 

CONTROL POLICY AND ROLES AND RESPONSIBILITIES 

Sec. 101. Amendments to definitions. 

Sec. 102. Establishment of the Office of National Drug Control Policy. 

Sec. 103. Appointment and responsibilities of the Director. 

Sec. 104. Amendments to ensure coordination with other agencies. 

TITLE II—THE NATIONAL DRUG CONTROL STRATEGY 

Sec. 201. Annual preparation and submission of National Drug Control Strategy. 

Sec. 202. Performance measurements. 

Sec. 203. Annual report requirement. 

TITLE III—HIGH INTENSITY DRUG TRAFFICKING AREAS 

Sec. 301. High Intensity Drug Trafficking Areas Program. 

Sec. 302. Funding for certain high intensity drug trafficking areas. 

Sec. 303. Assessment. 

TITLE IV—TECHNOLOGY 

Sec. 401. Counterdrug Technology Assessment Center. 

TITLE V—REAUTHORIZATION AND IMPROVEMENT OF THE 

NATIONAL ANTI-DRUG MEDIA CAMPAIGN 

Sec. 501. Short title. 

Sec. 502. Purposes of the National Youth Anti-Drug Media Campaign. 

Sec. 503. Roles and responsibilities of the Director, the Partnership for a 

Drug-Free America, and a media buying contractor. 


ccoleman on PROD1PC71 with BILLS
3 

•S 2560 RS

Sec. 504. Responsible use of Federal funds for the National Youth Anti-Drug 

Media Campaign. 

Sec. 505. Authorization for National Youth Anti-Drug Media Campaign. 

TITLE VI—AUTHORIZATIONS AND EXTENSION OF TERMINATION 

DATE 

Sec. 601. Authorization of appropriations. 

Sec. 602. Extension of termination date. 

TITLE VII—ANTI-DOPING AGENCY 

Sec. 701. Designation of United States Anti-Doping Agency. 

Sec. 702. Records, audit, and report. 

Sec. 703. Authorization of appropriations. 

TITLE VIII—DRUG-FREE COMMUNITIES 

Sec. 801. Reauthorization. 

Sec. 802. Suspension of grants. 

Sec. 803. Grant award increase. 

Sec. 804. Prohibition on additional eligibility criteria. 

Sec. 805. Supplemental grants for coalitions. 

Sec. 806. National Community Antidrug Coalition Institute. 

Sec. 807. Contracting requirement. 

TITLE IX—NATIONAL GUARD COUNTERDRUG SCHOOLS 

Sec. 901. National Guard Counterdrug Schools. 

TITLE X—MISCELLANEOUS PROVISIONS 

Sec. 1001. Repeals. 

Sec. 1002. Controlled Substances Act amendments. 

Sec. 1003. Report on intelligence sharing. 

Sec. 1004. Requirement for South American heroin strategy. 

Sec. 1005. Model Acts. 

1 TITLE I—ORGANIZATION OF OF2 FICE OF NATIONAL DRUG 

3 CONTROL POLICY AND ROLES 

4 AND RESPONSIBILITIES 

5 SEC. 101. AMENDMENTS TO DEFINITIONS. 

6 (a) DEMAND REDUCTION.—Section 702(1) is amend7 ed— 

8 (1) in subparagraph (F), by striking ‘‘and’’ 

9 after the semicolon; and 


ccoleman on PROD1PC71 with BILLS
4 

•S 2560 RS

1 (2) in subparagraph (G), by striking the period 

2 and inserting ‘‘; and’’; and 

3 (3) by adding at the end the following: 

4 ‘‘(H) international drug abuse education, 

5 prevention, treatment, research, rehabilitation 

6 activities, and interventions for drug abuse and 

7 dependence.’’. 

8 (b) OFFICE.—Section 702(9) is amended by striking 

9 ‘‘implicates’’ and inserting ‘‘indicates’’. 

10 (c) STATE AND LOCAL AFFAIRS.—Paragraph (10) of 

11 section 702 is amended to read as follows: 

12 ‘‘(10) STATE AND LOCAL AFFAIRS.—The term 

13 ‘State and local affairs’ means domestic activities 

14 conducted by a National Drug Control Program 

15 agency that are intended to reduce the availability 

16 and use of illegal drugs, including— 

17 ‘‘(A) coordination and enhancement of 

18 Federal, State, and local law enforcement drug 

19 control efforts; 

20 ‘‘(B) coordination and enhancement of ef21 forts among National Drug Control Program 

22 agencies and State and local demand reduction 

23 and supply reduction agencies; 

24 ‘‘(C) coordination and enhancement of 

25 Federal, State, and local law enforcement initiaVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00004 Fmt 6652 Sfmt 6401 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
5 

•S 2560 RS

1 tives to gather, analyze, and disseminate infor2 mation and intelligence relating to drug control 

3 among domestic law enforcement agencies; and 

4 ‘‘(D) other coordinated and joint initiatives 

5 among Federal, State, and local agencies to 

6 promote comprehensive drug control strategies 

7 designed to reduce the demand for, and the 

8 availability of, illegal drugs.’’. 

9 (d) SUPPLY REDUCTION.—Section 702(11) is 

10 amended to read as follows: 

11 ‘‘(11) SUPPLY REDUCTION.—The term ‘supply 

12 reduction’ means any activity or program conducted 

13 by a National Drug Control Program agency that is 

14 intended to reduce the availability or use of illegal 

15 drugs in the United States or abroad, including— 

16 ‘‘(A) activities to control international traf17 ficking in, and availability of, illegal drugs, in18 cluding— 

19 ‘‘(i) accurate assessment and moni20 toring of international drug production and 

21 interdiction programs and policies; and 

22 ‘‘(ii) coordination and promotion of 

23 compliance with international treaties re24 lating to the production, transportation, or 

25 interdiction of illegal drugs; 


ccoleman on PROD1PC71 with BILLS
6 

•S 2560 RS

1 ‘‘(B) activities to conduct and promote 

2 international law enforcement programs and 

3 policies to reduce the supply of drugs; and 

4 ‘‘(C) activities to facilitate and enhance the 

5 sharing of domestic and foreign intelligence in6 formation among National Drug Control Pro7 gram agencies, relating to the production and 

8 trafficking of drugs in the United States and in 

9 foreign countries.’’. 

10 (e) DEFINITION OF APPROPRIATE CONGRESSIONAL

11 COMMITTEES.—Section 702 is amended by adding at the 

12 end the following: 

13 ‘‘(12) APPROPRIATE CONGRESSIONAL COMMIT14 TEES.—Except where otherwise provided, the term 

15 ‘appropriate congressional committees’ means the 

16 Committee on the Judiciary, the Committee on Ap17 propriations, and the Caucus on International Nar18 cotics Control of the Senate and the Committee on 

19 Government Reform, the Committee on the Judici20 ary, and the Committee on Appropriations of the 

21 House of Representatives.’’. 

22 SEC. 102. ESTABLISHMENT OF THE OFFICE OF NATIONAL 

23 DRUG CONTROL POLICY. 

24 (a) RESPONSIBILITIES.—Section 703(a) is amended 

25 to read as follows: 


ccoleman on PROD1PC71 with BILLS
7 

•S 2560 RS

1 ‘‘(a) ESTABLISHMENT OF OFFICE.—There is estab2 lished in the Executive Office of the President an Office 

3 of National Drug Control Policy, which shall— 

4 ‘‘(1) develop national drug control policy; 

5 ‘‘(2) coordinate and oversee the implementation 

6 of the national drug control policy; 

7 ‘‘(3) assess and certify the adequacy of Na8 tional Drug Control Programs and the budget for 

9 those programs; 

10 ‘‘(4) evaluate the effectiveness of National Drug 

11 Control Program agencies’ programs; and 

12 ‘‘(5) develop specific goals and performance 

13 measurements needed to assess the effectiveness 

14 of— 

15 ‘‘(A) the national drug control policy; and 

16 ‘‘(B) the programs of the National Drug 

17 Control Program agencies.’’. 

18 (b) POSITIONS.—Section 703(b) is amended to read 

19 as follows: 

20 ‘‘(b) DIRECTOR OF NATIONAL DRUG CONTROL POL21 ICY AND DEPUTY DIRECTORS.— 

22 ‘‘(1) DIRECTOR.—There shall be a Director of 

23 National Drug Control Policy who shall head the Of24 fice (referred to in this Act as the ‘Director’). 


ccoleman on PROD1PC71 with BILLS
8 

•S 2560 RS

1 ‘‘(2) DEPUTY DIRECTOR.—There shall be a 

2 Deputy Director of National Drug Control Policy 

3 who shall report directly to the Director (referred to 

4 in this Act as the ‘Deputy Director’). 

5 ‘‘(3) OTHER DEPUTY DIRECTORS.— 

6 ‘‘(A) IN GENERAL.—There shall be a Dep7 uty Director for Demand Reduction, a Deputy 

8 Director for Supply Reduction, and a Deputy 

9 Director for State and Local Affairs. 

10 ‘‘(B) REPORTING.—The Deputy Director 

11 for Demand Reduction, the Deputy Director for 

12 Supply Reduction, and the Deputy Director for 

13 State and Local Affairs shall report directly to 

14 the Deputy Director of the Office of National 

15 Drug Control Policy. 

16 ‘‘(C) DEPUTY DIRECTOR FOR DEMAND RE17 DUCTION.—The Deputy Director for Demand 

18 Reduction shall be responsible for the activi19 ties— 

20 ‘‘(i) in subparagraphs (A) through 

21 (H) of section 702(l); and 

22 ‘‘(ii) in section 709, the National 

23 Youth Anti-Drug Media Campaign Act. 

24 ‘‘(D) DEPUTY DIRECTOR FOR SUPPLY RE25 DUCTION.—The Deputy Director for Supply 


ccoleman on PROD1PC71 with BILLS
9 

•S 2560 RS

1 Reduction shall be responsible for the activities 

2 in subparagraphs (A) through (C) in section 

3 702(11). 

4 ‘‘(E) DEPUTY DIRECTOR FOR STATE AND

5 LOCAL AFFAIRS.—The Deputy Director for 

6 State and Local Affairs shall be responsible for 

7 the activities— 

8 ‘‘(i) in subparagraphs (A) through 

9 (D) of section 702(10); 

10 ‘‘(ii) in section 707, the High Inten11 sity Drug Trafficking Areas Program; and 

12 ‘‘(iii) in section 708, the Counterdrug 

13 Technology Assessment Center.’’. 

14 SEC. 103. APPOINTMENT AND RESPONSIBILITIES OF THE 

15 DIRECTOR. 

16 (a) SUCCESSION.—Section 704(a) is amended by 

17 amending paragraph (3) to read as follows: 

18 ‘‘(3) ACTING DIRECTOR.—If the Director dies, 

19 resigns, or is otherwise unable to perform the func20 tions and duties of the office, the Deputy Director 

21 shall perform the functions and duties of the Direc22 tor temporarily in an acting capacity pursuant to 

23 subchapter III of chapter 33 of title 5, United 

24 States Code.’’. 


ccoleman on PROD1PC71 with BILLS
10 

•S 2560 RS

1 (b) RESPONSIBILITIES.—Section 704(b) is amend2 ed— 

3 (1) in paragraph (4), by striking ‘‘Federal de4 partments and agencies engaged in drug enforce5 ment’’ and inserting ‘‘National Drug Control Pro6 gram agencies’’; 

7 (2) in paragraph (7), by inserting after ‘‘Presi8 dent’’ the following: ‘‘and the appropriate congres9 sional committees’’; 

10 (3) in paragraph (13), by striking ‘‘(beginning 

11 in 1999)’’; 

12 (4) by striking paragraph (14) and inserting 

13 the following: 

14 ‘‘(14) shall submit to the appropriate congres15 sional committees on an annual basis, not later than 

16 60 days after the date of the last day of the applica17 ble period, a summary of— 

18 ‘‘(A) each of the evaluations received by 

19 the Director under paragraph (13); and 

20 ‘‘(B) the progress of each National Drug 

21 Control Program agency toward the drug con22 trol program goals of the agency using the per23 formance measures for the agency developed 

24 under section 706(c);’’; 


ccoleman on PROD1PC71 with BILLS
11 

•S 2560 RS

1 (5) in paragraph (15), by striking subpara2 graph (C) and inserting the following: 

3 ‘‘(C) supporting the substance abuse infor4 mation clearinghouse administered by the Ad5 ministrator of the Substance Abuse and Mental 

6 Health Services Administration and established 

7 in section 501(d)(16) of the Public Health 

8 Service Act by— 

9 ‘‘(i) encouraging all National Drug 

10 Control Program agencies to provide all 

11 appropriate and relevant information; and 

12 ‘‘(ii) supporting the dissemination of 

13 information to all interested entities;’’; and 

14 (6) by inserting at the end the following: 

15 ‘‘(16) shall coordinate with the private sector to 

16 promote private research and development of medi17 cations to treat addiction; 

18 ‘‘(17) shall seek the support and commitment of 

19 State and local officials in the formulation and im20 plementation of the National Drug Control Strategy; 

21 ‘‘(18) shall monitor and evaluate the allocation 

22 of resources among Federal law enforcement agen23 cies in response to significant local and regional 

24 drug trafficking and production threats; and 


ccoleman on PROD1PC71 with BILLS
12 

•S 2560 RS

1 ‘‘(19) shall submit an annual report to Con2 gress detailing how the Office of National Drug 

3 Control Policy has consulted with and assisted State 

4 and local governments with respect to the formula5 tion and implementation of the National Drug Con6 trol Strategy and other relevant issues.’’. 

7 (c) REVIEW AND CERTIFICATION OF NATIONAL

8 DRUG CONTROL PROGRAM BUDGET.—Section 704(c)(3) 

9 is amended— 

10 (1) in subparagraph (C)(iii), by inserting ‘‘and 

11 the appropriate congressional committees,’’ after 

12 ‘‘House of Representatives’’; and 

13 (2) in subparagraph (D)(ii)(II)(bb), by insert14 ing ‘‘and the appropriate congressional committees,’’ 

15 after ‘‘House of Representatives’’. 

16 (d) POWERS OF DIRECTOR.—Section 704(d) is 

17 amended— 

18 (1) in paragraph (9)— 

19 (A) by inserting ‘‘notwithstanding any 

20 other provision of law,’’ after ‘‘(9)’’; and 

21 (B) by striking ‘‘Strategy; and’’ and insert22 ing ‘‘Strategy and notify the appropriate con23 gressional committees of any fund control no24 tice issued in accordance with section 

25 704(f)(5);’’; and 


ccoleman on PROD1PC71 with BILLS
13 

•S 2560 RS

1 (2) in paragraph (10), by inserting before the 

2 period the following: ‘‘and section 706 of the De3 partment of State Authorization Act for Fiscal Year 

4 2003 (22 U.S.C. 229j–1)’’. 

5 (e) FUND CONTROL NOTICES.—Section 704(f) is 

6 amended by adding at the end the following: 

7 ‘‘(4) CONGRESSIONAL NOTICE.—A copy of each 

8 fund control notice shall be transmitted to the ap9 propriate congressional committees. 

10 ‘‘(5) RESTRICTIONS.—The Director shall not 

11 issue a fund control notice to direct that all or part 

12 of an amount appropriated to the National Drug 

13 Control Program agency account be obligated, modi14 fied, or altered in any manner— 

15 ‘‘(A) contrary, in whole or in part, to a 

16 specific appropriation; or 

17 ‘‘(B) contrary, in whole or in part, to the 

18 expressed intent of Congress.’’. 

19 (f) UNITED STATES INTERDICTION COORDINATOR.— 

20 (1) IN GENERAL.—Section 704 is amended by 

21 adding at the end the following: 

22 ‘‘(i) UNITED STATES INTERDICTION COORDI23 NATOR.— 

24 ‘‘(1) IN GENERAL.—There shall be a United 

25 States Interdiction Coordinator, who shall be desVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00013 Fmt 6652 Sfmt 6401 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
14 

•S 2560 RS

1 ignated by the Director and who shall be responsible 

2 for the coordination of interdiction operations among 

3 National Drug Control Program agencies to prevent 

4 and reduce the illegal importation of drugs into the 

5 United States. 

6 ‘‘(2) RESPONSIBILITIES.—The United States 

7 Interdiction Coordinator shall be responsible to the 

8 Director for— 

9 ‘‘(A) coordinating the interdiction activities 

10 of the National Drug Control Program agencies 

11 to ensure consistency with the National Drug 

12 Control Strategy; 

13 ‘‘(B) developing a National Drug Control 

14 Interdiction plan to ensure consistency with the 

15 National Drug Control Strategy; 

16 ‘‘(C) assessing the sufficiency of assets of 

17 the National Drug Control Program agencies 

18 committed to illicit drug interdiction; and 

19 ‘‘(D) advising the Director on the efforts 

20 of each National Drug Control Program Agency 

21 to implement the National Drug Control Inter22 diction plan.’’. 

23 (2) AMENDMENT TO HOMELAND SECURITY ACT

24 OF 2002.—Section 878 of the Homeland Security Act 

25 of 2002 (6 U.S.C. 458) is amended by striking 


ccoleman on PROD1PC71 with BILLS
15 

•S 2560 RS

1 ‘‘shall—’’ through paragraph (2) and inserting 

2 ‘‘shall ensure the adequacy of resources within the 

3 Department for illicit drug interdiction.’’. 

4 SEC. 104. AMENDMENTS TO ENSURE COORDINATION WITH 

5 OTHER AGENCIES. 

6 Section 705 is amended— 

7 (1) in subsection (a)(1)(A), by striking 

8 ‘‘abuse’’; 

9 (2) by amending subsection (a)(3) to read as 

10 follows: 

11 ‘‘(3) REQUIRED REPORTS.— 

12 ‘‘(A) SECRETARIES OF THE INTERIOR AND

13 AGRICULTURE.—Not later than July 1 of each 

14 year, the Secretaries of Agriculture and the In15 terior shall jointly submit to the Director and 

16 the appropriate congressional committees an as17 sessment of the quantity of illegal drug cultiva18 tion and manufacturing in the United States on 

19 lands owned or under the jurisdiction of the 

20 Federal Government for the preceding year. 

21 ‘‘(B) SECRETARY OF HOMELAND SECU22 RITY.—Not later than July 1 of each year, the 

23 Secretary of Homeland Security shall submit to 

24 the Director and the appropriate congressional 


ccoleman on PROD1PC71 with BILLS
16 

•S 2560 RS

1 committees information for the preceding year 

2 regarding— 

3 ‘‘(i) the number and type of seizures 

4 of drugs by each component of the Depart5 ment of Homeland Security seizing drugs, 

6 as well as statistical information on the ge7 ographic areas of such seizures; and 

8 ‘‘(ii) the number of air and maritime 

9 patrol hours primarily dedicated to drug 

10 supply reduction missions undertaken by 

11 each component of the Department of 

12 Homeland Security. 

13 ‘‘(C) SECRETARY OF DEFENSE.—The Sec14 retary of Defense shall, by July 1 of each year, 

15 submit to the Director and the appropriate con16 gressional committees information for the pre17 ceding year regarding the number of air and 

18 maritime patrol hours primarily dedicated to 

19 drug supply reduction missions undertaken by 

20 each component of the Department of De21 fense.’’; and 

22 (3) in subsection (b)(2)(B), by striking ‘‘Pro23 gram’’ and inserting ‘‘Strategy’’. 


ccoleman on PROD1PC71 with BILLS
17 

•S 2560 RS

1 TITLE II—THE NATIONAL DRUG 

2 CONTROL STRATEGY 

3 SEC. 201. ANNUAL PREPARATION AND SUBMISSION OF NA4 TIONAL DRUG CONTROL STRATEGY. 

5 Section 706 is amended to read as follows: 

6 ‘‘SEC. 706. DEVELOPMENT, SUBMISSION, IMPLEMENTATION, 

7 AND ASSESSMENT OF NATIONAL DRUG CON8 TROL STRATEGY. 

9 ‘‘(a) TIMING, CONTENTS, AND PROCESS FOR DEVEL10 OPMENT AND SUBMISSION OF NATIONAL DRUG CONTROL

11 STRATEGY.— 

12 ‘‘(1) TIMING.—Not later than February 1 of 

13 each year, the President shall submit to Congress a 

14 National Drug Control Strategy, which shall set 

15 forth a comprehensive plan for the year to reduce 

16 drug abuse and the consequences of such drug abuse 

17 in the United States by limiting the availability of, 

18 and reducing the demand for, illegal drugs. 

19 ‘‘(2) CONTENTS.— 

20 ‘‘(A) IN GENERAL.—The National Drug 

21 Control Strategy submitted under paragraph 

22 (1) shall include— 

23 ‘‘(i) comprehensive, research-based, 

24 long-range, quantifiable goals for reducing 


ccoleman on PROD1PC71 with BILLS
18 

•S 2560 RS

1 drug abuse and the consequences of drug 

2 abuse in the United States; 

3 ‘‘(ii) annual quantifiable and measur4 able objectives and specific targets to ac5 complish long-term quantifiable goals that 

6 the Director determines may be achieved 

7 during each year beginning on the date on 

8 which the National Drug Control Strategy 

9 is submitted; 

10 ‘‘(iii) 5-year projections for program 

11 and budget priorities; 

12 ‘‘(iv) a review of international, State, 

13 local, and private sector drug control ac14 tivities to ensure that the United States 

15 pursues coordinated and effective drug 

16 control at all levels of government; 

17 ‘‘(v) an assessment of current illicit 

18 drug use (including inhalants) and avail19 ability, impact of illicit drug use, and 

20 treatment availability, which assessment 

21 shall include— 

22 ‘‘(I) estimates of drug prevalence 

23 and frequency of use as measured by 

24 national, State, and local surveys of il25 licit drug use and by other special 


ccoleman on PROD1PC71 with BILLS
19 

•S 2560 RS

1 studies of nondependent and depend2 ent illicit drug use; 

3 ‘‘(II) illicit drug use in the work4 place and the productivity lost by such 

5 use; and 

6 ‘‘(III) illicit drug use by 

7 arrestees, probationers, and parolees; 

8 ‘‘(vi) an assessment of the reduction 

9 of illicit drug availability, as measured 

10 by— 

11 ‘‘(I) the quantities of cocaine, 

12 heroin, marijuana, methamphetamine, 

13 ecstasy, and other drugs available for 

14 consumption in the United States; 

15 ‘‘(II) the amount of marijuana, 

16 cocaine, heroin, methamphetamine, ec17 stasy, and precursor chemicals and 

18 other drugs entering the United 

19 States; 

20 ‘‘(III) the number of illicit drug 

21 manufacturing laboratories seized and 

22 destroyed and the number of hectares 

23 of marijuana, poppy, and coca cul24 tivated and destroyed domestically 

25 and in other countries; 


ccoleman on PROD1PC71 with BILLS
20 

•S 2560 RS

1 ‘‘(IV) the number of metric tons 

2 of marijuana, heroin, cocaine, and 

3 methamphetamine seized and other 

4 drugs; and 

5 ‘‘(V) changes in the price and 

6 purity of heroin, methamphetamine, 

7 and cocaine, changes in the price of 

8 ecstasy, and changes in 

9 tetrahydrocannabinol level of mari10 juana and other drugs; 

11 ‘‘(vii) an assessment of the reduction 

12 of the consequences of illicit drug use and 

13 availability, which shall include— 

14 ‘‘(I) the burden illicit drug users 

15 placed on hospital emergency depart16 ments in the United States, such as 

17 the quantity of illicit drug-related 

18 services provided; 

19 ‘‘(II) the annual national health 

20 care cost of illicit drug use; and 

21 ‘‘(III) the extent of illicit drug22 related crime and criminal activity; 

23 ‘‘(viii) a determination of the status of 

24 drug treatment in the United States, by 

25 assessing— 


ccoleman on PROD1PC71 with BILLS
21 

•S 2560 RS

1 ‘‘(I) public and private treatment 

2 utilization; and 

3 ‘‘(II) the number of illicit drug 

4 users the Director estimates meet di5 agnostic criteria for treatment; 

6 ‘‘(ix) a review of the research agenda 

7 of the Counterdrug Technology Assessment 

8 Center to reduce the availability and abuse 

9 of drugs; and 

10 ‘‘(x) a summary of the efforts made to 

11 coordinate with private sector entities to 

12 conduct private research and development 

13 of medications to treat addiction by— 

14 ‘‘(I) screening chemicals for po15 tential therapeutic value; 

16 ‘‘(II) developing promising com17 pounds; 

18 ‘‘(III) conducting clinical trials; 

19 ‘‘(IV) seeking Food and Drug 

20 Administration approval for drugs to 

21 treat addiction; 

22 ‘‘(V) marketing the drug for the 

23 treatment of addiction; 


ccoleman on PROD1PC71 with BILLS
22 

•S 2560 RS

1 ‘‘(VI) urging physicians to use 

2 the drug in the treatment of addic3 tion; and 

4 ‘‘(VII) encouraging insurance 

5 companies to reimburse the cost of 

6 the drug for the treatment of addic7 tion. 

8 ‘‘(B) CLASSIFIED INFORMATION.—Any 

9 contents of the National Drug Control Strategy 

10 that involve information properly classified 

11 under criteria established by an Executive order 

12 shall be presented to Congress separately from 

13 the rest of the National Drug Control Strategy. 

14 ‘‘(3) PROCESS FOR DEVELOPMENT AND SUB15 MISSION.—In developing and effectively imple16 menting the National Drug Control Strategy, the 

17 Director— 

18 ‘‘(A) shall consult with— 

19 ‘‘(i) the heads of the National Drug 

20 Control Program agencies; 

21 ‘‘(ii) Congress; 

22 ‘‘(iii) State and local officials; 

23 ‘‘(iv) private citizens and organiza24 tions with experience and expertise in de25 mand reduction; 


ccoleman on PROD1PC71 with BILLS
23 

•S 2560 RS

1 ‘‘(v) private citizens and organizations 

2 with experience and expertise in supply re3 duction; and 

4 ‘‘(vi) appropriate representatives of 

5 foreign governments; 

6 ‘‘(B) in satisfying the requirements of sub7 paragraph (A), shall ensure, to the maximum 

8 extent possible, that State and local officials 

9 and relevant private organizations commit to 

10 support and take steps to achieve the goals and 

11 objectives of the National Drug Control Strat12 egy; 

13 ‘‘(C) with the concurrence of the Attorney 

14 General, may require the El Paso Intelligence 

15 Center to undertake specific tasks or projects to 

16 support or implement the National Drug Con17 trol Strategy; and 

18 ‘‘(D) with the concurrence of the Director 

19 of National Intelligence and the Attorney Gen20 eral, may request that the National Drug Intel21 ligence Center undertake specific tasks or 

22 projects to support or implement the National 

23 Drug Control Strategy. 

24 ‘‘(b) SUBMISSION OF REVISED STRATEGY.—The 

25 President may submit to Congress a revised National 


ccoleman on PROD1PC71 with BILLS
24 

•S 2560 RS

1 Drug Control Strategy that meets the requirements of this 

2 section— 

3 ‘‘(1) at any time, upon a determination of the 

4 President, in consultation with the Director, that the 

5 National Drug Control Strategy in effect is not suf6 ficiently effective; or 

7 ‘‘(2) if a new President or Director takes of8 fice.’’. 

9 SEC. 202. PERFORMANCE MEASUREMENTS. 

10 Section 706 is amended by adding at the end the fol11 lowing: 

12 ‘‘(c) PERFORMANCE MEASUREMENT SYSTEM.—Not 

13 later than February 1 of each year, the Director shall sub14 mit to Congress as part of the National Drug Control 

15 Strategy, a description of a national drug control perform16 ance measurement system, that— 

17 ‘‘(1) develops 2-year and 5-year performance 

18 measures and targets for each National Drug Con19 trol Strategy goal and objective established for re20 ducing drug use, availability, and the consequences 

21 of drug use; 

22 ‘‘(2) describes the sources of information and 

23 data that will be used for each performance measure 

24 incorporated into the performance measurement sys25 tem; 


ccoleman on PROD1PC71 with BILLS
25 

•S 2560 RS

1 ‘‘(3) identifies major programs and activities of 

2 the National Drug Control Program agencies that 

3 support the goals and annual objectives of the Na4 tional Drug Control Strategy; 

5 ‘‘(4) evaluates the contribution of demand re6 duction and supply reduction activities as defined in 

7 section 702 implemented by each National Drug 

8 Control Program agency in support of the National 

9 Drug Control Strategy; 

10 ‘‘(5) monitors consistency between the drug-re11 lated goals and objectives of the National Drug Con12 trol Program agencies and ensures that each agen13 cy’s goals and budgets support and are fully con14 sistent with the National Drug Control Strategy; 

15 and 

16 ‘‘(6) coordinates the development and imple17 mentation of national drug control data collection 

18 and reporting systems to support policy formulation 

19 and performance measurement, including an assess20 ment of— 

21 ‘‘(A) the quality of current drug use meas22 urement instruments and techniques to measure 

23 supply reduction and demand reduction activi24 ties; 


ccoleman on PROD1PC71 with BILLS
26 

•S 2560 RS

1 ‘‘(B) the adequacy of the coverage of exist2 ing national drug use measurement instruments 

3 and techniques to measure the casual drug use 

4 population, the addicted drug user population, 

5 and groups that are at risk for drug use; 

6 ‘‘(C) the adequacy of the coverage of exist7 ing national treatment outcome monitoring sys8 tems to measure the effectiveness of drug abuse 

9 treatment in reducing drug use and criminal 

10 behavior during and after the completion of 

11 substance abuse treatment; and 

12 ‘‘(D) the actions the Director shall take to 

13 correct any deficiencies and limitations identi14 fied pursuant to subparagraphs (A) and (B) of 

15 this subsection. 

16 ‘‘(d) MODIFICATIONS.—A description of any modi17 fications made during the preceding year to the national 

18 drug performance measurement system described in sub19 section (c) shall be included in each report submitted 

20 under subsection (b).’’. 

21 SEC. 203. ANNUAL REPORT REQUIREMENT. 

22 (a) IN GENERAL.—On or before February 1 of each 

23 year, the Director shall submit a report to Congress that 

24 describes— 


ccoleman on PROD1PC71 with BILLS
27 

•S 2560 RS

1 (1) the strategy of the national media campaign 

2 and whether specific objectives of the campaign were 

3 accomplished; 

4 (2) steps taken to ensure that the national 

5 media campaign operates in an effective and effi6 cient manner consistent with the overall strategy 

7 and focus of the campaign; 

8 (3) plans to purchase advertising time and 

9 space; 

10 (4) policies and practices implemented to ensure 

11 that Federal funds are used responsibly to purchase 

12 advertising time and space and eliminate the poten13 tial for waste, fraud, and abuse; 

14 (5) all contracts entered into with a corpora15 tion, partnership, or individual working on behalf of 

16 the national media campaign; 

17 (6) specific policies and steps implemented to 

18 ensure compliance with title IV of this Act; 

19 (7) steps taken to ensure that the national 

20 media campaign will secure, to the maximum extent 

21 possible, no cost matches of advertising time and 

22 space or in-kind contributions that are directly re23 lated to the campaign in accordance with title IV of 

24 this Act; and 


ccoleman on PROD1PC71 with BILLS
28 

•S 2560 RS

1 (8) a review and evaluation of the effectiveness 

2 of the national media campaign strategy for the past 

3 year. 

4 (b) AUDIT.—The Government Accountability Office 

5 shall, at a frequency of not less than once per year— 

6 (1) conduct and supervise an audit and inves7 tigation relating to the programs and operations of 

8 the— 

9 (A) Office; or 

10 (B) certain programs within the Office, in11 cluding— 

12 (i) the High Intensity Drug Traf13 ficking Areas Program; 

14 (ii) the Counterdrug Technology As15 sessment Center; or 

16 (iii) the National Youth Anti-drug 

17 Media Campaign; and 

18 (2) provide the Director and the appropriate 

19 congressional committees with a report containing 

20 an evaluation of and recommendations on the— 

21 (A) policies and activities of the programs 

22 and operations subject to the audit and inves23 tigation; 


ccoleman on PROD1PC71 with BILLS
29 

•S 2560 RS

1 (B) economy, efficiency, and effectiveness 

2 in the administration of the reviewed programs 

3 and operations; and 

4 (C) policy or management changes needed 

5 to prevent and detect fraud and abuse in such 

6 programs and operations. 

7 TITLE III—HIGH INTENSITY 

8 DRUG TRAFFICKING AREAS 

9 SEC. 301. HIGH INTENSITY DRUG TRAFFICKING AREAS 

10 PROGRAM. 

11 Section 707 is amended to read as follows: 

12 ‘‘SEC. 707. HIGH INTENSITY DRUG TRAFFICKING AREAS 

13 PROGRAM. 

14 ‘‘(a) ESTABLISHMENT.— 

15 ‘‘(1) IN GENERAL.—There is established in the 

16 Office a program to be known as the High Intensity 

17 Drug Trafficking Areas Program (in this section re18 ferred to as the ‘Program’). 

19 ‘‘(2) PURPOSE.—The purpose of the Program 

20 is to reduce drug trafficking and drug production in 

21 the United States by— 

22 ‘‘(A) facilitating cooperation among Fed23 eral, State, and local law enforcement agencies 

24 to share information and implement coordinated 

25 enforcement activities; 


ccoleman on PROD1PC71 with BILLS
30 

•S 2560 RS

1 ‘‘(B) enhancing intelligence sharing among 

2 Federal, State, and local law enforcement agen3 cies; 

4 ‘‘(C) providing reliable intelligence to law 

5 enforcement agencies needed to design effective 

6 enforcement strategies and operations; and 

7 ‘‘(D) supporting coordinated law enforce8 ment strategies which maximize use of available 

9 resources to reduce the supply of illegal drugs 

10 in designated areas and in the United States as 

11 a whole. 

12 ‘‘(b) DESIGNATION.— 

13 ‘‘(1) IN GENERAL.—The Director, in consulta14 tion with the Attorney General, the Secretary of the 

15 Treasury, the Secretary of Homeland Security, 

16 heads of the National Drug Control Program agen17 cies, and the Governor of each applicable State, may 

18 designate any specified area of the United States as 

19 a high intensity drug trafficking area. 

20 ‘‘(2) ACTIVITIES.—After making a designation 

21 under paragraph (1) and in order to provide Federal 

22 assistance to the area so designated, the Director 

23 may— 

24 ‘‘(A) obligate such sums as are appro25 priated for the Program; 


ccoleman on PROD1PC71 with BILLS
31 

•S 2560 RS

1 ‘‘(B) direct the temporary reassignment of 

2 Federal personnel to such area, subject to the 

3 approval of the head of the department or agen4 cy that employs such personnel; 

5 ‘‘(C) take any other action authorized 

6 under section 704 to provide increased Federal 

7 assistance to those areas; and 

8 ‘‘(D) coordinate activities under this sec9 tion (specifically administrative, recordkeeping, 

10 and funds management activities) with State 

11 and local officials. 

12 ‘‘(c) PETITIONS FOR DESIGNATION.—The Director 

13 shall establish regulations under which a coalition of inter14 ested law enforcement agencies from an area may petition 

15 for designation as a high intensity drug trafficking area. 

16 Such regulations shall provide for a regular review by the 

17 Director of the petition, including a recommendation re18 garding the merit of the petition to the Director by a panel 

19 of qualified, independent experts. 

20 ‘‘(d) FACTORS FOR CONSIDERATION.—In considering 

21 whether to designate an area under this section as a high 

22 intensity drug trafficking area, the Director shall consider, 

23 in addition to such other criteria as the Director considers 

24 to be appropriate, the extent to which— 


ccoleman on PROD1PC71 with BILLS
32 

•S 2560 RS

1 ‘‘(1) the area is a significant center of illegal 

2 drug production, manufacturing, importation, or dis3 tribution; 

4 ‘‘(2) State and local law enforcement agencies 

5 have committed resources to respond to the drug 

6 trafficking problem in the area, thereby indicating a 

7 determination to respond aggressively to the prob8 lem; 

9 ‘‘(3) drug-related activities in the area are hav10 ing a significant harmful impact in the area, and in 

11 other areas of the country; and 

12 ‘‘(4) a significant increase in allocation of Fed13 eral resources is necessary to respond adequately to 

14 drug-related activities in the area. 

15 ‘‘(e) ORGANIZATION OF HIGH INTENSITY DRUG

16 TRAFFICKING AREAS.— 

17 ‘‘(1) EXECUTIVE BOARD AND OFFICERS.—To 

18 be eligible for funds appropriated under this section, 

19 each high intensity drug trafficking area shall be 

20 governed by an Executive Board. The Executive 

21 Board shall designate a chairman, vice chairman, 

22 and any other officers to the Executive Board that 

23 it determines are necessary. 


ccoleman on PROD1PC71 with BILLS
33 

•S 2560 RS

1 ‘‘(2) RESPONSIBILITIES.—The Executive Board 

2 of a high intensity drug trafficking area shall be re3 sponsible for— 

4 ‘‘(A) providing direction and oversight in 

5 establishing and achieving the goals of the high 

6 intensity drug trafficking area; 

7 ‘‘(B) managing the funds of the high in8 tensity drug trafficking area; 

9 ‘‘(C) reviewing and approving all funding 

10 proposals consistent with the overall objective of 

11 the high intensity drug trafficking area; and 

12 ‘‘(D) reviewing and approving all reports 

13 to the Director on the activities of the high in14 tensity drug trafficking area. 

15 ‘‘(3) BOARD REPRESENTATION.—None of the 

16 funds appropriated under this section may be ex17 pended for any high intensity drug trafficking area, 

18 or for a partnership or region of a high intensity 

19 drug trafficking area, if the Executive Board for 

20 such area, region, or partnership, does not apportion 

21 an equal number of votes between representatives of 

22 participating Federal agencies and representatives of 

23 participating State and local agencies. Where it is 

24 impractical for an equal number of representatives 

25 of Federal agencies and State and local agencies to 


ccoleman on PROD1PC71 with BILLS
34 

•S 2560 RS

1 attend a meeting of an Executive Board in person, 

2 the Executive Board may use a system of proxy 

3 votes or weighted votes to achieve the voting balance 

4 required by this paragraph. 

5 ‘‘(4) NO AGENCY RELATIONSHIP.—The eligi6 bility requirements of this section are intended to 

7 ensure the responsible use of Federal funds. Nothing 

8 in this section is intended to create an agency rela9 tionship between individual high intensity drug traf10 ficking areas and the Federal Government. 

11 ‘‘(f) USE OF FUNDS.—The Director shall ensure that 

12 no Federal funds appropriated for the Program are ex13 pended for the establishment or expansion of drug treat14 ment programs, and shall ensure that not more than 5 

15 percent of the Federal funds appropriated for the Pro16 gram are expended for the establishment of drug preven17 tion programs. 

18 ‘‘(g) COUNTERTERRORISM ACTIVITIES.— 

19 ‘‘(1) ASSISTANCE AUTHORIZED.—The Director 

20 may authorize use of resources available for the Pro21 gram to assist Federal, State, and local law enforce22 ment agencies in investigations and activities related 

23 to terrorism and prevention of terrorism, especially 

24 but not exclusively with respect to such investigaVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00034 Fmt 6652 Sfmt 6401 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
35 

•S 2560 RS

1 tions and activities that are also related to drug 

2 trafficking. 

3 ‘‘(2) LIMITATION.—The Director shall ensure— 

4 ‘‘(A) that assistance provided under para5 graph (1) remains incidental to the purpose of 

6 the Program to reduce drug availability and 

7 carry out drug-related law enforcement activi8 ties; and 

9 ‘‘(B) that significant resources of the Pro10 gram are not redirected to activities exclusively 

11 related to terrorism, except on a temporary 

12 basis under extraordinary circumstances, as de13 termined by the Director. 

14 ‘‘(h) ROLE OF DRUG ENFORCEMENT ADMINISTRA15 TION.—The Director, in consultation with the Attorney 

16 General, shall ensure that a representative of the Drug 

17 Enforcement Administration is included in the Intelligence 

18 Support Center for each high intensity drug trafficking 

19 area. 

20 ‘‘(i) ANNUAL HIDTA PROGRAM BUDGET SUBMIS21 SIONS.—As part of the documentation that supports the 

22 President’s annual budget request for the Office, the Di23 rector shall submit to Congress a budget justification that 

24 includes— 


ccoleman on PROD1PC71 with BILLS
36 

•S 2560 RS

1 ‘‘(1) the amount requested for each high inten2 sity drug trafficking area, with supporting narrative 

3 descriptions and rationale for each request; and 

4 ‘‘(2) a detailed justification for each funding re5 quest that explains— 

6 ‘‘(A) the reasons for the requested funding 

7 level; how such funding level was determined 

8 based on a current assessment of the drug traf9 ficking threat in each high intensity drug traf10 ficking area; 

11 ‘‘(B) how such funding will ensure that the 

12 goals and objectives of each such area will be 

13 achieved; and 

14 ‘‘(C) how such funding supports the Na15 tional Drug Control Strategy. 

16 ‘‘(j) EMERGING THREAT RESPONSE FUND.— 

17 ‘‘(1) IN GENERAL.—Subject to the availability 

18 of appropriations, the Director may expend up to 10 

19 percent of the amounts appropriated under this sec20 tion on a discretionary basis, to respond to any 

21 emerging drug trafficking threat in an existing high 

22 intensity drug trafficking area, or to establish a new 

23 high intensity drug trafficking area or expand an ex24 isting high intensity drug trafficking area, in accordVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00036 Fmt 6652 Sfmt 6401 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
37 

•S 2560 RS

1 ance with the criteria established under paragraph 

2 (2). 

3 ‘‘(2) CONSIDERATION OF IMPACT.—In allo4 cating funds under this subsection, the Director 

5 shall consider— 

6 ‘‘(A) the impact of activities funded on re7 ducing overall drug traffic in the United States, 

8 or minimizing the probability that an emerging 

9 drug trafficking threat will spread to other 

10 areas of the United States; and 

11 ‘‘(B) such other criteria as the Director 

12 considers appropriate. 

13 ‘‘(k) EVALUATION.— 

14 ‘‘(1) INITIAL REPORT.—Not later than 90 days 

15 after the date of the enactment of this section, the 

16 Director shall, after consulting with the Executive 

17 Boards of each designated high intensity drug traf18 ficking area, submit a report to Congress that de19 scribes, for each designated high intensity drug traf20 ficking area— 

21 ‘‘(A) the specific purposes for the high in22 tensity drug trafficking area; 

23 ‘‘(B) the specific long-term and short-term 

24 goals and objectives for the high intensity drug 

25 trafficking area; 


ccoleman on PROD1PC71 with BILLS
38 

•S 2560 RS

1 ‘‘(C) the measurements that will be used to 

2 evaluate the performance of the high intensity 

3 drug trafficking area in achieving the long-term 

4 and short-term goals; and 

5 ‘‘(D) the reporting requirements needed to 

6 evaluate the performance of the high intensity 

7 drug trafficking area in achieving the long-term 

8 and short-term goals. 

9 ‘‘(2) EVALUATION OF HIDTA PROGRAM AS PART

10 OF NATIONAL DRUG CONTROL STRATEGY.—For each 

11 designated high intensity drug trafficking area, the 

12 Director shall submit, as part of the annual National 

13 Drug Control Strategy report, a report that— 

14 ‘‘(A) describes— 

15 ‘‘(i) the specific purposes for the high 

16 intensity drug trafficking area; and 

17 ‘‘(ii) the specific long-term and short18 term goals and objectives for the high in19 tensity drug trafficking area; and 

20 ‘‘(B) includes an evaluation of the per21 formance of the high intensity drug trafficking 

22 area in accomplishing the specific long-term 

23 and short-term goals and objectives identified 

24 under paragraph (1)(B). 


ccoleman on PROD1PC71 with BILLS
39 

•S 2560 RS

1 ‘‘(l) ASSESSMENT OF DRUG ENFORCEMENT TASK

2 FORCES IN HIGH INTENSITY DRUG TRAFFICKING

3 AREAS.—Not later than 180 days after the date of enact4 ment of this subsection, and as part of each subsequent 

5 annual National Drug Control Strategy report, the Direc6 tor shall submit to Congress a report— 

7 ‘‘(1) assessing the number and operation of all 

8 federally funded drug enforcement task forces within 

9 each high intensity drug trafficking area; and 

10 ‘‘(2) describing— 

11 ‘‘(A) each Federal, State, and local drug 

12 enforcement task force operating in the high in13 tensity drug trafficking area; 

14 ‘‘(B) how such task forces coordinate with 

15 each other, with any high intensity drug traf16 ficking area task force, and with investigations 

17 receiving funds from the Organized Crime and 

18 Drug Enforcement Task Force; 

19 ‘‘(C) what steps, if any, each such task 

20 force takes to share information regarding drug 

21 trafficking and drug production with other fed22 erally funded drug enforcement task forces in 

23 the high intensity drug trafficking area; 


ccoleman on PROD1PC71 with BILLS
40 

•S 2560 RS

1 ‘‘(D) the role of the high intensity drug 

2 trafficking area in coordinating the sharing of 

3 such information among task forces; 

4 ‘‘(E) the nature and extent of cooperation 

5 by each Federal, State, and local participant in 

6 ensuring that such information is shared among 

7 law enforcement agencies and with the high in8 tensity drug trafficking area; 

9 ‘‘(F) the nature and extent to which infor10 mation sharing and enforcement activities are 

11 coordinated with joint terrorism task forces in 

12 the high intensity drug trafficking area; and 

13 ‘‘(G) any recommendations for measures 

14 needed to ensure that task force resources are 

15 utilized efficiently and effectively to reduce the 

16 availability of illegal drugs in the high intensity 

17 drug trafficking areas. 

18 ‘‘(m) ASSESSMENT OF INTELLIGENCE SHARING IN

19 HIGH INTENSITY DRUG TRAFFICKING AREAS PRO20 GRAM.—Not later than 180 days after the date of the en21 actment of this section, and as part of each subsequent 

22 annual National Drug Control Strategy report, the Direc23 tor, in consultation with the Director of National Intel24 ligence, shall submit to Congress a report— 


ccoleman on PROD1PC71 with BILLS
41 

•S 2560 RS

1 ‘‘(1) evaluating existing and planned intel2 ligence systems supported by each high intensity 

3 drug trafficking area, or utilized by task forces re4 ceiving any funding under the Program, including 

5 the extent to which such systems ensure access and 

6 availability of intelligence to Federal, State, and 

7 local law enforcement agencies within the high inten8 sity drug trafficking area and outside of it; 

9 ‘‘(2) the extent to which Federal, State, and 

10 local law enforcement agencies participating in each 

11 high intensity drug trafficking area are sharing in12 telligence information to assess current drug traf13 ficking threats and design appropriate enforcement 

14 strategies; and 

15 ‘‘(3) the measures needed to improve effective 

16 sharing of information and intelligence regarding 

17 drug trafficking and drug production among Fed18 eral, State, and local law enforcement participating 

19 in a high intensity drug trafficking area, and be20 tween such agencies and similar agencies outside the 

21 high intensity drug trafficking area. 

22 ‘‘(n) COORDINATION OF INTELLIGENCE SHARING

23 WITH ORGANIZED CRIME DRUG ENFORCEMENT TASK

24 FORCE PROGRAM.—The Director, in consultation with the 

25 Attorney General, shall ensure that any drug enforcement 


ccoleman on PROD1PC71 with BILLS
42 

•S 2560 RS

1 intelligence obtained by the Intelligence Support Center 

2 for each high intensity drug trafficking area is shared, on 

3 a timely basis, with the drug intelligence fusion center op4 erated by the Organized Crime Drug Enforcement Task 

5 Force of the Department of Justice. 

6 ‘‘(o) USE OF FUNDS TO COMBAT METHAMPHET7 AMINE TRAFFICKING.— 

8 ‘‘(1) IN GENERAL.— 

9 ‘‘(A) REQUIREMENT.—The Director shall 

10 ensure that, of the amounts appropriated for a 

11 fiscal year for the Program, at least 

12 $15,000,000 is allocated to combat the traf13 ficking of methamphetamine in areas des14 ignated by the Director as high intensity drug 

15 trafficking areas. 

16 ‘‘(B) ACTIVITIES.—In meeting the require17 ment in subparagraph (A), the Director shall 

18 transfer funds to appropriate Federal, State, 

19 and local governmental agencies for employing 

20 additional Federal law enforcement personnel, 

21 or facilitating the employment of additional 

22 State and local law enforcement personnel, in23 cluding agents, investigators, prosecutors, lab24 oratory technicians, chemists, investigative as25 sistants, and drug prevention specialists. 


ccoleman on PROD1PC71 with BILLS
43 

•S 2560 RS

1 ‘‘(2) APPORTIONMENT OF FUNDS.— 

2 ‘‘(A) FACTORS IN APPORTIONMENT.—The 

3 Director shall apportion amounts allocated 

4 under paragraph (1) among areas designated by 

5 the Director as high intensity drug trafficking 

6 areas based on the following factors: 

7 ‘‘(i) The number of methamphetamine 

8 manufacturing facilities discovered by Fed9 eral, State, or local law enforcement offi10 cials in the area during the previous fiscal 

11 year. 

12 ‘‘(ii) The number of methamphet13 amine prosecutions in Federal, State, or 

14 local courts in the area during the previous 

15 fiscal year. 

16 ‘‘(iii) The number of methamphet17 amine arrests by Federal, State, or local 

18 law enforcement officials in the area dur19 ing the previous fiscal year. 

20 ‘‘(iv) The amounts of methamphet21 amine or listed chemicals (as that term is 

22 defined in section 102(33) of the Con23 trolled Substances Act (21 U.S.C. 

24 802(33)) seized by Federal, State, or local 


ccoleman on PROD1PC71 with BILLS
44 

•S 2560 RS

1 law enforcement officials in the area dur2 ing the previous fiscal year. 

3 ‘‘(v) Intelligence and predictive data 

4 from the Drug Enforcement Administra5 tion showing patterns and trends in abuse, 

6 trafficking, and transportation in meth7 amphetamine and listed chemicals (as that 

8 term is so defined). 

9 ‘‘(B) CERTIFICATION.—Before the Direc10 tor apportions any funds under this paragraph 

11 to a high intensity drug trafficking area, the 

12 Director shall certify that the law enforcement 

13 entities responsible for clandestine methamphet14 amine laboratory seizures in that area are pro15 viding laboratory seizure data to the national 

16 clandestine laboratory database at the El Paso 

17 Intelligence Center. 

18 ‘‘(p) AUTHORIZATION OF APPROPRIATIONS.—There 

19 is authorized to be appropriated to the Office of National 

20 Drug Control Policy to carry out this section— 

21 ‘‘(1) $280,000,000 for fiscal year 2007; 

22 ‘‘(2) $290,000,000 for each of fiscal years 2008 

23 and 2009; and 

24 ‘‘(3) $300,000,000 for each of fiscal years 2010 

25 and 2011.’’. 


ccoleman on PROD1PC71 with BILLS
45 

•S 2560 RS

1 SEC. 302. FUNDING FOR CERTAIN HIGH INTENSITY DRUG 

2 TRAFFICKING AREAS. 

3 (a) SHORT TITLE.—This section may be cited as the 

4 ‘‘Dawson Family Community Protection Act’’. 

5 (b) FINDINGS.—Congress finds the following: 

6 (1) In the early morning hours of October 16, 

7 2002, the home of Carnell and Angela Dawson was 

8 firebombed in apparent retaliation for Mrs. 

9 Dawson’s notification to police about persistent drug 

10 distribution activity in their East Baltimore City 

11 neighborhood. 

12 (2) The arson claimed the lives of Mr. and Mrs. 

13 Dawson and their 5 young children, aged 9 to 14. 

14 (3) The horrific murder of the Dawson family 

15 is a stark example of domestic narco-terrorism. 

16 (4) In all phases of counternarcotics law en17 forcement—from prevention to investigation to pros18 ecution to reentry—the voluntary cooperation of or19 dinary citizens is a critical component. 

20 (5) Voluntary cooperation is difficult for law en21 forcement officials to obtain when citizens feel that 

22 cooperation carries the risk of violent retaliation by 

23 illegal drug trafficking organizations and their affili24 ates. 

25 (6) Public confidence that law enforcement is 

26 doing all it can to make communities safe is a preVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00045 Fmt 6652 Sfmt 6401 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
46 

•S 2560 RS

1 requisite for voluntary cooperation among people 

2 who may be subject to intimidation or reprisal (or 

3 both). 

4 (7) Witness protection programs are insufficient 

5 on their own to provide security because many indi6 viduals and families who strive every day to make 

7 distressed neighborhoods livable for their children, 

8 other relatives, and neighbors will resist or refuse of9 fers of relocation by local, State, and Federal pros10 ecutorial agencies and because, moreover, the contin11 ued presence of strong individuals and families is 

12 critical to preserving and strengthening the social 

13 fabric in such communities. 

14 (8) Where (as in certain sections of Baltimore 

15 City) interstate trafficking of illegal drugs has severe 

16 ancillary local consequences within areas designated 

17 as high intensity drug trafficking areas, it is impor18 tant that supplementary High Intensity Drug Traf19 ficking Areas Program funds be committed to sup20 port initiatives aimed at making the affected com21 munities safe for the residents of those communities 

22 and encouraging their cooperation with local, State, 

23 and Federal law enforcement efforts to combat ille24 gal drug trafficking. 


ccoleman on PROD1PC71 with BILLS
47 

•S 2560 RS

1 (c) FUNDING FOR CERTAIN HIGH INTENSITY DRUG

2 TRAFFICKING AREAS.—Section 707, as amended by sec3 tion 301, is amended by adding at the end the following: 

4 ‘‘(q) SPECIFIC PURPOSES.— 

5 ‘‘(1) IN GENERAL.—The Director shall ensure 

6 that, of the amounts appropriated for a fiscal year 

7 for the Program, at least $7,000,000 is used in high 

8 intensity drug trafficking areas with severe neigh9 borhood safety and illegal drug distribution prob10 lems. 

11 ‘‘(2) REQUIRED USES.—The funds used under 

12 paragraph (1) shall be used— 

13 ‘‘(A) to ensure the safety of neighborhoods 

14 and the protection of communities, including 

15 the prevention of the intimidation of potential 

16 witnesses of illegal drug distribution and related 

17 activities; and 

18 ‘‘(B) to combat illegal drug trafficking 

19 through such methods as the Director considers 

20 appropriate, such as establishing or operating 

21 (or both) a toll-free telephone hotline for use by 

22 the public to provide information about illegal 

23 drug-related activities.’’. 


ccoleman on PROD1PC71 with BILLS
48 

•S 2560 RS

1 SEC. 303. ASSESSMENT. 

2 The Director shall assess the ability of the HIDTA 

3 Program to respond to the so-called ‘‘balloon effect’’, 

4 whereby urban drug traffickers facing intensive law en5 forcement efforts expand and spread their trafficking and 

6 distribution into rural, suburban, and smaller urban areas 

7 by conducting a demonstration project examining the abil8 ity of the New York/New Jersey HIDTA, with its new sin9 gle colocated Organized Crime and Drug Enforcement 

10 Task Force/High Intensity Drug Trafficking Area Strike 

11 Force and HIDTA Regional Intelligence Center, to ad12 dress the movement of drug traffickers into the more 

13 rural, suburban, and smaller areas encompassed by the 

14 counties of Albany, Onondaga, Monroe, and Erie in New 

15 York State and by annexing these counties into the exist16 ing New York/New Jersey HIDTA. 

17 TITLE IV—TECHNOLOGY 

18 SEC. 401. COUNTERDRUG TECHNOLOGY ASSESSMENT CEN19 TER. 

20 (a) CHIEF SCIENTIST.—Section 708(b) is amended 

21 to read as follows: 

22 ‘‘(b) CHIEF SCIENTIST.—There shall be at the head 

23 of the Center the Chief Scientist, who shall be appointed 

24 by the Director from among individuals qualified and dis25 tinguished in the area of science, medicine, engineering, 

26 or technology.’’. 


ccoleman on PROD1PC71 with BILLS
49 

•S 2560 RS

1 (b) RESPONSIBILITIES.— 

2 (1) RESEARCH AND DEVELOPMENT.—Section 

3 708 is amended by— 

4 (A) redesignating subsection (d) as sub5 section (e); and 

6 (B) striking subsection (c) and inserting 

7 the following: 

8 ‘‘(c) RESEARCH AND DEVELOPMENT RESPONSIBIL9 ITIES.—The Chief Scientist shall be responsible to the Di10 rector for— 

11 ‘‘(1) identifying and defining the short-, me12 dium-, and long-term scientific and technological 

13 needs of Federal, State, and local drug supply re14 duction agencies, including— 

15 ‘‘(A) advanced surveillance, tracking, and 

16 radar imaging; 

17 ‘‘(B) electronic support measures; 

18 ‘‘(C) communications; 

19 ‘‘(D) data fusion, advanced computer sys20 tems, and artificial intelligence; and 

21 ‘‘(E) chemical, biological, radiological (in22 cluding neutron and electron), and other means 

23 of detection; 

24 ‘‘(2) identifying demand reduction basic and 

25 applied research needs and initiatives, in consultaVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00049 Fmt 6652 Sfmt 6401 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
50 

•S 2560 RS

1 tion with affected National Drug Control Program 

2 agencies, including— 

3 ‘‘(A) improving treatment through 

4 neuroscientific advances; 

5 ‘‘(B) improving the transfer of biomedical 

6 research to the clinical setting; and 

7 ‘‘(C) in consultation with the National In8 stitute of Drug Abuse, and through interagency 

9 agreements or grants, examining addiction and 

10 rehabilitation research and the application of 

11 technology to expanding the effectiveness and 

12 availability of drug treatment; 

13 ‘‘(3) making a priority ranking of such needs 

14 identified in paragraphs (1) and (2) according to fis15 cal and technological feasibility, as part of a Na16 tional Counterdrug Research and Development Pro17 gram; 

18 ‘‘(4) overseeing and coordinating counterdrug 

19 technology initiatives with related activities of other 

20 Federal civilian and military departments; 

21 ‘‘(5) providing support to the development and 

22 implementation of the national drug control per23 formance measurement system established under 

24 subsection (c) of section 706; and 


ccoleman on PROD1PC71 with BILLS
51 

•S 2560 RS

1 ‘‘(6) transferring funds made available to a Na2 tional Drug Control Program Agency for 

3 counterdrug technology research and development to 

4 another account within such agency or to another 

5 National Drug Control Program Agency for 

6 counterdrug technology research and development, 

7 pursuant to the authority of the Director under sec8 tion 704. 

9 ‘‘(d) LIMITATION ON AUTHORITY.—The authority 

10 granted to the Director under this section shall not extend 

11 to the awarding of contracts, management of individual 

12 projects, or other operational activities.’’. 

13 (2) ASSISTANCE AND SUPPORT.—Subsection (e) 

14 of section 708, as redesignated by this section, is 

15 amended to read as follows: 

16 ‘‘(e) ASSISTANCE AND SUPPORT TO THE OFFICE OF

17 NATIONAL DRUG CONTROL POLICY.—The Secretary of 

18 Defense, the Secretary of Homeland Security, and the 

19 Secretary of Health and Human Services shall, to the 

20 maximum extent practicable, render assistance and sup21 port to the Office and to the Director in the conduct of 

22 counterdrug technology assessment.’’. 

23 (3) TECHNOLOGY TRANSFER PROGRAM.—Sec24 tion 708 is amended by adding at the end the fol25 lowing: 


ccoleman on PROD1PC71 with BILLS
52 

•S 2560 RS

1 ‘‘(f) TECHNOLOGY TRANSFER PROGRAM.— 

2 ‘‘(1) PROGRAM.—The Chief Scientist, with the 

3 advice and counsel of experts from State and local 

4 law enforcement agencies, shall be responsible to the 

5 Director for coordination and implementation of a 

6 counterdrug technology transfer program. 

7 ‘‘(2) PURPOSE.—The purpose of the Tech8 nology Transfer Program shall be for the 

9 Counterdrug Technology Assessment Center to 

10 transfer technology and associated training directly 

11 to State and local law enforcement agencies. 

12 ‘‘(3) PRIORITY OF RECEIPTS.—Transfers shall 

13 be made in priority order based on— 

14 ‘‘(A) the need of potential recipients for 

15 such technology; 

16 ‘‘(B) the effectiveness of the technology to 

17 enhance current counterdrug activities of poten18 tial recipients; and 

19 ‘‘(C) the ability and willingness of potential 

20 recipients to evaluate transferred technology. 

21 ‘‘(4) AGREEMENT AUTHORITY.—The Director 

22 may enter into an agreement with the Secretary of 

23 Homeland Security to transfer technology with both 

24 counterdrug and homeland security applications to 


ccoleman on PROD1PC71 with BILLS
53 

•S 2560 RS

1 State and local law enforcement agencies on a reim2 bursable basis. 

3 ‘‘(5) REPORT.—On or before July 1 of each 

4 year, the Director shall submit a report to the ap5 propriate congressional committees which addresses 

6 the following: 

7 ‘‘(A) The number of requests received dur8 ing the previous 12 months. 

9 ‘‘(B) The number of requests fulfilled dur10 ing the previous 12 months. 

11 ‘‘(C) A summary of the criteria used in 

12 making the determination on what requests 

13 were funded and what requests were not fund14 ed. 

15 ‘‘(D) A general assessment of the future 

16 needs of the program, based on expected 

17 changes in threats, expected technologies, and 

18 likely need from potential recipients. 

19 ‘‘(E) An assessment of the effectiveness of 

20 the technologies transferred, based in part on 

21 the evaluations provided by the recipients, with 

22 a recommendation whether the technology 

23 should continue to be offered through the pro24 gram.’’. 


ccoleman on PROD1PC71 with BILLS
54 

•S 2560 RS

1 TITLE V—REAUTHORIZATION 

2 AND IMPROVEMENT OF THE 

3 NATIONAL ANTI-DRUG MEDIA 

4 CAMPAIGN 

5 SEC. 501. SHORT TITLE. 

6 This title may be cited as the ‘‘National Youth Anti7 Drug Media Campaign Reauthorization Act of 2006’’. 

8 SEC. 502. PURPOSES OF THE NATIONAL YOUTH ANTI-DRUG 

9 MEDIA CAMPAIGN. 

10 The Drug-Free Media Campaign Act of 1998 (21 

11 U.S.C. 1801 et seq.) is amended— 

12 (1) in section 101, by striking ‘‘Drug-Free 

13 Media Campaign Act of 1998’’ and inserting ‘‘Na14 tional Youth Anti-Drug Media Campaign Act’’; and 

15 (2) in section 102— 

16 (A) in subsection (a), by striking ‘‘national 

17 media campaign’’ and all that follows through 

18 the period and inserting the following: ‘‘national 

19 youth anti-drug media campaign (referred to in 

20 this subtitle as the ‘national media campaign’) 

21 in accordance with this subtitle for the purposes 

22 of— 

23 ‘‘(1) preventing drug abuse among young peo24 ple in the United States; 


ccoleman on PROD1PC71 with BILLS
55 

•S 2560 RS

1 ‘‘(2) increasing awareness of adults of the im2 pact of drug abuse on young people; and 

3 ‘‘(3) encouraging parents and other interested 

4 adults to discuss with young people the dangers of 

5 illegal drug use.’’; and 

6 (B) in subsection (b), by striking ‘‘105’’ 

7 and inserting ‘‘104’’. 

8 SEC. 503. ROLES AND RESPONSIBILITIES OF THE DIREC9 TOR, THE PARTNERSHIP FOR A DRUG-FREE 

10 AMERICA, AND A MEDIA BUYING CON11 TRACTOR. 

12 The Drug-Free Media Campaign Act of 1998 (21 

13 U.S.C. 1801 et seq.) is amended— 

14 (1) by adding at the end the following: 

15 ‘‘(c) DIVISION OF RESPONSIBILITIES AND FUNC16 TIONS UNDER THE PROGRAM.— 

17 ‘‘(1) IN GENERAL.—The Director, in consulta18 tion with the Partnership for a Drug-Free America, 

19 shall determine the overall purposes and strategy of 

20 the national media campaign. 

21 ‘‘(2) RESPONSIBILITIES.— 

22 ‘‘(A) DIRECTOR.—The Director shall be 

23 responsible for implementing a focused national 

24 media campaign to meet the purposes set forth 

25 in section 102(a), and shall approve— 


ccoleman on PROD1PC71 with BILLS
56 

•S 2560 RS

1 ‘‘(i) the strategy of the national media 

2 campaign; 

3 ‘‘(ii) all advertising and promotional 

4 material used in the national media cam5 paign; and 

6 ‘‘(iii) the plan for the purchase of ad7 vertising time and space for the national 

8 media campaign. 

9 ‘‘(B) THE PARTNERSHIP FOR A DRUG10 FREE AMERICA.—The Director shall request 

11 that the Partnership for a Drug-Free Amer12 ica— 

13 ‘‘(i) develop and recommend strategies 

14 to achieve the goals of the national media 

15 campaign, including addressing national 

16 and local drug threats in specific regions 

17 or States, such as methamphetamine and 

18 ecstasy; 

19 ‘‘(ii) create all advertising to be used 

20 in the national media campaign, except ad21 vertisements that are— 

22 ‘‘(I) provided by other nonprofit 

23 entities pursuant to section 103(c); 

24 ‘‘(II) intended to reach a minor25 ity, ethnic, or other special audience 


ccoleman on PROD1PC71 with BILLS
57 

•S 2560 RS

1 that cannot be obtained at no cost 

2 (not including production costs and 

3 talent reuse payments), provided that 

4 any such advertising material is re5 viewed by the Partnership for a Drug6 Free America; or 

7 ‘‘(III) any other advertisements 

8 that the Partnership for a Drug-Free 

9 America determines it is unable to 

10 provide. 

11 ‘‘(C) MEDIA BUYING CONTRACTOR.—The 

12 Director shall enter into a contract with a 

13 media buying contractor to plan and purchase 

14 advertising time and space for the national 

15 media campaign. The media buying contractor 

16 shall not provide any service or material, or 

17 conduct any function or activity which can be 

18 provided by the Partnership for a Drug-Free 

19 America, as defined in section 403(2)(B)’’; and 

20 (2) in section 103— 

21 (A) in subparagraph (A), by inserting ‘‘, 

22 including the strategic planning for, and ac23 counting of, such purchases’’ after ‘‘space’’; 

24 (B) in subparagraph (C), by striking ‘‘out25 of-pocket’’; and 


ccoleman on PROD1PC71 with BILLS
58 

•S 2560 RS

1 (C) in subparagraph (F), by striking ‘‘the 

2 Office of National Drug Control Policy’’ and in3 serting ‘‘either the Office of National Drug 

4 Control Policy or the designee of the Office’’. 

5 SEC. 504. RESPONSIBLE USE OF FEDERAL FUNDS FOR THE 

6 NATIONAL YOUTH ANTI-DRUG MEDIA CAM7 PAIGN. 

8 The Drug-Free Media Campaign Act of 1998 (21 

9 U.S.C. 1801 et seq.) is amended— 

10 (1) in section 103, by striking paragraph (2) 

11 and inserting the following: 

12 ‘‘(2) ADVERTISING.— 

13 ‘‘(A) IN GENERAL.—Except as provided in 

14 subparagraph (B), in carrying out this subtitle, 

15 the Director shall ensure that sufficient funds 

16 are allocated to meet the stated goals of the na17 tional media campaign. 

18 ‘‘(B) EXCEPTION.—No funds shall be used 

19 for the creative development of advertisements 

20 (not including out-of-pocket production costs 

21 and talent reuse payments) except when— 

22 ‘‘(i) the advertisements are intended 

23 to reach a minority, ethnic, or other special 

24 audience that cannot be obtained at no 


ccoleman on PROD1PC71 with BILLS
59 

•S 2560 RS

1 cost (not including production costs and 

2 talent reuse payments); or 

3 ‘‘(ii) the Partnership for a Drug-Free 

4 America, determines that it is unable to 

5 provide such advertisements.’’; 

6 (2) in subsection (b), by striking ‘‘105’’ and in7 serting ‘‘104’’; 

8 (3) by striking subsection (c) and inserting the 

9 following: 

10 ‘‘(c) MATCHING REQUIREMENT.— 

11 ‘‘(1) NO COST MATCH.— 

12 ‘‘(A) IN GENERAL.—Except as provided in 

13 subparagraph (B), amounts made available for 

14 the national media campaign under section 106 

15 shall be used to require a no cost match of 

16 equivalent value of advertising broadcast time, 

17 print space, or in-kind contributions to the na18 tional media campaign. 

19 ‘‘(B) EXCEPTION.—The Director shall en20 sure that all no cost matches of advertising ma21 terial, time, space, or in-kind contributions pro22 vided pursuant to subparagraph (A) directly re23 late to substance abuse prevention and specifi24 cally promote 1 or more of the specific purposes 

25 set forth in section 102(a). This may include 


ccoleman on PROD1PC71 with BILLS
60 

•S 2560 RS

1 antismoking messages that are produced by 

2 nonprofit organizations and are targeted toward 

3 minors. 

4 ‘‘(2) SPONSORSHIP IDENTIFICATION.—Any ad5 vertising material donated to the national media 

6 campaign at no cost shall not be subject to the spon7 sorship identification provisions in section 317 of the 

8 Communications Act of 1934 (47 U.S.C. 317).’’; 

9 (4) by adding at the end the following: 

10 ‘‘(d) RESPONSIBLE USE OF FEDERAL FUNDS.— 

11 ‘‘(1) IN GENERAL.—The Director shall ensure 

12 that— 

13 ‘‘(A) for each fiscal year, not less than 77 

14 percent of the amounts appropriated under this 

15 subtitle shall be used for the activities allowed 

16 under section 103(a)(1)(A); 

17 ‘‘(B) no Federal funds provided under this 

18 subtitle are used to pay any entity for any ac19 tivity or service that duplicates, in whole or in 

20 part, any material, function, activity, or service 

21 provided by the Partnership for a Drug-Free 

22 America, as defined in section 403(2)(B); and 

23 ‘‘(C) no more than $5,000,000 is used in 

24 each fiscal year to develop advertising material 

25 pursuant to subsection (a)(2)(B)(ii).’’. 


ccoleman on PROD1PC71 with BILLS
61 

•S 2560 RS

1 SEC. 505. AUTHORIZATION FOR NATIONAL YOUTH ANTI2 DRUG MEDIA CAMPAIGN. 

3 The Drug-Free Media Campaign Act of 1998 (21 

4 U.S.C. 1801 et seq.) is amended by striking sections 104 

5 and 105 and inserting the following: 

6 ‘‘SEC. 104. AUTHORIZATION OF APPROPRIATIONS. 

7 ‘‘There is authorized to be appropriated to the Office 

8 of National Drug Control Policy to carry out this subtitle, 

9 $195,000,000 for each of the fiscal years 2006 through 

10 2010.’’. 

11 TITLE VI—AUTHORIZATIONS 

12 AND EXTENSION OF TERMI13 NATION DATE 

14 SEC. 601. AUTHORIZATION OF APPROPRIATIONS. 

15 Section 714 is amended— 

16 (1) by striking ‘‘title,’’ and inserting ‘‘title ex17 cept activities otherwise specified,’’; and 

18 (2) by striking ‘‘1999 through 2003’’ and in19 serting ‘‘2006 through 2010’’. 

20 SEC. 602. EXTENSION OF TERMINATION DATE. 

21 Section 715(a) is amended by striking ‘‘September 

22 30, 2003, this title and the amendments made by this 

23 title’’ and inserting ‘‘September 30, 2008, this title and 

24 the amendments made to this title’’. 


ccoleman on PROD1PC71 with BILLS
62 

•S 2560 RS

1 TITLE VII—ANTI-DOPING 

2 AGENCY 

3 SEC. 701. DESIGNATION OF UNITED STATES ANTI-DOPING 

4 AGENCY. 

5 (a) DEFINITIONS.—In this title: 

6 (1) UNITED STATES OLYMPIC COMMITTEE.— 

7 The term ‘‘United States Olympic Committee’’ 

8 means the organization established by the ‘‘Ted Ste9 vens Olympic and Amateur Sports Act’’ (36 U.S.C. 

10 220501 et seq.). 

11 (2) AMATEUR ATHLETIC COMPETITION.—The 

12 term ‘‘amateur athletic competition’’ means a con13 test, game, meet, match, tournament, regatta, or 

14 other event in which amateur athletes compete (36 

15 U.S.C. 220501(b)(2)). 

16 (3) AMATEUR ATHLETE.—The term ‘‘amateur 

17 athlete’’ means an athlete who meets the eligibility 

18 standards established by the national governing body 

19 or paralympic sports organization for the sport in 

20 which the athlete competes (36 U.S.C. 22501(b)(1)). 

21 (b) IN GENERAL.—The United States Anti-Doping 

22 Agency shall— 

23 (1) serve as the independent anti-doping organi24 zation for the amateur athletic competitions recog25 nized by the United States Olympic Committee; 


ccoleman on PROD1PC71 with BILLS
63 

•S 2560 RS

1 (2) ensure that athletes participating in ama2 teur athletic activities recognized by the United 

3 States Olympic Committee are prevented from using 

4 performance-enhancing drugs; 

5 (3) implement anti-doping education, research, 

6 testing, and adjudication programs to prevent 

7 United States Amateur Athletes participating in any 

8 activity recognized by the United States Olympic 

9 Committee from using performance-enhancing 

10 drugs; and 

11 (4) serve as the United States representative 

12 responsible for coordination with other anti-doping 

13 organizations coordinating amateur athletic competi14 tions recognized by the United States Olympic Com15 mittee to ensure the integrity of athletic competition, 

16 the health of the athletes and the prevention of use 

17 of performance-enhancing drugs by United States 

18 amateur athletes. 

19 SEC. 702. RECORDS, AUDIT, AND REPORT. 

20 (a) RECORDS.—The United States Anti-Doping 

21 Agency shall keep correct and complete records of account. 

22 (b) REPORT.—The United States Anti-Doping Agen23 cy shall submit an annual report to Congress which shall 

24 include— 


ccoleman on PROD1PC71 with BILLS
64 

•S 2560 RS

1 (1) an audit conducted and submitted in ac2 cordance with section 10101 of title 36, United 

3 States Code; and 

4 (2) a description of the activities of the agency. 

5 SEC. 703. AUTHORIZATION OF APPROPRIATIONS. 

6 There are authorized to be appropriated to the 

7 United States Anti-Doping Agency— 

8 (1) for fiscal year 2007, $9,700,000; 

9 (2) for fiscal year 2008, $10,300,000; 

10 (3) for fiscal year 2009, $10,600,000; 

11 (4) for fiscal year 2010, $11,000,000; and 

12 (5) for fiscal year 2011, $11,500,000. 

13 TITLE VIII—DRUG-FREE 

14 COMMUNITIES 

15 SEC. 801. REAUTHORIZATION. 

16 Section 1024(a) of the Drug-Free Communities Act 

17 of 1997 (21 U.S.C. 1524(a)) is amended— 

18 (1) in paragraph (9), by striking ‘‘and’’ after 

19 the semicolon; 

20 (2) in paragraph (10), by striking the period 

21 and inserting a semicolon; and 

22 (3) by adding at the end the following: 

23 ‘‘(11) $109,000,000 for fiscal year 2008; 

24 ‘‘(12) $119,000,000 for fiscal year 2009; 

25 ‘‘(13) $129,000,000 for fiscal year 2010; 


ccoleman on PROD1PC71 with BILLS
65 

•S 2560 RS

1 ‘‘(14) $139,000,000 for fiscal year 2011; and 

2 ‘‘(15) $149,000,000 for fiscal year 2012.’’. 

3 SEC. 802. SUSPENSION OF GRANTS. 

4 (a) IN GENERAL.—Section 1032(b) of the Drug-Free 

5 Communities Act of 1997 (21 U.S.C. 1532(b)) is amended 

6 by adding at the end the following: 

7 ‘‘(4) PROCESS FOR SUSPENSION.—A grantee 

8 shall not be suspended or terminated under para9 graph (1)(A)(ii), (2)(A)(iii), or (3)(E) unless that 

10 grantee is afforded a fair, timely, and independent 

11 appeal prior to such suspension or termination.’’. 

12 (b) REPORT TO CONGRESS.—Not later than 60 days 

13 after the date of enactment of this Act, the Director of 

14 the Office of National Drug Control Policy shall submit 

15 to Congress a report detailing the appeals process required 

16 by section 1032 (b)(4) of the Drug-Free Communities Act 

17 of 1997, as added by subsection (a). 

18 SEC. 803. GRANT AWARD INCREASE. 

19 Subsections (b)(1)(A)(iv), (b)(2)(C)(i), and (b)(3)(F) 

20 of section 1032 of the Drug-Free Communities Act of 

21 1997 (21 U.S.C. 1532) are amended by striking 

22 ‘‘$100,000’’ and inserting ‘‘$125,000’’. 


ccoleman on PROD1PC71 with BILLS
66 

•S 2560 RS

1 SEC. 804. PROHIBITION ON ADDITIONAL ELIGIBILITY CRI2 TERIA. 

3 Section 1032(a) of the Drug-Free Communities Act 

4 of 1997 (21 U.S.C. 1532(a)) is amended by adding at the 

5 end the following: 

6 ‘‘(7) ADDITIONAL CRITERIA.—The Director 

7 shall not impose any eligibility criteria on new appli8 cants or renewal grantees not provided in this chap9 ter.’’. 

10 SEC. 805. SUPPLEMENTAL GRANTS FOR COALITIONS. 

11 The Drug-Free Communities Act of 1997 (21 U.S.C. 

12 1521 et seq.) is amended by inserting after section 1035 

13 the following: 

14 ‘‘SEC. 1036. SUPPLEMENTAL GRANTS FOR COALITIONS 

15 WITH A MAJOR LOCAL DRUG CRISIS. 

16 ‘‘(a) AUTHORITY TO MAKE GRANTS.—As part of the 

17 program established under section 1031, the Director may 

18 award an initial grant under this subsection, and renewal 

19 grants under subsection (f), to any coalition awarded a 

20 grant under section 1032 that meets the criteria specified 

21 in subsection (d) in order to fund a coalition dealing with 

22 a major local drug crisis. 

23 ‘‘(b) TREATMENT WITH OTHER GRANTS.— 

24 ‘‘(1) SUPPLEMENT.—A grant awarded to a coa25 lition under this section is in addition to any grant 

26 awarded to the coalition under section 1032. 


ccoleman on PROD1PC71 with BILLS
67 

•S 2560 RS

1 ‘‘(2) REQUIREMENT FOR BASIC GRANT.—A coa2 lition may not be awarded a grant under this section 

3 for a fiscal year unless the coalition was awarded a 

4 grant or renewal grant under section 1032(b) for 

5 that fiscal year. 

6 ‘‘(c) APPLICATION.—A coalition seeking a grant 

7 under this section shall submit to the Administrator an 

8 application for the grant in such form and manner as the 

9 Administrator may require. 

10 ‘‘(d) CRITERIA.—A coalition meets the criteria speci11 fied in this subsection if the coalition— 

12 ‘‘(1) has achieved by or through it’s own efforts 

13 measurable results in the prevention and reduction 

14 of substance use among youth generally; 

15 ‘‘(2) has documented a highly, statistically sig16 nificant increase in a specific drug, from a baseline 

17 determined by locally collected data, that can be de18 fined as a local drug crisis; and 

19 ‘‘(3) submits to the Administrator a detailed 

20 plan for addressing the specific local drug crisis. 

21 ‘‘(e) USE OF GRANT FUNDS.—A coalition awarded 

22 a grant under this section shall use the grant amount for 

23 implementing comprehensive, community-wide strategies 

24 that address their local drug crises in accordance with the 


ccoleman on PROD1PC71 with BILLS
68 

•S 2560 RS

1 detailed plan submitted to the Administrator under sub2 section (d)(3). 

3 ‘‘(f) RENEWAL GRANTS.—The Administrator may 

4 make a renewal grant to any coalition awarded a grant 

5 under subsection (a), or a previous renewal grant under 

6 this subsection, if the coalition at the time of the applica7 tion for such renewal grant— 

8 ‘‘(1) continues to meet the criteria specified in 

9 subsection (d); and 

10 ‘‘(2) has made demonstrable progress in ad11 dressing the specific local drug crisis. 

12 ‘‘(g) GRANT AMOUNTS.— 

13 ‘‘(1) IN GENERAL.—Subject to paragraphs (2) 

14 and (3) the total amount of grants awarded to a co15 alition under this section for a fiscal year may not 

16 exceed the amount of non-Federal funds raised by 

17 the coalition, including in kind contributions, for 

18 that fiscal year. 

19 ‘‘(2) INITIAL GRANTS.—The amount of the ini20 tial grant awarded to a coalition under subsection 

21 (a) may not exceed $50,000. 

22 ‘‘(3) RENEWAL GRANTS.—The total amount of 

23 renewal grants awarded to a coalition under sub24 section (f) for any fiscal year may not exceed 

25 $50,000. 


ccoleman on PROD1PC71 with BILLS
69 

•S 2560 RS

1 ‘‘(h) FISCAL YEAR LIMITATION ON THE AMOUNT

2 AVAILABLE FOR GRANTS.—The total amount available for 

3 grants under this section, including renewal grants under 

4 subsection (f), in any fiscal year may not exceed the 

5 amount equal to 5 percent of the actual amount appro6 priated for that fiscal year.’’. 

7 SEC. 806. NATIONAL COMMUNITY ANTIDRUG COALITION IN8 STITUTE. 

9 Section 4 of Public Law 107–82 (21 U.S.C. 1521 

10 note), reauthorizing the Drug-Free Communities Support 

11 Program, is amended— 

12 (1) by amending subsection (a) to read as fol13 lows: 

14 ‘‘(a) IN GENERAL.—The Director of the Office of 

15 National Drug Control Policy shall, using amounts au16 thorized to be appropriated by subsection (d), make a di17 rected grant to Community Anti-Drug Coalitions of Amer18 ica to provide for the continuation of the National Com19 munity Antidrug Coalition Institute.’’; 

20 (2) by striking subsection (b) and redesignating 

21 subsections (c) and (d) as (b) and (c), respectively; 

22 and 

23 (3) in subsection (c), as redesignated by para24 graph (2), by adding at the end the following: 


ccoleman on PROD1PC71 with BILLS
70 

•S 2560 RS

1 ‘‘(4) For each of the fiscal years 2008 through 

2 2012, $2,000,000.’’. 

3 SEC. 807. CONTRACTING REQUIREMENT. 

4 Section 1031(d) of the Drug-Free Communities Act 

5 of 1997 (21 U.S.C. 1531(d)) is amended by adding at the 

6 end the following: ‘‘The Director shall delegate all author7 ity for grant eligibility determinations, review, selection, 

8 management, and appeals to another qualified national 

9 drug control agency.’’. 

10 TITLE IX—NATIONAL GUARD 

11 COUNTERDRUG SCHOOLS 

12 SEC. 901. NATIONAL GUARD COUNTERDRUG SCHOOLS. 

13 (a) AUTHORITY TO OPERATE.—Under such regula14 tions as the Secretary of Defense may prescribe, the Chief 

15 of the National Guard Bureau may establish and operate, 

16 or provide financial assistance to the States to establish 

17 and operate, not more than five schools (to be known gen18 erally as ‘‘National Guard counterdrug schools’’). 

19 (b) PURPOSE.—The purpose of the National Guard 

20 counterdrug schools shall be the provision by the National 

21 Guard of training in drug interdiction and counterdrug 

22 activities and drug demand reduction activities to per23 sonnel of the following: 

24 (1) Federal agencies. 

25 (2) State and local law enforcement agencies. 


ccoleman on PROD1PC71 with BILLS
71 

•S 2560 RS

1 (3) Community-based organizations engaged in 

2 such activities. 

3 (4) Other non-Federal governmental and pri4 vate entities and organizations engaged in such ac5 tivities. 

6 (c) COUNTERDRUG SCHOOLS SPECIFIED.—The Na7 tional Guard counterdrug schools operated under the au8 thority in subsection (a) are as follows: 

9 (1) The National Interagency Civil-Military In10 stitute (NICI), San Luis Obispo, California. 

11 (2) The Multi-Jurisdictional Counterdrug Task 

12 Force Training (MCTFT), St. Petersburg, Florida. 

13 (3) The Midwest Counterdrug Training Center 

14 (MCTC), Johnston, Iowa. 

15 (4) The Regional Counterdrug Training Acad16 emy (RCTA), Meridian, Mississippi. 

17 (5) The Northeast Regional Counterdrug Train18 ing Center (NCTC), Fort Indiantown Gap, Pennsyl19 vania. 

20 (d) USE OF NATIONAL GUARD PERSONNEL.— 

21 (1) IN GENERAL.—To the extent provided for 

22 in the State drug interdiction and counterdrug ac23 tivities plan of a State in which a National Guard 

24 counterdrug school is located, personnel of the Na25 tional Guard of that State who are ordered to perVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00071 Fmt 6652 Sfmt 6401 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
72 

•S 2560 RS

1 form full-time National Guard duty authorized 

2 under section 112(b) of that title 32, United States 

3 Code, may provide training referred to in subsection 

4 (b) at that school. 

5 (2) DEFINITION.—In this subsection, the term 

6 ‘‘State drug interdiction and counterdrug activities 

7 plan’’, in the case of a State, means the current plan 

8 submitted by the Governor of the State to the Sec9 retary of Defense under section 112 of title 32, 

10 United States Code. 

11 (e) TREATMENT UNDER AUTHORITY TO PROVIDE

12 COUNTERDRUG SUPPORT.—The provisions of section 

13 1004 of the National Defense Authorization Act for Fiscal 

14 Year 1991 (Public Law 101–510; 10 U.S.C. 374 note) 

15 shall apply to any activities of a National Guard 

16 counterdrug school under this section that are for an 

17 agency referred to in subsection (a) of such section 1004 

18 and for a purpose set forth in subsection (b) of such sec19 tion 1004. 

20 (f) ANNUAL REPORTS ON ACTIVITIES.— 

21 (1) IN GENERAL.—Not later than February 1 

22 each year, the Secretary of Defense shall submit to 

23 Congress a report on the activities of the National 

24 Guard counterdrug schools during the preceding 

25 year. 


ccoleman on PROD1PC71 with BILLS
73 

•S 2560 RS

1 (2) CONTENTS.—Each report under paragraph 

2 (1) shall set forth the following: 

3 (A) FUNDING.—The amount made avail4 able for each National Guard counterdrug 

5 school during the fiscal year ending in the year 

6 preceding the year in which such report is sub7 mitted. 

8 (B) ACTIVITIES.—A description of the ac9 tivities of each National Guard counterdrug 

10 school during the year preceding the year in 

11 which such report is submitted. 

12 (g) AUTHORIZATION OF APPROPRIATIONS.— 

13 (1) IN GENERAL.—There is hereby authorized 

14 to be appropriated for the Department of Defense 

15 for the National Guard for each of fiscal years 2006 

16 through 2010, $30,000,000 for purposes of the Na17 tional Guard counterdrug schools in such fiscal year. 

18 (2) CONSTRUCTION.—The amount authorized 

19 to be appropriated by paragraph (1) for a fiscal year 

20 is in addition to any other amount authorized to be 

21 appropriated for the Department of Defense for the 

22 National Guard for such fiscal year. 


ccoleman on PROD1PC71 with BILLS
74 

•S 2560 RS

1 TITLE X—MISCELLANEOUS 

2 PROVISIONS 

3 SEC. 1001. REPEALS. 

4 (a) ACT.—Sections 709, 710, and 711 are repealed. 

5 (b) FORFEITURE ASSETS.—Section 6073 of the As6 sets Forfeiture Amendments Act of 1988 (21 U.S.C. 

7 1509) is repealed. 

8 SEC. 1002. CONTROLLED SUBSTANCES ACT AMENDMENTS. 

9 Section 303(g)(2)(B)(iii) of the Controlled Sub10 stances Act (21 U.S.C. 823(g)(2)(B)(iii)) is amended by 

11 striking ‘‘except that the Secretary’’ and inserting the fol12 lowing: ‘‘unless, not sooner than 1 year after the date on 

13 which the practitioner submitted the initial notification, 

14 the practitioner submits a second notification to the Sec15 retary of the need and intent of the practitioner to treat 

16 more than such applicable number of patients. A second 

17 notification under this clause shall contain the certifi18 cations required by clauses (i) and (ii) of this subpara19 graph. The Secretary’’. 

20 SEC. 1003. REPORT ON INTELLIGENCE SHARING. 

21 Not later than 180 days after the date of enactment 

22 of this Act, the Director shall submit to Congress a re23 port— 

24 (1) evaluating existing and planned intelligence 

25 systems used by Federal, State, and local law enVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00074 Fmt 6652 Sfmt 6401 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
75 

•S 2560 RS

1 forcement agencies responsible for drug trafficking 

2 and drug production enforcement; and 

3 (2) addressing— 

4 (A) the current intelligence systems used 

5 by Federal, State, and local law enforcement 

6 agencies; 

7 (B) the compatibility of such systems in 

8 ensuring access and availability of intelligence 

9 to Federal, State, and local law enforcement; 

10 (C) the extent to which Federal, State, and 

11 local law enforcement are sharing intelligence 

12 information to assess current threats and de13 sign appropriate enforcement strategies; and 

14 (D) the measures needed to ensure and to 

15 promote effective information sharing among 

16 intelligence systems operated by Federal, State, 

17 and local law enforcement agencies responsible 

18 for drug trafficking and drug production en19 forcement. 

20 SEC. 1004. REQUIREMENT FOR SOUTH AMERICAN HEROIN 

21 STRATEGY. 

22 (a) IN GENERAL.—Not later than 90 days after the 

23 date of enactment of this Act, the Director shall submit 

24 to Congress a comprehensive strategy that addresses the 

25 increased threat from South American heroin, and in parVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00075 Fmt 6652 Sfmt 6401 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
76 

•S 2560 RS

1 ticular Colombian heroin, and the emerging threat from 

2 opium poppy grown in Peru and often intended for transit 

3 to Columbia for processing into heroin. 

4 (b) CONTENTS.—The strategy submitted under sub5 section (a) shall include— 

6 (1) opium eradication efforts to eliminate the 

7 problem at the source to prevent heroin from enter8 ing the stream of commerce; 

9 (2) interdiction and precursor chemical con10 trols; 

11 (3) demand reduction and treatment; 

12 (4) alternative development programs, including 

13 direct assistance to regional governments to demobi14 lize and provide alternative livelihoods to former 

15 members of insurgent or other groups engaged in 

16 heroin, cocoa, or other illicit drug production or traf17 ficking; 

18 (5) efforts to inform and involve local citizens 

19 in the programs described in paragraphs (1) through 

20 (4), such as through leaflets advertising rewards for 

21 information; 

22 (6) provisions that ensure the maintenance at 

23 current levels of efforts to eradicate coca in Colom24 bia; and 


ccoleman on PROD1PC71 with BILLS
77 

•S 2560 RS

1 (7) an assessment of the specific level of fund2 ing and resources necessary to simultaneously ad3 dress the threat from South American heroin and 

4 the threat from Colombian and Peruvian coca. 

5 (c) TREATMENT OF CLASSIFIED OR LAW ENFORCE6 MENT SENSITIVE INFORMATION.—Any content of the 

7 strategy submitted under subsection (a) that involves in8 formation classified under criteria established by an Exec9 utive order, or whose public disclosure, as determined by 

10 the Director or the head of any relevant Federal agency, 

11 would be detrimental to the law enforcement of national 

12 security activities of any Federal, foreign, or international 

13 agency, shall be presented to Congress separately from the 

14 rest of the strategy. 

15 SEC. 1005. MODEL ACTS. 

16 (a) IN GENERAL.—The Director shall enter into an 

17 agreement with a nonprofit corporation that works with 

18 States on laws and policies to address alcohol and other 

19 drug issues, under which the corporation shall revise the 

20 model State drug laws developed by the President’s Com21 mission on Model State Drug Laws and draft supple22 mentary model acts to meet changes in States’ substance 

23 abuse issues. 


ccoleman on PROD1PC71 with BILLS
78 

•S 2560 RS

1 (b) AUTHORIZATION OF APPROPRIATIONS.—There 

2 are authorized to be appropriated $1,500,000 to carry out 

3 this section. 

4 SECTION 1. SHORT TITLE, REFERENCE, AND TABLE OF 

5 CONTENTS. 

6 (a) SHORT TITLE.—This Act may be cited as the ‘‘Of7 fice of National Drug Control Policy Reauthorization Act 

8 of 2006’’. 

9 (b) AMENDMENT OF OFFICE OF NATIONAL DRUG CON10 TROL POLICY REAUTHORIZATION ACT OF 1998.—Except as 

11 otherwise expressly provided, whenever in this Act an 

12 amendment or repeal is expressed in terms of an amend13 ment to, or repeal of, a section or other provision, the ref14 erence shall be considered to be made to a section or other 

15 provision of the Office of National Drug Control Policy Re16 authorization Act of 1998 (Public Law 105–277; 21 U.S.C. 

17 1701 et seq.). 

18 (c) TABLE OF CONTENTS.—The table of contents for 

19 this Act is as follows: 

Sec. 1. Short title, reference, and table of contents. 

TITLE I—ORGANIZATION OF OFFICE OF NATIONAL DRUG CONTROL 

POLICY AND ROLES AND RESPONSIBILITIES 

Sec. 101. Amendments to definitions. 

Sec. 102. Establishment of the Office of National Drug Control Policy. 

Sec. 103. Appointment and responsibilities of the Director. 

Sec. 104. Amendments to ensure coordination with other agencies. 

Sec. 105. Budgetary matters. 

TITLE II—THE NATIONAL DRUG CONTROL STRATEGY 

Sec. 201. Annual preparation and submission of National Drug Control Strategy. 

Sec. 202. Performance measurements. 


ccoleman on PROD1PC71 with BILLS
79 

•S 2560 RS

Sec. 203. Annual report requirement. 

TITLE III—HIGH INTENSITY DRUG TRAFFICKING AREAS 

Sec. 301. High Intensity Drug Trafficking Areas Program. 

Sec. 302. Funding for certain high intensity drug trafficking areas. 

Sec. 303. Assessment. 

TITLE IV—TECHNOLOGY 

Sec. 401. Counterdrug Technology Assessment Center. 

TITLE V—REAUTHORIZATION AND IMPROVEMENT OF THE 

NATIONAL ANTI-DRUG MEDIA CAMPAIGN 

Sec. 501. Short title. 

Sec. 502. Purposes of the National Youth Anti-Drug Media Campaign. 

Sec. 503. Roles and responsibilities of the Director, the Partnership for a DrugFree America, and a media buying contractor. 

Sec. 504. Responsible use of Federal funds for the National Youth Anti-Drug 

Media Campaign. 

Sec. 505. Authorization for National Youth Anti-Drug Media Campaign. 

TITLE VI—AUTHORIZATIONS AND EXTENSION OF TERMINATION 

DATE 

Sec. 601. Authorization of appropriations. 

Sec. 602. Extension of termination date. 

TITLE VII—ANTI-DOPING AGENCY 

Sec. 701. Designation of United States Anti-Doping Agency. 

Sec. 702. Records, audit, and report. 

Sec. 703. Authorization of appropriations. 

TITLE VIII—DRUG-FREE COMMUNITIES 

Sec. 801. Reauthorization. 

Sec. 802. Suspension of grants. 

Sec. 803. Grant award increase. 

Sec. 804. Prohibition on additional eligibility criteria. 

Sec. 805. Supplemental grants for coalitions. 

Sec. 806. National Community Anti-Drug Coalition Institute. 

Sec. 807. Contracting requirement. 

TITLE IX—NATIONAL GUARD COUNTERDRUG SCHOOLS 

Sec. 901. National Guard counterdrug schools. 

TITLE X—NATIONAL METHAMPHETAMINE INFORMATION 

CLEARINGHOUSE ACT OF 2006 

Sec. 1001. Short title. 

Sec. 1002. Definitions. 

Sec. 1003. Establishment of clearinghouse and advisory council. 

Sec. 1004. NMIC requirements and review. 

Sec. 1005. Authorization of appropriations. 


ccoleman on PROD1PC71 with BILLS
80 

•S 2560 RS

TITLE XI—MISCELLANEOUS PROVISIONS 

Sec. 1101. Repeals. 

Sec. 1102. Controlled Substances Act amendments. 

Sec. 1103. Report on intelligence sharing. 

Sec. 1104. Requirement for South American heroin strategy. 

Sec. 1105. Model acts. 

Sec. 1106. Study on iatrogenic addiction associated with prescription opioid analgesic drugs. 

Sec. 1107. Requirement for strategy to stop Internet advertising of prescription 

medicines without a prescription. 

Sec. 1108. Requirement for study on diversion and inappropriate uses of prescription drugs. 

1 TITLE I—ORGANIZATION OF OF2 FICE OF NATIONAL DRUG 

3 CONTROL POLICY AND ROLES 

4 AND RESPONSIBILITIES 

5 SEC. 101. AMENDMENTS TO DEFINITIONS. 

6 (a) DEMAND REDUCTION.—Section 702(1) is amend7 ed— 

8 (1) in subparagraph (F), by striking ‘‘and’’ after 

9 the semicolon; and 

10 (2) in subparagraph (G), by striking the period 

11 and inserting ‘‘; and’’; and 

12 (3) by adding at the end the following: 

13 ‘‘(H) international drug abuse education, 

14 prevention, treatment, research, rehabilitation 

15 activities, and interventions for drug abuse and 

16 dependence.’’. 

17 (b) NATIONAL DRUG CONTROL PROGRAM.—Section 

18 702(6) is amended by adding before the period the folVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00080 Fmt 6652 Sfmt 6203 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
81 

•S 2560 RS

1 lowing: ‘‘, including any activities involving supply reduc2 tion, demand reduction, or State and local affairs’’. 

3 (c) OFFICE.—Section 702(9) is amended by striking 

4 ‘‘implicates’’ and inserting ‘‘indicates’’. 

5 (d) STATE AND LOCAL AFFAIRS.—Paragraph (10) of 

6 section 702 is amended to read as follows: 

7 ‘‘(10) STATE AND LOCAL AFFAIRS.—The term 

8 ‘State and local affairs’ means domestic activities 

9 conducted by a National Drug Control Program agen10 cy that are intended to reduce the availability and 

11 use of illegal drugs, including— 

12 ‘‘(A) coordination and enhancement of Fed13 eral, State, and local law enforcement drug con14 trol efforts; 

15 ‘‘(B) coordination and enhancement of ef16 forts among National Drug Control Program 

17 agencies and State and local demand reduction 

18 and supply reduction agencies; 

19 ‘‘(C) coordination and enhancement of Fed20 eral, State, and local law enforcement initiatives 

21 to gather, analyze, and disseminate information 

22 and intelligence relating to drug control among 

23 domestic law enforcement agencies; and 

24 ‘‘(D) other coordinated and joint initiatives 

25 among Federal, State, and local agencies to proVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00081 Fmt 6652 Sfmt 6203 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
82 

•S 2560 RS

1 mote comprehensive drug control strategies de2 signed to reduce the demand for, and the avail3 ability of, illegal drugs.’’. 

4 (e) SUPPLY REDUCTION.—Section 702(11) is amended 

5 to read as follows: 

6 ‘‘(11) SUPPLY REDUCTION.—The term ‘supply 

7 reduction’ means any activity or program conducted 

8 by a National Drug Control Program agency that is 

9 intended to reduce the availability or use of illegal 

10 drugs in the United States or abroad, including— 

11 ‘‘(A) law enforcement outside the United 

12 States; 

13 ‘‘(B) source country programs, including 

14 economic development programs primarily in15 tended to reduce the production or trafficking of 

16 illicit drugs; 

17 ‘‘(C) activities to control international traf18 ficking in, and availability of, illegal drugs, in19 cluding— 

20 ‘‘(i) accurate assessment and moni21 toring of international drug production and 

22 interdiction programs and policies; and 

23 ‘‘(ii) coordination and promotion of 

24 compliance with international treaties reVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00082 Fmt 6652 Sfmt 6203 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
83 

•S 2560 RS

1 lating to the production, transportation, or 

2 interdiction of illegal drugs; 

3 ‘‘(D) activities to conduct and promote 

4 international law enforcement programs and 

5 policies to reduce the supply of drugs; and 

6 ‘‘(E) activities to facilitate and enhance the 

7 sharing of domestic and foreign intelligence in8 formation among National Drug Control Pro9 gram agencies, relating to the production and 

10 trafficking of drugs in the United States and in 

11 foreign countries.’’. 

12 (f) DEFINITIONS OF APPROPRIATE CONGRESSIONAL

13 COMMITTEES AND LAW ENFORCEMENT.—Section 702 is 

14 amended by adding at the end the following: 

15 ‘‘(12) APPROPRIATE CONGRESSIONAL COMMIT16 TEES.—Except where otherwise provided, the term 

17 ‘appropriate congressional committees’ means the 

18 Committee on the Judiciary, the Committee on Ap19 propriations, and the Caucus on International Nar20 cotics Control of the Senate and the Committee on 

21 Government Reform, the Committee on the Judiciary, 

22 and the Committee on Appropriations of the House of 

23 Representatives. 

24 ‘‘(13) LAW ENFORCEMENT.—The term ‘law en25 forcement’ or ‘drug law enforcement’ means all efforts 


ccoleman on PROD1PC71 with BILLS
84 

•S 2560 RS

1 by a Federal, State, or local government agency to en2 force the drug laws of the United States or any State, 

3 including investigation, arrest, prosecution, and in4 carceration or other punishments or penalities.’’. 

5 SEC. 102. ESTABLISHMENT OF THE OFFICE OF NATIONAL 

6 DRUG CONTROL POLICY. 

7 (a) RESPONSIBILITIES.—Section 703(a) is amended to 

8 read as follows: 

9 ‘‘(a) ESTABLISHMENT OF OFFICE.—There is estab10 lished in the Executive Office of the President an Office of 

11 National Drug Control Policy, which shall— 

12 ‘‘(1) develop national drug control policy; 

13 ‘‘(2) coordinate and oversee the implementation 

14 of the national drug control policy; 

15 ‘‘(3) assess and certify the adequacy of National 

16 Drug Control Programs and the budget for those pro17 grams; 

18 ‘‘(4) evaluate the effectiveness of National Drug 

19 Control Program agencies’ programs; and 

20 ‘‘(5) develop specific goals and performance 

21 measurements needed to assess the effectiveness of— 

22 ‘‘(A) the national drug control policy; and 

23 ‘‘(B) the programs of the National Drug 

24 Control Program agencies.’’. 


ccoleman on PROD1PC71 with BILLS
85 

•S 2560 RS

1 (b) POSITIONS.—Section 703(b) is amended to read as 

2 follows: 

3 ‘‘(b) DIRECTOR OF NATIONAL DRUG CONTROL POLICY

4 AND DEPUTY DIRECTORS.— 

5 ‘‘(1) DIRECTOR.—There shall be a Director of 

6 National Drug Control Policy who shall head the Of7 fice (referred to in this Act as the ‘Director’). 

8 ‘‘(2) DEPUTY DIRECTOR.—There shall be a Dep9 uty Director of National Drug Control Policy who 

10 shall report directly to the Director (referred to in 

11 this Act as the ‘Deputy Director’). 

12 ‘‘(3) OTHER DEPUTY DIRECTORS.— 

13 ‘‘(A) IN GENERAL.—There shall be a Dep14 uty Director for Demand Reduction, a Deputy 

15 Director for Supply Reduction, and a Deputy 

16 Director for State and Local Affairs. 

17 ‘‘(B) REPORTING.—The Deputy Director for 

18 Demand Reduction, the Deputy Director for 

19 Supply Reduction, and the Deputy Director for 

20 State and Local Affairs shall report directly to 

21 the Deputy Director of the Office of National 

22 Drug Control Policy. 

23 ‘‘(C) DEPUTY DIRECTOR FOR DEMAND RE24 DUCTION.—The Deputy Director for Demand Re25 duction shall be responsible for the activities— 


ccoleman on PROD1PC71 with BILLS
86 

•S 2560 RS

1 ‘‘(i) in subparagraphs (A) through (H) 

2 of section 702(l); and 

3 ‘‘(ii) in section 709, the National 

4 Youth Anti-Drug Media Campaign Act. 

5 ‘‘(D) DEPUTY DIRECTOR FOR SUPPLY RE6 DUCTION.—The Deputy Director for Supply Re7 duction shall be responsible for the activities in 

8 subparagraphs (A) through (C) in section 

9 702(11). 

10 ‘‘(E) DEPUTY DIRECTOR FOR STATE AND

11 LOCAL AFFAIRS.—The Deputy Director for State 

12 and Local Affairs shall be responsible for the ac13 tivities— 

14 ‘‘(i) in subparagraphs (A) through (D) 

15 of section 702(10); 

16 ‘‘(ii) in section 707, the High Intensity 

17 Drug Trafficking Areas Program; and 

18 ‘‘(iii) in section 708, the Counterdrug 

19 Technology Assessment Center.’’. 

20 SEC. 103. APPOINTMENT AND RESPONSIBILITIES OF THE 

21 DIRECTOR. 

22 (a) SUCCESSION.—Section 704(a) is amended by 

23 amending paragraph (3) to read as follows: 

24 ‘‘(3) ACTING DIRECTOR.—If the Director dies, re25 signs, or is otherwise unable to perform the functions 


ccoleman on PROD1PC71 with BILLS
87 

•S 2560 RS

1 and duties of the office, the Deputy Director shall per2 form the functions and duties of the Director tempo3 rarily in an acting capacity pursuant to subchapter 

4 III of chapter 33 of title 5, United States Code.’’. 

5 (b) RESPONSIBILITIES.—Section 704(b) is amended— 

6 (1) in paragraph (4), by striking ‘‘Federal de7 partments and agencies engaged in drug enforcement’’ 

8 and inserting ‘‘National Drug Control Program agen9 cies’’; 

10 (2) in paragraph (7), by inserting after ‘‘Presi11 dent’’ the following: ‘‘and the appropriate congres12 sional committees’’; 

13 (3) in paragraph (13), by striking ‘‘(beginning 

14 in 1999)’’; 

15 (4) by striking paragraph (14) and inserting the 

16 following: 

17 ‘‘(14) shall submit to the appropriate congres18 sional committees on an annual basis, not later than 

19 60 days after the date of the last day of the applicable 

20 period, a summary of— 

21 ‘‘(A) each of the evaluations received by the 

22 Director under paragraph (13); and 

23 ‘‘(B) the progress of each National Drug 

24 Control Program agency toward the drug control 

25 program goals of the agency using the performVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00087 Fmt 6652 Sfmt 6203 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
88 

•S 2560 RS

1 ance measures for the agency developed under 

2 section 706(c);’’; 

3 (5) in paragraph (15), by striking subparagraph 

4 (C) and inserting the following: 

5 ‘‘(C) supporting the substance abuse infor6 mation clearinghouse administered by the Ad7 ministrator of the Substance Abuse and Mental 

8 Health Services Administration and established 

9 in section 501(d)(16) of the Public Health Serv10 ice Act by— 

11 ‘‘(i) encouraging all National Drug 

12 Control Program agencies to provide all ap13 propriate and relevant information; and 

14 ‘‘(ii) supporting the dissemination of 

15 information to all interested entities;’’; and 

16 (6) by inserting at the end the following: 

17 ‘‘(16) shall coordinate with the private sector to 

18 promote private research and development of medica19 tions to treat addiction; 

20 ‘‘(17) shall seek the support and commitment of 

21 State and local officials in the formulation and im22 plementation of the National Drug Control Strategy; 

23 ‘‘(18) shall monitor and evaluate the allocation 

24 of resources among Federal law enforcement agencies 


ccoleman on PROD1PC71 with BILLS
89 

•S 2560 RS

1 in response to significant local and regional drug 

2 trafficking and production threats; and 

3 ‘‘(19) shall submit an annual report to Congress 

4 detailing how the Office of National Drug Control 

5 Policy has consulted with and assisted State and local 

6 governments with respect to the formulation and im7 plementation of the National Drug Control Strategy 

8 and other relevant issues.’’. 

9 (c) REVIEW AND CERTIFICATION OF NATIONAL DRUG

10 CONTROL PROGRAM BUDGET.—Section 704(c)(3) is amend11 ed— 

12 (1) in subparagraph (C)(iii), by inserting ‘‘and 

13 the appropriate congressional committees,’’ after 

14 ‘‘House of Representatives’’; and 

15 (2) in subparagraph (D)(ii)(II)(bb), by inserting 

16 ‘‘and the appropriate congressional committees,’’ after 

17 ‘‘House of Representatives’’. 

18 (d) POWERS OF DIRECTOR.—Section 704(d) is amend19 ed— 

20 (1) in paragraph (9)— 

21 (A) by inserting ‘‘notwithstanding any 

22 other provision of law,’’ after ‘‘(9)’’; and 

23 (B) by striking ‘‘Strategy; and’’ and insert24 ing ‘‘Strategy and notify the appropriate con25 gressional committees of any fund control notice 


ccoleman on PROD1PC71 with BILLS
90 

•S 2560 RS

1 issued in accordance with section 704(f)(5);’’; 

2 and 

3 (2) in paragraph (10), by inserting before the pe4 riod the following: ‘‘and section 706 of the Depart5 ment of State Authorization Act for Fiscal Year 2003 

6 (22 U.S.C. 229j–1)’’. 

7 (e) FUND CONTROL NOTICES.—Section 704(f) is 

8 amended by adding at the end the following: 

9 ‘‘(4) CONGRESSIONAL NOTICE.—A copy of each 

10 fund control notice shall be transmitted to the appro11 priate congressional committees. 

12 ‘‘(5) RESTRICTIONS.—The Director shall not 

13 issue a fund control notice to direct that all or part 

14 of an amount appropriated to the National Drug 

15 Control Program agency account be obligated, modi16 fied, or altered in any manner— 

17 ‘‘(A) contrary, in whole or in part, to a spe18 cific appropriation; or 

19 ‘‘(B) contrary, in whole or in part, to the 

20 expressed intent of Congress.’’. 

21 (f) UNITED STATES INTERDICTION COORDINATOR.— 

22 (1) IN GENERAL.—Section 704 is amended by 

23 adding at the end the following: 

24 ‘‘(i) UNITED STATES INTERDICTION COORDINATOR.— 


ccoleman on PROD1PC71 with BILLS
91 

•S 2560 RS

1 ‘‘(1) IN GENERAL.—There shall be a United 

2 States Interdiction Coordinator, who shall be des3 ignated by the Director and who shall be responsible 

4 for the coordination of interdiction operations among 

5 National Drug Control Program agencies to prevent 

6 and reduce the illegal importation of drugs into the 

7 United States. 

8 ‘‘(2) RESPONSIBILITIES.—The United States 

9 Interdiction Coordinator shall be responsible to the 

10 Director for— 

11 ‘‘(A) coordinating the interdiction activities 

12 of the National Drug Control Program agencies 

13 to ensure consistency with the National Drug 

14 Control Strategy; 

15 ‘‘(B) developing a National Drug Control 

16 Interdiction plan to ensure consistency with the 

17 National Drug Control Strategy; 

18 ‘‘(C) assessing the sufficiency of assets of the 

19 National Drug Control Program agencies com20 mitted to illicit drug interdiction; and 

21 ‘‘(D) advising the Director on the efforts of 

22 each National Drug Control Program Agency to 

23 implement the National Drug Control Interdic24 tion plan.’’. 


ccoleman on PROD1PC71 with BILLS
92 

•S 2560 RS

1 (2) AMENDMENT TO HOMELAND SECURITY ACT

2 OF 2002.—Section 878 of the Homeland Security Act 

3 of 2002 (6 U.S.C. 458) is amended by striking 

4 ‘‘shall—’’ through paragraph (2) and inserting ‘‘shall 

5 ensure the adequacy of resources within the Depart6 ment for illicit drug interdiction.’’. 

7 SEC. 104. AMENDMENTS TO ENSURE COORDINATION WITH 

8 OTHER AGENCIES. 

9 Section 705 is amended— 

10 (1) in subsection (a)(1)(A), by striking ‘‘abuse’’; 

11 (2) by amending subsection (a)(3) to read as fol12 lows: 

13 ‘‘(3) REQUIRED REPORTS.— 

14 ‘‘(A) SECRETARIES OF THE INTERIOR AND

15 AGRICULTURE.—Not later than July 1 of each 

16 year, the Secretaries of Agriculture and the Inte17 rior shall jointly submit to the Director and the 

18 appropriate congressional committees an assess19 ment of the quantity of illegal drug cultivation 

20 and manufacturing in the United States on 

21 lands owned or under the jurisdiction of the Fed22 eral Government for the preceding year. 

23 ‘‘(B) SECRETARY OF HOMELAND SECU24 RITY.—Not later than July 1 of each year, the 

25 Secretary of Homeland Security shall submit to 


ccoleman on PROD1PC71 with BILLS
93 

•S 2560 RS

1 the Director and the appropriate congressional 

2 committees information for the preceding year 

3 regarding— 

4 ‘‘(i) the number and type of seizures of 

5 drugs by each component of the Department 

6 of Homeland Security seizing drugs, as well 

7 as statistical information on the geographic 

8 areas of such seizures; and 

9 ‘‘(ii) the number of air and maritime 

10 patrol hours primarily dedicated to drug 

11 supply reduction missions undertaken by 

12 each component of the Department of 

13 Homeland Security. 

14 ‘‘(C) SECRETARY OF DEFENSE.—The Sec15 retary of Defense shall, by July 1 of each year, 

16 submit to the Director and the appropriate con17 gressional committees information for the pre18 ceding year regarding the number of air and 

19 maritime patrol hours primarily dedicated to 

20 drug supply reduction missions undertaken by 

21 each component of the Department of Defense.’’; 

22 and 

23 (3) in subsection (b)(2)(B), by striking ‘‘Pro24 gram’’ and inserting ‘‘Strategy’’. 


ccoleman on PROD1PC71 with BILLS
94 

•S 2560 RS

1 SEC. 105. BUDGETARY MATTERS. 

2 (a) SUBMISSION OF DRUG CONTROL BUDGET RE3 QUESTS.—Section 704(c)(1) is amended by adding at the 

4 end the following: 

5 ‘‘(C) CONTENT OF DRUG CONTROL BUDGET

6 REQUESTS.—A drug control budget request sub7 mitted by a department, agency, or program 

8 under this paragraph shall include all requests 

9 for funds for any drug control activity under10 taken by that department, agency, or program, 

11 including demand reduction, supply reduction, 

12 and State and local affairs, including any drug 

13 law enforcement activities. If an activity has 

14 both drug control and nondrug control purposes 

15 or applications, the department, agency, or pro16 gram shall estimate by a documented calculation 

17 the total funds requested for that activity that 

18 would be used for drug control, and shall set 

19 forth in its request the basis and method for 

20 making the estimate.’’. 

21 (b) NATIONAL DRUG CONTROL BUDGET PROPOSAL.— 

22 (1) NATIONAL ORGANIZATIONS.—Section 

23 704(c)(2) is amended by inserting ‘‘and the head of 

24 each major national organization that represents law 

25 enforcement officers, agencies, or associations’’ after 

26 ‘‘agency’’. 


ccoleman on PROD1PC71 with BILLS
95 

•S 2560 RS

1 (2) TOTAL BUDGET.—Section 704(c)(2)(A) is 

2 amended by inserting before the semicolon: ‘‘and to 

3 inform Congress and the public about the total 

4 amount proposed to be spent on all supply reduction, 

5 demand reduction, State and local affairs, including 

6 any drug law enforcement, and other drug control ac7 tivities by the Federal Government, which shall con8 form to the content requirements set forth in para9 graph (1)(C)’’. 

10 (c) REVIEW AND CERTIFICATION OF NATIONAL DRUG

11 CONTROL PROGRAM BUDGET.—Section 704(c)(3) is amend12 ed— 

13 (1) by redesignating subparagraphs (C) and (D) 

14 as subparagraphs (D) and (E), respectively; 

15 (2) by inserting after subparagraph (B) the fol16 lowing new subparagraph: 

17 ‘‘(C) SPECIFIC REQUESTS.—The Director 

18 shall not confirm the adequacy of any budget re19 quest that— 

20 ‘‘(i) requests funding for Federal law 

21 enforcement activities that do not ade22 quately compensate for transfers of drug en23 forcement resources and personnel to law 

24 enforcement and investigation activities; 


ccoleman on PROD1PC71 with BILLS
96 

•S 2560 RS

1 ‘‘(ii) requests funding for law enforce2 ment activities on the borders of the United 

3 States that do not adequately direct re4 sources to drug interdiction and enforce5 ment; 

6 ‘‘(iii) requests funding for drug treat7 ment activities that do not provide adequate 

8 results and accountability measures; 

9 ‘‘(iv) requests funding for any activi10 ties of the Safe and Drug-Free Schools Pro11 gram that do not include a clear antidrug 

12 message or purpose intended to reduce drug 

13 use; 

14 ‘‘(v) requests funding for drug treat15 ment activities that do not adequately sup16 port and enhance Federal drug treatment 

17 programs and capacity; 

18 ‘‘(vi) requests funding for fiscal year 

19 2007 for activities of the Department of 

20 Education, unless it is accompanied by a 

21 report setting forth a plan for providing ex22 pedited consideration of student loan appli23 cations for all individuals who submitted 

24 an application for any Federal grant, loan, 

25 or work assistance that was rejected or deVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00096 Fmt 6652 Sfmt 6203 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
97 

•S 2560 RS

1 nied pursuant to 484(r)(1) of the Higher 

2 Education Act of 1965 (20 U.S.C. 

3 1091(r)(1)) by reason of a conviction for a 

4 drug-related offense not occurring during a 

5 period of enrollment for which the indi6 vidual was receiving any Federal grant, 

7 loan, or work assistance; and 

8 ‘‘(vii) requests funding for the oper9 ations and management of the Department 

10 of Homeland Security that does not include 

11 a specific request for funds for the Office of 

12 Counternarcotics Enforcement to carry out 

13 its responsibilities under section 878 of the 

14 Homeland Security Act of 2002 (6 U.S.C. 

15 458).’’; 

16 (3) in subparagraph (D)(iii), as so redesignated, 

17 by inserting ‘‘and the appropriate congressional com18 mittees’’ after ‘‘House of Representatives’’; and 

19 (4) in subparagraph (E)(ii)(II)(bb), as so redes20 ignated, by inserting ‘‘and the appropriate congres21 sional committees’’ after ‘‘House of Representatives’’. 

22 (d) POWERS OF DIRECTOR.—Section 704(d) is amend23 ed— 


ccoleman on PROD1PC71 with BILLS
98 

•S 2560 RS

1 (1) in paragraph (8)(D), by striking ‘‘have been 

2 authorized by Congress;’’ and inserting ‘‘authorized 

3 by law;’’; 

4 (2) in paragraph (9)— 

5 (A) by inserting ‘‘notwithstanding any 

6 other provision of law,’’ after ‘‘(9)’’; and 

7 (B) by striking ‘‘Strategy; and’’ and insert8 ing ‘‘Strategy and notify the appropriate con9 gressional committees of any fund control notice 

10 issued;’’; 

11 (3) in paragraph (10), by striking ‘‘(22 U.S.C. 

12 2291j).’’ and inserting ‘‘(22 U.S.C. 2291j) and section 

13 706 of the Foreign Relations Authorization Act, Fis14 cal Year 2003 (22 U.S.C. 2291j–1); and’’; and 

15 (4) by adding at the end the following new para16 graph: 

17 ‘‘(11) not later than August 1 of each year, sub18 mit to the President a report, and transmit copies of 

19 the report to the Secretary of State and the appro20 priate congressional committees, that— 

21 ‘‘(A) provides the Director’s assessment of 

22 which countries are major drug transit countries 

23 or major illicit drug producing countries as de24 fined in section 481(e) of the Foreign Assistance 

25 Act of 1961 (22 U.S.C. 2291(e)); 


ccoleman on PROD1PC71 with BILLS
99 

•S 2560 RS

1 ‘‘(B) provides the Director’s assessment of 

2 whether each country identified under subpara3 graph (A) has cooperated fully with the United 

4 States or has taken adequate steps on its own to 

5 achieve full compliance with the goals and objec6 tives established by the United Nations Conven7 tion Against Illicit Traffic in Narcotic Drugs 

8 and Psychotropic Substances and otherwise has 

9 assisted in reducing the supply of illicit drugs to 

10 the United States; and 

11 ‘‘(C) provides the Director’s assessment of 

12 whether application of procedures set forth in 

13 section 490 of the Foreign Assistance Act of 1961 

14 (22 U.S.C. 2291j), as provided in section 706 of 

15 the Foreign Relations Authorization Act, Fiscal 

16 Year 2003 (22 U.S.C. 2291j–1), is warranted 

17 with respect to countries the Director assesses 

18 have not cooperated fully.’’. 

19 (e) FUND CONTROL NOTICES.—Section 704(f) (21 

20 U.S.C. 1703(f)) is amended by adding at the end the fol21 lowing: 

22 ‘‘(4) CONGRESSIONAL NOTICE.—A copy of each 

23 fund control notice shall be transmitted to the appro24 priate congressional committees. 


ccoleman on PROD1PC71 with BILLS
100 

•S 2560 RS

1 ‘‘(5) RESTRICTIONS.—The Director shall not 

2 issue a fund control notice to direct that all or part 

3 of an amount appropriated to the National Drug 

4 Control Program agency account be obligated, modi5 fied, or altered in any manner contrary, in whole or 

6 in part, to a specific appropriation or statute.’’. 

7 TITLE II—THE NATIONAL DRUG 

8 CONTROL STRATEGY 

9 SEC. 201. ANNUAL PREPARATION AND SUBMISSION OF NA10 TIONAL DRUG CONTROL STRATEGY. 

11 Section 706 is amended to read as follows: 

12 ‘‘SEC. 706. DEVELOPMENT, SUBMISSION, IMPLEMENTATION, 

13 AND ASSESSMENT OF NATIONAL DRUG CON14 TROL STRATEGY. 

15 ‘‘(a) TIMING, CONTENTS, AND PROCESS FOR DEVELOP16 MENT AND SUBMISSION OF NATIONAL DRUG CONTROL

17 STRATEGY.— 

18 ‘‘(1) TIMING.—Not later than February 1 of each 

19 year, the President shall submit to Congress a Na20 tional Drug Control Strategy, which shall set forth a 

21 comprehensive plan for the year to reduce drug abuse 

22 and the consequences of such drug abuse in the United 

23 States by limiting the availability of, and reducing 

24 the demand for, illegal drugs. 

25 ‘‘(2) CONTENTS.— 


ccoleman on PROD1PC71 with BILLS
101 

•S 2560 RS

1 ‘‘(A) IN GENERAL.—The National Drug 

2 Control Strategy submitted under paragraph (1) 

3 shall include— 

4 ‘‘(i) comprehensive, research-based, 

5 long-range, quantifiable goals for reducing 

6 drug abuse and the consequences of drug 

7 abuse in the United States; 

8 ‘‘(ii) annual quantifiable and measur9 able objectives and specific targets to accom10 plish long-term quantifiable goals that the 

11 Director determines may be achieved during 

12 each year beginning on the date on which 

13 the National Drug Control Strategy is sub14 mitted; 

15 ‘‘(iii) 5-year projections for program 

16 and budget priorities; 

17 ‘‘(iv) a review of international, State, 

18 local, and private sector drug control activi19 ties to ensure that the United States pursues 

20 coordinated and effective drug control at all 

21 levels of government; 

22 ‘‘(v) an assessment of current illicit 

23 drug use (including inhalants) and avail24 ability, impact of illicit drug use, and 


ccoleman on PROD1PC71 with BILLS
102 

•S 2560 RS

1 treatment availability, which assessment 

2 shall include— 

3 ‘‘(I) estimates of drug prevalence 

4 and frequency of use as measured by 

5 national, State, and local surveys of il6 licit drug use and by other special 

7 studies of nondependent and dependent 

8 illicit drug use; 

9 ‘‘(II) illicit drug use in the work10 place and the productivity lost by such 

11 use; and 

12 ‘‘(III) illicit drug use by arrestees, 

13 probationers, and parolees; 

14 ‘‘(vi) an assessment of the reduction of 

15 illicit drug availability, as measured by— 

16 ‘‘(I) the quantities of cocaine, her17 oin, marijuana, methamphetamine, ec18 stasy, and other drugs available for 

19 consumption in the United States; 

20 ‘‘(II) the amount of marijuana, 

21 cocaine, heroin, methamphetamine, ec22 stasy, and precursor chemicals and 

23 other drugs entering the United States; 

24 ‘‘(III) the number of illicit drug 

25 manufacturing laboratories seized and 


ccoleman on PROD1PC71 with BILLS
103 

•S 2560 RS

1 destroyed and the number of hectares of 

2 marijuana, poppy, and coca cultivated 

3 and destroyed domestically and in 

4 other countries; 

5 ‘‘(IV) the number of metric tons of 

6 marijuana, heroin, cocaine, and meth7 amphetamine seized and other drugs; 

8 and 

9 ‘‘(V) changes in the price and pu10 rity of heroin, methamphetamine, and 

11 cocaine, changes in the price of ecstasy, 

12 and changes in tetrahydrocannabinol 

13 level of marijuana and other drugs; 

14 ‘‘(vii) an assessment of the reduction of 

15 the consequences of illicit drug use and 

16 availability, which shall include— 

17 ‘‘(I) the burden illicit drug users 

18 placed on hospital emergency depart19 ments in the United States, such as the 

20 quantity of illicit drug-related services 

21 provided; 

22 ‘‘(II) the annual national health 

23 care cost of illicit drug use; and 

24 ‘‘(III) the extent of illicit drug-re25 lated crime and criminal activity; 


ccoleman on PROD1PC71 with BILLS
104 

•S 2560 RS

1 ‘‘(viii) a determination of the status of 

2 drug treatment in the United States, by as3 sessing— 

4 ‘‘(I) public and private treatment 

5 utilization; and 

6 ‘‘(II) the number of illicit drug 

7 users the Director estimates meet diag8 nostic criteria for treatment; 

9 ‘‘(ix) a review of the research agenda of 

10 the Counterdrug Technology Assessment 

11 Center to reduce the availability and abuse 

12 of drugs; and 

13 ‘‘(x) a summary of the efforts made to 

14 coordinate with private sector entities to 

15 conduct private research and development of 

16 medications to treat addiction by— 

17 ‘‘(I) screening chemicals for poten18 tial therapeutic value; 

19 ‘‘(II) developing promising com20 pounds; 

21 ‘‘(III) conducting clinical trials; 

22 ‘‘(IV) seeking Food and Drug Ad23 ministration approval for drugs to 

24 treat addiction; 


ccoleman on PROD1PC71 with BILLS
105 

•S 2560 RS

1 ‘‘(V) marketing the drug for the 

2 treatment of addiction; 

3 ‘‘(VI) urging physicians to use the 

4 drug in the treatment of addiction; 

5 and 

6 ‘‘(VII) encouraging insurance 

7 companies to reimburse the cost of the 

8 drug for the treatment of addiction. 

9 ‘‘(B) CLASSIFIED INFORMATION.—Any con10 tents of the National Drug Control Strategy that 

11 involve information properly classified under 

12 criteria established by an Executive order shall 

13 be presented to Congress separately from the rest 

14 of the National Drug Control Strategy. 

15 ‘‘(3) PROCESS FOR DEVELOPMENT AND SUBMIS16 SION.—In developing and effectively implementing 

17 the National Drug Control Strategy, the Director— 

18 ‘‘(A) shall consult with— 

19 ‘‘(i) the heads of the National Drug 

20 Control Program agencies; 

21 ‘‘(ii) Congress; 

22 ‘‘(iii) State and local officials; 

23 ‘‘(iv) private citizens and organiza24 tions with experience and expertise in de25 mand reduction; 


ccoleman on PROD1PC71 with BILLS
106 

•S 2560 RS

1 ‘‘(v) private citizens and organizations 

2 with experience and expertise in supply re3 duction; and 

4 ‘‘(vi) appropriate representatives of 

5 foreign governments; 

6 ‘‘(B) in satisfying the requirements of sub7 paragraph (A), shall ensure, to the maximum ex8 tent possible, that State and local officials and 

9 relevant private organizations commit to support 

10 and take steps to achieve the goals and objectives 

11 of the National Drug Control Strategy; 

12 ‘‘(C) with the concurrence of the Attorney 

13 General, may require the El Paso Intelligence 

14 Center to undertake specific tasks or projects to 

15 support or implement the National Drug Control 

16 Strategy; and 

17 ‘‘(D) with the concurrence of the Director of 

18 National Intelligence and the Attorney General, 

19 may request that the National Drug Intelligence 

20 Center undertake specific tasks or projects to 

21 support or implement the National Drug Control 

22 Strategy. 

23 ‘‘(b) SUBMISSION OF REVISED STRATEGY.—The Presi24 dent may submit to Congress a revised National Drug Con25 trol Strategy that meets the requirements of this section— 


ccoleman on PROD1PC71 with BILLS
107 

•S 2560 RS

1 ‘‘(1) at any time, upon a determination of the 

2 President, in consultation with the Director, that the 

3 National Drug Control Strategy in effect is not suffi4 ciently effective; or 

5 ‘‘(2) if a new President or Director takes office.’’. 

6 SEC. 202. PERFORMANCE MEASUREMENTS. 

7 Section 706 is amended by adding at the end the fol8 lowing: 

9 ‘‘(c) PERFORMANCE MEASUREMENT SYSTEM.—Not 

10 later than February 1 of each year, the Director shall sub11 mit to Congress as part of the National Drug Control Strat12 egy, a description of a national drug control performance 

13 measurement system, that— 

14 ‘‘(1) develops 2-year and 5-year performance 

15 measures and targets for each National Drug Control 

16 Strategy goal and objective established for reducing 

17 drug use, availability, and the consequences of drug 

18 use; 

19 ‘‘(2) describes the sources of information and 

20 data that will be used for each performance measure 

21 incorporated into the performance measurement sys22 tem; 

23 ‘‘(3) identifies major programs and activities of 

24 the National Drug Control Program agencies that 


ccoleman on PROD1PC71 with BILLS
108 

•S 2560 RS

1 support the goals and annual objectives of the Na2 tional Drug Control Strategy; 

3 ‘‘(4) evaluates the contribution of demand reduc4 tion and supply reduction activities as defined in sec5 tion 702 implemented by each National Drug Control 

6 Program agency in support of the National Drug 

7 Control Strategy; 

8 ‘‘(5) monitors consistency between the drug-re9 lated goals and objectives of the National Drug Con10 trol Program agencies and ensures that each agency’s 

11 goals and budgets support and are fully consistent 

12 with the National Drug Control Strategy; and 

13 ‘‘(6) coordinates the development and implemen14 tation of national drug control data collection and re15 porting systems to support policy formulation and 

16 performance measurement, including an assessment 

17 of— 

18 ‘‘(A) the quality of current drug use meas19 urement instruments and techniques to measure 

20 supply reduction and demand reduction activi21 ties; 

22 ‘‘(B) the adequacy of the coverage of exist23 ing national drug use measurement instruments 

24 and techniques to measure the casual drug use 


ccoleman on PROD1PC71 with BILLS
109 

•S 2560 RS

1 population, the addicted drug user population, 

2 and groups that are at risk for drug use; 

3 ‘‘(C) the adequacy of the coverage of existing 

4 national treatment outcome monitoring systems 

5 to measure the effectiveness of drug abuse treat6 ment in reducing drug use and criminal behav7 ior during and after the completion of substance 

8 abuse treatment; and 

9 ‘‘(D) the actions the Director shall take to 

10 correct any deficiencies and limitations identi11 fied pursuant to subparagraphs (A) and (B) of 

12 this subsection. 

13 ‘‘(d) MODIFICATIONS.—A description of any modifica14 tions made during the preceding year to the national drug 

15 performance measurement system described in subsection 

16 (c) shall be included in each report submitted under sub17 section (b).’’. 

18 SEC. 203. ANNUAL REPORT REQUIREMENT. 

19 (a) IN GENERAL.—On or before February 1 of each 

20 year, the Director shall submit a report to Congress that 

21 describes— 

22 (1) the strategy of the national media campaign 

23 and whether specific objectives of the campaign were 

24 accomplished; 


ccoleman on PROD1PC71 with BILLS
110 

•S 2560 RS

1 (2) steps taken to ensure that the national media 

2 campaign operates in an effective and efficient man3 ner consistent with the overall strategy and focus of 

4 the campaign; 

5 (3) plans to purchase advertising time and 

6 space; 

7 (4) policies and practices implemented to ensure 

8 that Federal funds are used responsibly to purchase 

9 advertising time and space and eliminate the poten10 tial for waste, fraud, and abuse; 

11 (5) all contracts entered into with a corporation, 

12 partnership, or individual working on behalf of the 

13 national media campaign; 

14 (6) specific policies and steps implemented to en15 sure compliance with title IV of this Act; 

16 (7) steps taken to ensure that the national media 

17 campaign will secure, to the maximum extent pos18 sible, no cost matches of advertising time and space 

19 or in-kind contributions that are directly related to 

20 the campaign in accordance with title IV of this Act; 

21 and 

22 (8) a review and evaluation of the effectiveness 

23 of the national media campaign strategy for the past 

24 year. 


ccoleman on PROD1PC71 with BILLS
111 

•S 2560 RS

1 (b) AUDIT.—The Government Accountability Office 

2 shall, at a frequency of not less than once per year— 

3 (1) conduct and supervise an audit and inves4 tigation relating to the programs and operations of 

5 the— 

6 (A) Office; or 

7 (B) certain programs within the Office, in8 cluding— 

9 (i) the High Intensity Drug Traf10 ficking Areas Program; 

11 (ii) the Counterdrug Technology As12 sessment Center; or 

13 (iii) the National Youth Anti-drug 

14 Media Campaign; and 

15 (2) provide the Director and the appropriate 

16 congressional committees with a report containing an 

17 evaluation of and recommendations on the— 

18 (A) policies and activities of the programs 

19 and operations subject to the audit and inves20 tigation; 

21 (B) economy, efficiency, and effectiveness in 

22 the administration of the reviewed programs and 

23 operations; and 


ccoleman on PROD1PC71 with BILLS
112 

•S 2560 RS

1 (C) policy or management changes needed 

2 to prevent and detect fraud and abuse in such 

3 programs and operations. 

4 TITLE III—HIGH INTENSITY 

5 DRUG TRAFFICKING AREAS 

6 SEC. 301. HIGH INTENSITY DRUG TRAFFICKING AREAS PRO7 GRAM. 

8 Section 707 is amended to read as follows: 

9 ‘‘SEC. 707. HIGH INTENSITY DRUG TRAFFICKING AREAS 

10 PROGRAM. 

11 ‘‘(a) ESTABLISHMENT.— 

12 ‘‘(1) IN GENERAL.—There is established in the 

13 Office a program to be known as the High Intensity 

14 Drug Trafficking Areas Program (in this section re15 ferred to as the ‘Program’). 

16 ‘‘(2) PURPOSE.—The purpose of the Program is 

17 to reduce drug trafficking and drug production in the 

18 United States by— 

19 ‘‘(A) facilitating cooperation among Fed20 eral, State, and local law enforcement agencies to 

21 share information and implement coordinated 

22 enforcement activities; 

23 ‘‘(B) enhancing intelligence sharing among 

24 Federal, State, and local law enforcement agen25 cies; 


ccoleman on PROD1PC71 with BILLS
113 

•S 2560 RS

1 ‘‘(C) providing reliable intelligence to law 

2 enforcement agencies needed to design effective 

3 enforcement strategies and operations; and 

4 ‘‘(D) supporting coordinated law enforce5 ment strategies which maximize use of available 

6 resources to reduce the supply of illegal drugs in 

7 designated areas and in the United States as a 

8 whole. 

9 ‘‘(b) DESIGNATION.— 

10 ‘‘(1) IN GENERAL.—The Director, in consultation 

11 with the Attorney General, the Secretary of the Treas12 ury, the Secretary of Homeland Security, heads of the 

13 National Drug Control Program agencies, and the 

14 Governor of each applicable State, may designate any 

15 specified area of the United States as a high intensity 

16 drug trafficking area. 

17 ‘‘(2) ACTIVITIES.—After making a designation 

18 under paragraph (1) and in order to provide Federal 

19 assistance to the area so designated, the Director 

20 may— 

21 ‘‘(A) obligate such sums as are appropriated 

22 for the Program; 

23 ‘‘(B) direct the temporary reassignment of 

24 Federal personnel to such area, subject to the apVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00113 Fmt 6652 Sfmt 6203 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
114 

•S 2560 RS

1 proval of the head of the department or agency 

2 that employs such personnel; 

3 ‘‘(C) take any other action authorized under 

4 section 704 to provide increased Federal assist5 ance to those areas; and 

6 ‘‘(D) coordinate activities under this section 

7 (specifically administrative, recordkeeping, and 

8 funds management activities) with State and 

9 local officials. 

10 ‘‘(c) PETITIONS FOR DESIGNATION.—The Director 

11 shall establish regulations under which a coalition of inter12 ested law enforcement agencies from an area may petition 

13 for designation as a high intensity drug trafficking area. 

14 Such regulations shall provide for a regular review by the 

15 Director of the petition, including a recommendation re16 garding the merit of the petition to the Director by a panel 

17 of qualified, independent experts. 

18 ‘‘(d) FACTORS FOR CONSIDERATION.—In considering 

19 whether to designate an area under this section as a high 

20 intensity drug trafficking area, the Director shall consider, 

21 in addition to such other criteria as the Director considers 

22 to be appropriate, the extent to which— 

23 ‘‘(1) the area is a significant center of illegal 

24 drug production, manufacturing, importation, or dis25 tribution; 


ccoleman on PROD1PC71 with BILLS
115 

•S 2560 RS

1 ‘‘(2) State and local law enforcement agencies 

2 have committed resources to respond to the drug traf3 ficking problem in the area, thereby indicating a de4 termination to respond aggressively to the problem; 

5 ‘‘(3) drug-related activities in the area are hav6 ing a significant harmful impact in the area, and in 

7 other areas of the country; and 

8 ‘‘(4) a significant increase in allocation of Fed9 eral resources is necessary to respond adequately to 

10 drug-related activities in the area. 

11 ‘‘(e) ORGANIZATION OF HIGH INTENSITY DRUG TRAF12 FICKING AREAS.— 

13 ‘‘(1) EXECUTIVE BOARD AND OFFICERS.—To be 

14 eligible for funds appropriated under this section, 

15 each high intensity drug trafficking area shall be gov16 erned by an Executive Board. The Executive Board 

17 shall designate a chairman, vice chairman, and any 

18 other officers to the Executive Board that it deter19 mines are necessary. 

20 ‘‘(2) RESPONSIBILITIES.—The Executive Board 

21 of a high intensity drug trafficking area shall be re22 sponsible for— 

23 ‘‘(A) providing direction and oversight in 

24 establishing and achieving the goals of the high 

25 intensity drug trafficking area; 


ccoleman on PROD1PC71 with BILLS
116 

•S 2560 RS

1 ‘‘(B) managing the funds of the high inten2 sity drug trafficking area; 

3 ‘‘(C) reviewing and approving all funding 

4 proposals consistent with the overall objective of 

5 the high intensity drug trafficking area; and 

6 ‘‘(D) reviewing and approving all reports to 

7 the Director on the activities of the high inten8 sity drug trafficking area. 

9 ‘‘(3) BOARD REPRESENTATION.—None of the 

10 funds appropriated under this section may be ex11 pended for any high intensity drug trafficking area, 

12 or for a partnership or region of a high intensity 

13 drug trafficking area, if the Executive Board for such 

14 area, region, or partnership, does not apportion an 

15 equal number of votes between representatives of par16 ticipating Federal agencies and representatives of 

17 participating State and local agencies. Where it is 

18 impractical for an equal number of representatives of 

19 Federal agencies and State and local agencies to at20 tend a meeting of an Executive Board in person, the 

21 Executive Board may use a system of proxy votes or 

22 weighted votes to achieve the voting balance required 

23 by this paragraph. 

24 ‘‘(4) NO AGENCY RELATIONSHIP.—The eligibility 

25 requirements of this section are intended to ensure the 


ccoleman on PROD1PC71 with BILLS
117 

•S 2560 RS

1 responsible use of Federal funds. Nothing in this sec2 tion is intended to create an agency relationship be3 tween individual high intensity drug trafficking areas 

4 and the Federal Government. 

5 ‘‘(f) USE OF FUNDS.—The Director shall ensure that 

6 no Federal funds appropriated for the Program are ex7 pended for the establishment or expansion of drug treatment 

8 programs, and shall ensure that not more than 5 percent 

9 of the Federal funds appropriated for the Program are ex10 pended for the establishment of drug prevention programs. 

11 ‘‘(g) COUNTERTERRORISM ACTIVITIES.— 

12 ‘‘(1) ASSISTANCE AUTHORIZED.—The Director 

13 may authorize use of resources available for the Pro14 gram to assist Federal, State, and local law enforce15 ment agencies in investigations and activities related 

16 to terrorism and prevention of terrorism, especially 

17 but not exclusively with respect to such investigations 

18 and activities that are also related to drug trafficking. 

19 ‘‘(2) LIMITATION.—The Director shall ensure— 

20 ‘‘(A) that assistance provided under para21 graph (1) remains incidental to the purpose of 

22 the Program to reduce drug availability and 

23 carry out drug-related law enforcement activi24 ties; and 


ccoleman on PROD1PC71 with BILLS
118 

•S 2560 RS

1 ‘‘(B) that significant resources of the Pro2 gram are not redirected to activities exclusively 

3 related to terrorism, except on a temporary basis 

4 under extraordinary circumstances, as deter5 mined by the Director. 

6 ‘‘(h) ROLE OF DRUG ENFORCEMENT ADMINISTRA7 TION.—The Director, in consultation with the Attorney 

8 General, shall ensure that a representative of the Drug En9 forcement Administration is included in the Intelligence 

10 Support Center for each high intensity drug trafficking 

11 area. 

12 ‘‘(i) ANNUAL HIDTA PROGRAM BUDGET SUBMIS13 SIONS.—As part of the documentation that supports the 

14 President’s annual budget request for the Office, the Direc15 tor shall submit to Congress a budget justification that in16 cludes— 

17 ‘‘(1) the amount requested for each high intensity 

18 drug trafficking area, with supporting narrative de19 scriptions and rationale for each request; and 

20 ‘‘(2) a detailed justification for each funding re21 quest that explains— 

22 ‘‘(A) the reasons for the requested funding 

23 level; how such funding level was determined 

24 based on a current assessment of the drug trafVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00118 Fmt 6652 Sfmt 6203 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
119 

•S 2560 RS

1 ficking threat in each high intensity drug traf2 ficking area; 

3 ‘‘(B) how such funding will ensure that the 

4 goals and objectives of each such area will be 

5 achieved; and 

6 ‘‘(C) how such funding supports the Na7 tional Drug Control Strategy. 

8 ‘‘(j) EMERGING THREAT RESPONSE FUND.— 

9 ‘‘(1) IN GENERAL.—Subject to the availability of 

10 appropriations, the Director may expend up to 10 

11 percent of the amounts appropriated under this sec12 tion on a discretionary basis, to respond to any 

13 emerging drug trafficking threat in an existing high 

14 intensity drug trafficking area, or to establish a new 

15 high intensity drug trafficking area or expand an ex16 isting high intensity drug trafficking area, in accord17 ance with the criteria established under paragraph 

18 (2). 

19 ‘‘(2) CONSIDERATION OF IMPACT.—In allocating 

20 funds under this subsection, the Director shall con21 sider— 

22 ‘‘(A) the impact of activities funded on re23 ducing overall drug traffic in the United States, 

24 or minimizing the probability that an emerging 


ccoleman on PROD1PC71 with BILLS
120 

•S 2560 RS

1 drug trafficking threat will spread to other areas 

2 of the United States; and 

3 ‘‘(B) such other criteria as the Director con4 siders appropriate. 

5 ‘‘(k) EVALUATION.— 

6 ‘‘(1) INITIAL REPORT.—Not later than 90 days 

7 after the date of the enactment of this section, the Di8 rector shall, after consulting with the Executive 

9 Boards of each designated high intensity drug traf10 ficking area, submit a report to Congress that de11 scribes, for each designated high intensity drug traf12 ficking area— 

13 ‘‘(A) the specific purposes for the high in14 tensity drug trafficking area; 

15 ‘‘(B) the specific long-term and short-term 

16 goals and objectives for the high intensity drug 

17 trafficking area; 

18 ‘‘(C) the measurements that will be used to 

19 evaluate the performance of the high intensity 

20 drug trafficking area in achieving the long-term 

21 and short-term goals; and 

22 ‘‘(D) the reporting requirements needed to 

23 evaluate the performance of the high intensity 

24 drug trafficking area in achieving the long-term 

25 and short-term goals. 


ccoleman on PROD1PC71 with BILLS
121 

•S 2560 RS

1 ‘‘(2) EVALUATION OF HIDTA PROGRAM AS PART

2 OF NATIONAL DRUG CONTROL STRATEGY.—For each 

3 designated high intensity drug trafficking area, the 

4 Director shall submit, as part of the annual National 

5 Drug Control Strategy report, a report that— 

6 ‘‘(A) describes— 

7 ‘‘(i) the specific purposes for the high 

8 intensity drug trafficking area; and 

9 ‘‘(ii) the specific long-term and short10 term goals and objectives for the high inten11 sity drug trafficking area; and 

12 ‘‘(B) includes an evaluation of the perform13 ance of the high intensity drug trafficking area 

14 in accomplishing the specific long-term and 

15 short-term goals and objectives identified under 

16 paragraph (1)(B). 

17 ‘‘(l) ASSESSMENT OF DRUG ENFORCEMENT TASK

18 FORCES IN HIGH INTENSITY DRUG TRAFFICKING AREAS.— 

19 Not later than 180 days after the date of enactment of this 

20 subsection, and as part of each subsequent annual National 

21 Drug Control Strategy report, the Director shall submit to 

22 Congress a report— 

23 ‘‘(1) assessing the number and operation of all 

24 federally funded drug enforcement task forces within 

25 each high intensity drug trafficking area; and 


ccoleman on PROD1PC71 with BILLS
122 

•S 2560 RS

1 ‘‘(2) describing— 

2 ‘‘(A) each Federal, State, and local drug en3 forcement task force operating in the high inten4 sity drug trafficking area; 

5 ‘‘(B) how such task forces coordinate with 

6 each other, with any high intensity drug traf7 ficking area task force, and with investigations 

8 receiving funds from the Organized Crime and 

9 Drug Enforcement Task Force; 

10 ‘‘(C) what steps, if any, each such task force 

11 takes to share information regarding drug traf12 ficking and drug production with other federally 

13 funded drug enforcement task forces in the high 

14 intensity drug trafficking area; 

15 ‘‘(D) the role of the high intensity drug traf16 ficking area in coordinating the sharing of such 

17 information among task forces; 

18 ‘‘(E) the nature and extent of cooperation 

19 by each Federal, State, and local participant in 

20 ensuring that such information is shared among 

21 law enforcement agencies and with the high in22 tensity drug trafficking area; 

23 ‘‘(F) the nature and extent to which infor24 mation sharing and enforcement activities are 


ccoleman on PROD1PC71 with BILLS
123 

•S 2560 RS

1 coordinated with joint terrorism task forces in 

2 the high intensity drug trafficking area; and 

3 ‘‘(G) any recommendations for measures 

4 needed to ensure that task force resources are uti5 lized efficiently and effectively to reduce the 

6 availability of illegal drugs in the high intensity 

7 drug trafficking areas. 

8 ‘‘(m) ASSESSMENT OF INTELLIGENCE SHARING IN

9 HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM.— 

10 Not later than 180 days after the date of the enactment of 

11 this section, and as part of each subsequent annual Na12 tional Drug Control Strategy report, the Director, in con13 sultation with the Director of National Intelligence, shall 

14 submit to Congress a report— 

15 ‘‘(1) evaluating existing and planned intelligence 

16 systems supported by each high intensity drug traf17 ficking area, or utilized by task forces receiving any 

18 funding under the Program, including the extent to 

19 which such systems ensure access and availability of 

20 intelligence to Federal, State, and local law enforce21 ment agencies within the high intensity drug traf22 ficking area and outside of it; 

23 ‘‘(2) the extent to which Federal, State, and local 

24 law enforcement agencies participating in each high 

25 intensity drug trafficking area are sharing intelVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00123 Fmt 6652 Sfmt 6203 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
124 

•S 2560 RS

1 ligence information to assess current drug trafficking 

2 threats and design appropriate enforcement strategies; 

3 and 

4 ‘‘(3) the measures needed to improve effective 

5 sharing of information and intelligence regarding 

6 drug trafficking and drug production among Federal, 

7 State, and local law enforcement participating in a 

8 high intensity drug trafficking area, and between 

9 such agencies and similar agencies outside the high 

10 intensity drug trafficking area. 

11 ‘‘(n) COORDINATION OF INTELLIGENCE SHARING

12 WITH ORGANIZED CRIME DRUG ENFORCEMENT TASK

13 FORCE PROGRAM.—The Director, in consultation with the 

14 Attorney General, shall ensure that any drug enforcement 

15 intelligence obtained by the Intelligence Support Center for 

16 each high intensity drug trafficking area is shared, on a 

17 timely basis, with the drug intelligence fusion center oper18 ated by the Organized Crime Drug Enforcement Task Force 

19 of the Department of Justice. 

20 ‘‘(o) USE OF FUNDS TO COMBAT METHAMPHETAMINE

21 TRAFFICKING.— 

22 ‘‘(1) IN GENERAL.— 

23 ‘‘(A) REQUIREMENT.—The Director shall 

24 ensure that, of the amounts appropriated for a 

25 fiscal year for the Program, at least $15,000,000 


ccoleman on PROD1PC71 with BILLS
125 

•S 2560 RS

1 is allocated to combat the trafficking of meth2 amphetamine in areas designated by the Direc3 tor as high intensity drug trafficking areas. 

4 ‘‘(B) ACTIVITIES.—In meeting the require5 ment in subparagraph (A), the Director shall 

6 transfer funds to appropriate Federal, State, and 

7 local governmental agencies for employing addi8 tional Federal law enforcement personnel, or fa9 cilitating the employment of additional State 

10 and local law enforcement personnel, including 

11 agents, investigators, prosecutors, laboratory 

12 technicians, chemists, investigative assistants, 

13 and drug prevention specialists. 

14 ‘‘(2) APPORTIONMENT OF FUNDS.— 

15 ‘‘(A) FACTORS IN APPORTIONMENT.—The 

16 Director shall apportion amounts allocated 

17 under paragraph (1) among areas designated by 

18 the Director as high intensity drug trafficking 

19 areas based on the following factors: 

20 ‘‘(i) The number of methamphetamine 

21 manufacturing facilities discovered by Fed22 eral, State, or local law enforcement offi23 cials in the area during the previous fiscal 

24 year. 


ccoleman on PROD1PC71 with BILLS
126 

•S 2560 RS

1 ‘‘(ii) The number of methamphetamine 

2 prosecutions in Federal, State, or local 

3 courts in the area during the previous fiscal 

4 year. 

5 ‘‘(iii) The number of methamphet6 amine arrests by Federal, State, or local 

7 law enforcement officials in the area during 

8 the previous fiscal year. 

9 ‘‘(iv) The amounts of methamphet10 amine or listed chemicals (as that term is 

11 defined in section 102(33) of the Controlled 

12 Substances Act (21 U.S.C. 802(33)) seized 

13 by Federal, State, or local law enforcement 

14 officials in the area during the previous fis15 cal year. 

16 ‘‘(v) Intelligence and predictive data 

17 from the Drug Enforcement Administration 

18 showing patterns and trends in abuse, traf19 ficking, and transportation in methamphet20 amine and listed chemicals (as that term is 

21 so defined). 

22 ‘‘(B) CERTIFICATION.—Before the Director 

23 apportions any funds under this paragraph to a 

24 high intensity drug trafficking area, the Director 

25 shall certify that the law enforcement entities reVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00126 Fmt 6652 Sfmt 6203 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
127 

•S 2560 RS

1 sponsible for clandestine methamphetamine lab2 oratory seizures in that area are providing lab3 oratory seizure data to the national clandestine 

4 laboratory database at the El Paso Intelligence 

5 Center. 

6 ‘‘(p) AUTHORIZATION OF APPROPRIATIONS.—There is 

7 authorized to be appropriated to the Office of National 

8 Drug Control Policy to carry out this section— 

9 ‘‘(1) $280,000,000 for fiscal year 2007; 

10 ‘‘(2) $290,000,000 for each of fiscal years 2008 

11 and 2009; and 

12 ‘‘(3) $300,000,000 for each of fiscal years 2010 

13 and 2011.’’. 

14 SEC. 302. FUNDING FOR CERTAIN HIGH INTENSITY DRUG 

15 TRAFFICKING AREAS. 

16 (a) SHORT TITLE.—This section may be cited as the 

17 ‘‘Dawson Family Community Protection Act’’. 

18 (b) FINDINGS.—Congress finds the following: 

19 (1) In the early morning hours of October 16, 

20 2002, the home of Carnell and Angela Dawson was 

21 firebombed in apparent retaliation for Mrs. Dawson’s 

22 notification to police about persistent drug distribu23 tion activity in their East Baltimore City neighbor24 hood. 


ccoleman on PROD1PC71 with BILLS
128 

•S 2560 RS

1 (2) The arson claimed the lives of Mr. and Mrs. 

2 Dawson and their 5 young children, aged 9 to 14. 

3 (3) The horrific murder of the Dawson family is 

4 a stark example of domestic narco-terrorism. 

5 (4) In all phases of counternarcotics law enforce6 ment—from prevention to investigation to prosecu7 tion to reentry—the voluntary cooperation of ordi8 nary citizens is a critical component. 

9 (5) Voluntary cooperation is difficult for law en10 forcement officials to obtain when citizens feel that co11 operation carries the risk of violent retaliation by ille12 gal drug trafficking organizations and their affiliates. 

13 (6) Public confidence that law enforcement is 

14 doing all it can to make communities safe is a pre15 requisite for voluntary cooperation among people who 

16 may be subject to intimidation or reprisal (or both). 

17 (7) Witness protection programs are insufficient 

18 on their own to provide security because many indi19 viduals and families who strive every day to make 

20 distressed neighborhoods livable for their children, 

21 other relatives, and neighbors will resist or refuse of22 fers of relocation by local, State, and Federal prosecu23 torial agencies and because, moreover, the continued 

24 presence of strong individuals and families is critical 


ccoleman on PROD1PC71 with BILLS
129 

•S 2560 RS

1 to preserving and strengthening the social fabric in 

2 such communities. 

3 (8) Where (as in certain sections of Baltimore 

4 City) interstate trafficking of illegal drugs has severe 

5 ancillary local consequences within areas designated 

6 as high intensity drug trafficking areas, it is impor7 tant that supplementary High Intensity Drug Traf8 ficking Areas Program funds be committed to support 

9 initiatives aimed at making the affected communities 

10 safe for the residents of those communities and en11 couraging their cooperation with local, State, and 

12 Federal law enforcement efforts to combat illegal drug 

13 trafficking. 

14 (c) FUNDING FOR CERTAIN HIGH INTENSITY DRUG

15 TRAFFICKING AREAS.—Section 707, as amended by section 

16 301, is amended by adding at the end the following: 

17 ‘‘(q) SPECIFIC PURPOSES.— 

18 ‘‘(1) IN GENERAL.—The Director shall ensure 

19 that, of the amounts appropriated for a fiscal year for 

20 the Program, at least $7,000,000 is used in high in21 tensity drug trafficking areas with severe neighbor22 hood safety and illegal drug distribution problems. 

23 ‘‘(2) REQUIRED USES.—The funds used under 

24 paragraph (1) shall be used— 


ccoleman on PROD1PC71 with BILLS
130 

•S 2560 RS

1 ‘‘(A) to ensure the safety of neighborhoods 

2 and the protection of communities, including the 

3 prevention of the intimidation of potential wit4 nesses of illegal drug distribution and related ac5 tivities; and 

6 ‘‘(B) to combat illegal drug trafficking 

7 through such methods as the Director considers 

8 appropriate, such as establishing or operating 

9 (or both) a toll-free telephone hotline for use by 

10 the public to provide information about illegal 

11 drug-related activities.’’. 

12 SEC. 303. ASSESSMENT. 

13 The Director shall assess the ability of the HIDTA Pro14 gram to respond to the so-called ‘‘balloon effect’’, whereby 

15 urban drug traffickers facing intensive law enforcement ef16 forts expand and spread their trafficking and distribution 

17 into rural, suburban, and smaller urban areas by con18 ducting a demonstration project examining the ability of 

19 the New York/New Jersey HIDTA, with its new single co20 located Organized Crime and Drug Enforcement Task 

21 Force/High Intensity Drug Trafficking Area Strike Force 

22 and HIDTA Regional Intelligence Center, to address the 

23 movement of drug traffickers into the more rural, suburban, 

24 and smaller areas encompassed by the counties of Albany, 

25 Onondaga, Monroe, and Erie in New York State and by 


ccoleman on PROD1PC71 with BILLS
131 

•S 2560 RS

1 annexing these counties into the existing New York/New 

2 Jersey HIDTA. 

3 TITLE IV—TECHNOLOGY 

4 SEC. 401. COUNTERDRUG TECHNOLOGY ASSESSMENT CEN5 TER. 

6 (a) CHIEF SCIENTIST.—Section 708(b) is amended to 

7 read as follows: 

8 ‘‘(b) CHIEF SCIENTIST.—There shall be at the head of 

9 the Center the Chief Scientist, who shall be appointed by 

10 the Director from among individuals qualified and distin11 guished in the area of science, medicine, engineering, or 

12 technology.’’. 

13 (b) RESPONSIBILITIES.— 

14 (1) RESEARCH AND DEVELOPMENT.—Section 

15 708 is amended by— 

16 (A) redesignating subsection (d) as sub17 section (e); and 

18 (B) striking subsection (c) and inserting the 

19 following: 

20 ‘‘(c) RESEARCH AND DEVELOPMENT RESPONSIBIL21 ITIES.—The Chief Scientist shall be responsible to the Di22 rector for— 

23 ‘‘(1) identifying and defining the short-, me24 dium-, and long-term scientific and technological 


ccoleman on PROD1PC71 with BILLS
132 

•S 2560 RS

1 needs of Federal, State, and local drug supply reduc2 tion agencies, including— 

3 ‘‘(A) advanced surveillance, tracking, and 

4 radar imaging; 

5 ‘‘(B) electronic support measures; 

6 ‘‘(C) communications; 

7 ‘‘(D) data fusion, advanced computer sys8 tems, and artificial intelligence; and 

9 ‘‘(E) chemical, biological, radiological (in10 cluding neutron and electron), and other means 

11 of detection; 

12 ‘‘(2) identifying demand reduction basic and ap13 plied research needs and initiatives, in consultation 

14 with affected National Drug Control Program agen15 cies, including— 

16 ‘‘(A) improving treatment through 

17 neuroscientific advances; 

18 ‘‘(B) improving the transfer of biomedical 

19 research to the clinical setting; and 

20 ‘‘(C) in consultation with the National In21 stitute of Drug Abuse, and through interagency 

22 agreements or grants, examining addiction and 

23 rehabilitation research and the application of 

24 technology to expanding the effectiveness and 

25 availability of drug treatment; 


ccoleman on PROD1PC71 with BILLS
133 

•S 2560 RS

1 ‘‘(3) making a priority ranking of such needs 

2 identified in paragraphs (1) and (2) according to fis3 cal and technological feasibility, as part of a National 

4 Counterdrug Research and Development Program; 

5 ‘‘(4) overseeing and coordinating counterdrug 

6 technology initiatives with related activities of other 

7 Federal civilian and military departments; 

8 ‘‘(5) providing support to the development and 

9 implementation of the national drug control perform10 ance measurement system established under subsection 

11 (c) of section 706; and 

12 ‘‘(6) transferring funds made available to a Na13 tional Drug Control Program Agency for counterdrug 

14 technology research and development to another ac15 count within such agency or to another National 

16 Drug Control Program Agency for counterdrug tech17 nology research and development, pursuant to the au18 thority of the Director under section 704. 

19 ‘‘(d) LIMITATION ON AUTHORITY.—The authority 

20 granted to the Director under this section shall not extend 

21 to the awarding of contracts, management of individual 

22 projects, or other operational activities.’’. 

23 (2) ASSISTANCE AND SUPPORT.—Subsection (e) 

24 of section 708, as redesignated by this section, is 

25 amended to read as follows: 


ccoleman on PROD1PC71 with BILLS
134 

•S 2560 RS

1 ‘‘(e) ASSISTANCE AND SUPPORT TO THE OFFICE OF

2 NATIONAL DRUG CONTROL POLICY.—The Secretary of De3 fense, the Secretary of Homeland Security, and the Sec4 retary of Health and Human Services shall, to the max5 imum extent practicable, render assistance and support to 

6 the Office and to the Director in the conduct of counterdrug 

7 technology assessment.’’. 

8 (3) TECHNOLOGY TRANSFER PROGRAM.—Section 

9 708 is amended by adding at the end the following: 

10 ‘‘(f) TECHNOLOGY TRANSFER PROGRAM.— 

11 ‘‘(1) PROGRAM.—The Chief Scientist, with the 

12 advice and counsel of experts from State and local 

13 law enforcement agencies, shall be responsible to the 

14 Director for coordination and implementation of a 

15 counterdrug technology transfer program. 

16 ‘‘(2) PURPOSE.—The purpose of the Technology 

17 Transfer Program shall be for the Counterdrug Tech18 nology Assessment Center to transfer technology and 

19 associated training directly to State and local law en20 forcement agencies. 

21 ‘‘(3) PRIORITY OF RECEIPTS.—Transfers shall be 

22 made in priority order based on— 

23 ‘‘(A) the need of potential recipients for 

24 such technology; 


ccoleman on PROD1PC71 with BILLS
135 

•S 2560 RS

1 ‘‘(B) the effectiveness of the technology to 

2 enhance current counterdrug activities of poten3 tial recipients; and 

4 ‘‘(C) the ability and willingness of potential 

5 recipients to evaluate transferred technology. 

6 ‘‘(4) AGREEMENT AUTHORITY.—The Director 

7 may enter into an agreement with the Secretary of 

8 Homeland Security to transfer technology with both 

9 counterdrug and homeland security applications to 

10 State and local law enforcement agencies on a reim11 bursable basis. 

12 ‘‘(5) REPORT.—On or before July 1 of each year, 

13 the Director shall submit a report to the appropriate 

14 congressional committees which addresses the fol15 lowing: 

16 ‘‘(A) The number of requests received during 

17 the previous 12 months. 

18 ‘‘(B) The number of requests fulfilled during 

19 the previous 12 months. 

20 ‘‘(C) A summary of the criteria used in 

21 making the determination on what requests were 

22 funded and what requests were not funded. 

23 ‘‘(D) A general assessment of the future 

24 needs of the program, based on expected changes 


ccoleman on PROD1PC71 with BILLS
136 

•S 2560 RS

1 in threats, expected technologies, and likely need 

2 from potential recipients. 

3 ‘‘(E) An assessment of the effectiveness of 

4 the technologies transferred, based in part on the 

5 evaluations provided by the recipients, with a 

6 recommendation whether the technology should 

7 continue to be offered through the program.’’. 

8 TITLE V—REAUTHORIZATION 

9 AND IMPROVEMENT OF THE 

10 NATIONAL ANTI-DRUG MEDIA 

11 CAMPAIGN 

12 SEC. 501. SHORT TITLE. 

13 This title may be cited as the ‘‘National Youth Anti14 Drug Media Campaign Reauthorization Act of 2006’’. 

15 SEC. 502. PURPOSES OF THE NATIONAL YOUTH ANTI-DRUG 

16 MEDIA CAMPAIGN. 

17 The Drug-Free Media Campaign Act of 1998 (21 

18 U.S.C. 1801 et seq.) is amended— 

19 (1) in section 101, by striking ‘‘Drug-Free Media 

20 Campaign Act of 1998’’ and inserting ‘‘National 

21 Youth Anti-Drug Media Campaign Act’’; and 

22 (2) in section 102— 

23 (A) in subsection (a), by striking ‘‘national 

24 media campaign’’ and all that follows through 

25 the period and inserting the following: ‘‘national 


ccoleman on PROD1PC71 with BILLS
137 

•S 2560 RS

1 youth anti-drug media campaign (referred to in 

2 this subtitle as the ‘national media campaign’) 

3 in accordance with this subtitle for the purposes 

4 of— 

5 ‘‘(1) preventing drug abuse among young people 

6 in the United States; 

7 ‘‘(2) increasing awareness of adults of the impact 

8 of drug abuse on young people; and 

9 ‘‘(3) encouraging parents and other interested 

10 adults to discuss with young people the dangers of il11 legal drug use.’’; and 

12 (B) in subsection (b), by striking ‘‘105’’ and 

13 inserting ‘‘104’’. 

14 SEC. 503. ROLES AND RESPONSIBILITIES OF THE DIREC15 TOR, THE PARTNERSHIP FOR A DRUG-FREE 

16 AMERICA, AND A MEDIA BUYING CON17 TRACTOR. 

18 The Drug-Free Media Campaign Act of 1998 (21 

19 U.S.C. 1801 et seq.) is amended— 

20 (1) by adding at the end the following: 

21 ‘‘(c) DIVISION OF RESPONSIBILITIES AND FUNCTIONS

22 UNDER THE PROGRAM.— 

23 ‘‘(1) IN GENERAL.—The Director, in consultation 

24 with the Partnership for a Drug-Free America, shall 


ccoleman on PROD1PC71 with BILLS
138 

•S 2560 RS

1 determine the overall purposes and strategy of the na2 tional media campaign. 

3 ‘‘(2) RESPONSIBILITIES.— 

4 ‘‘(A) DIRECTOR.—The Director shall be re5 sponsible for implementing a focused national 

6 media campaign to meet the purposes set forth 

7 in section 102(a), and shall approve— 

8 ‘‘(i) the strategy of the national media 

9 campaign; 

10 ‘‘(ii) all advertising and promotional 

11 material used in the national media cam12 paign; and 

13 ‘‘(iii) the plan for the purchase of ad14 vertising time and space for the national 

15 media campaign. 

16 ‘‘(B) THE PARTNERSHIP FOR A DRUG-FREE

17 AMERICA.—The Director shall request that the 

18 Partnership for a Drug-Free America— 

19 ‘‘(i) develop and recommend strategies 

20 to achieve the goals of the national media 

21 campaign, including addressing national 

22 and local drug threats in specific regions or 

23 States, such as methamphetamine and ec24 stasy; 


ccoleman on PROD1PC71 with BILLS
139 

•S 2560 RS

1 ‘‘(ii) create all advertising to be used 

2 in the national media campaign, except ad3 vertisements that are— 

4 ‘‘(I) provided by other nonprofit 

5 entities pursuant to section 103(c); 

6 ‘‘(II) intended to reach a minor7 ity, ethnic, or other special audience 

8 that cannot be obtained at no cost (not 

9 including production costs and talent 

10 reuse payments), provided that any 

11 such advertising material is reviewed 

12 by the Partnership for a Drug-Free 

13 America; or 

14 ‘‘(III) any other advertisements 

15 that the Partnership for a Drug-Free 

16 America determines it is unable to pro17 vide. 

18 ‘‘(C) MEDIA BUYING CONTRACTOR.—The 

19 Director shall enter into a contract with a media 

20 buying contractor to plan and purchase adver21 tising time and space for the national media 

22 campaign. The media buying contractor shall 

23 not provide any service or material, or conduct 

24 any function or activity which can be provided 


ccoleman on PROD1PC71 with BILLS
140 

•S 2560 RS

1 by the Partnership for a Drug-Free America, as 

2 defined in section 403(2)(B)’’; and 

3 (2) in section 103— 

4 (A) in subparagraph (A), by inserting ‘‘, 

5 including the strategic planning for, and ac6 counting of, such purchases’’ after ‘‘space’’; 

7 (B) in subparagraph (C), by striking ‘‘out8 of-pocket’’; and 

9 (C) in subparagraph (F), by striking ‘‘the 

10 Office of National Drug Control Policy’’ and in11 serting ‘‘either the Office of National Drug Con12 trol Policy or the designee of the Office’’. 

13 SEC. 504. RESPONSIBLE USE OF FEDERAL FUNDS FOR THE 

14 NATIONAL YOUTH ANTI-DRUG MEDIA CAM15 PAIGN. 

16 The Drug-Free Media Campaign Act of 1998 (21 

17 U.S.C. 1801 et seq.) is amended— 

18 (1) in section 103, by striking paragraph (2) 

19 and inserting the following: 

20 ‘‘(2) ADVERTISING.— 

21 ‘‘(A) IN GENERAL.—Except as provided in 

22 subparagraph (B), in carrying out this subtitle, 

23 the Director shall ensure that sufficient funds are 

24 allocated to meet the stated goals of the national 

25 media campaign. 


ccoleman on PROD1PC71 with BILLS
141 

•S 2560 RS

1 ‘‘(B) EXCEPTION.—No funds shall be used 

2 for the creative development of advertisements 

3 (not including out-of-pocket production costs and 

4 talent reuse payments) except when— 

5 ‘‘(i) the advertisements are intended to 

6 reach a minority, ethnic, or other special 

7 audience that cannot be obtained at no cost 

8 (not including production costs and talent 

9 reuse payments); or 

10 ‘‘(ii) the Partnership for a Drug-Free 

11 America, determines that it is unable to 

12 provide such advertisements.’’; 

13 (2) in subsection (b), by striking ‘‘105’’ and in14 serting ‘‘104’’; 

15 (3) by striking subsection (c) and inserting the 

16 following: 

17 ‘‘(c) MATCHING REQUIREMENT.— 

18 ‘‘(1) NO COST MATCH.— 

19 ‘‘(A) IN GENERAL.—Except as provided in 

20 subparagraph (B), amounts made available for 

21 the national media campaign under section 106 

22 shall be used to require a no cost match of equiv23 alent value of advertising broadcast time, print 

24 space, or in-kind contributions to the national 

25 media campaign. 


ccoleman on PROD1PC71 with BILLS
142 

•S 2560 RS

1 ‘‘(B) EXCEPTION.—The Director shall en2 sure that all no cost matches of advertising mate3 rial, time, space, or in-kind contributions pro4 vided pursuant to subparagraph (A) directly re5 late to substance abuse prevention and specifi6 cally promote 1 or more of the specific purposes 

7 set forth in section 102(a). This may include 

8 antismoking messages that are produced by non9 profit organizations and are targeted toward mi10 nors. 

11 ‘‘(2) SPONSORSHIP IDENTIFICATION.—Any ad12 vertising material donated to the national media 

13 campaign at no cost shall not be subject to the spon14 sorship identification provisions in section 317 of the 

15 Communications Act of 1934 (47 U.S.C. 317).’’; 

16 (4) by adding at the end the following: 

17 ‘‘(d) RESPONSIBLE USE OF FEDERAL FUNDS.— 

18 ‘‘(1) IN GENERAL.—The Director shall ensure 

19 that— 

20 ‘‘(A) for each fiscal year, not less than 77 

21 percent of the amounts appropriated under this 

22 subtitle shall be used for the activities allowed 

23 under section 103(a)(1)(A); 

24 ‘‘(B) no Federal funds provided under this 

25 subtitle are used to pay any entity for any activVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00142 Fmt 6652 Sfmt 6203 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
143 

•S 2560 RS

1 ity or service that duplicates, in whole or in 

2 part, any material, function, activity, or service 

3 provided by the Partnership for a Drug-Free 

4 America, as defined in section 403(2)(B); and 

5 ‘‘(C) no more than $5,000,000 is used in 

6 each fiscal year to develop advertising material 

7 pursuant to subsection (a)(2)(B)(ii).’’. 

8 SEC. 505. AUTHORIZATION FOR NATIONAL YOUTH ANTI9 DRUG MEDIA CAMPAIGN. 

10 The Drug-Free Media Campaign Act of 1998 (21 

11 U.S.C. 1801 et seq.) is amended by striking sections 104 

12 and 105 and inserting the following: 

13 ‘‘SEC. 104. AUTHORIZATION OF APPROPRIATIONS. 

14 ‘‘There is authorized to be appropriated to the Office 

15 of National Drug Control Policy to carry out this subtitle, 

16 $195,000,000 for each of the fiscal years 2006 through 

17 2010.’’. 

18 TITLE VI—AUTHORIZATIONS 

19 AND EXTENSION OF TERMI20 NATION DATE 

21 SEC. 601. AUTHORIZATION OF APPROPRIATIONS. 

22 Section 714 is amended— 

23 (1) by striking ‘‘title,’’ and inserting ‘‘title except 

24 activities otherwise specified,’’; and 


ccoleman on PROD1PC71 with BILLS
144 

•S 2560 RS

1 (2) by striking ‘‘1999 through 2003’’ and insert2 ing ‘‘2006 through 2010’’. 

3 SEC. 602. EXTENSION OF TERMINATION DATE. 

4 Section 715(a) is amended by striking ‘‘September 30, 

5 2003, this title and the amendments made by this title’’ 

6 and inserting ‘‘September 30, 2010, this title and the 

7 amendments made to this title’’. 

8 TITLE VII—ANTI-DOPING 

9 AGENCY 

10 SEC. 701. DESIGNATION OF UNITED STATES ANTI-DOPING 

11 AGENCY. 

12 (a) DEFINITIONS.—In this title: 

13 (1) UNITED STATES OLYMPIC COMMITTEE.—The 

14 term ‘‘United States Olympic Committee’’ means the 

15 organization established by the ‘‘Ted Stevens Olympic 

16 and Amateur Sports Act’’ (36 U.S.C. 220501 et seq.). 

17 (2) AMATEUR ATHLETIC COMPETITION.—The 

18 term ‘‘amateur athletic competition’’ means a contest, 

19 game, meet, match, tournament, regatta, or other 

20 event in which amateur athletes compete (36 U.S.C. 

21 220501(b)(2)). 

22 (3) AMATEUR ATHLETE.—The term ‘‘amateur 

23 athlete’’ means an athlete who meets the eligibility 

24 standards established by the national governing body 


ccoleman on PROD1PC71 with BILLS
145 

•S 2560 RS

1 or paralympic sports organization for the sport in 

2 which the athlete competes (36 U.S.C. 22501(b)(1)). 

3 (b) IN GENERAL.—The United States Anti-Doping 

4 Agency shall— 

5 (1) serve as the independent anti-doping organi6 zation for the amateur athletic competitions recog7 nized by the United States Olympic Committee; 

8 (2) ensure that athletes participating in amateur 

9 athletic activities recognized by the United States 

10 Olympic Committee are prevented from using per11 formance-enhancing drugs; 

12 (3) implement anti-doping education, research, 

13 testing, and adjudication programs to prevent United 

14 States Amateur Athletes participating in any activity 

15 recognized by the United States Olympic Committee 

16 from using performance-enhancing drugs; and 

17 (4) serve as the United States representative re18 sponsible for coordination with other anti-doping or19 ganizations coordinating amateur athletic competi20 tions recognized by the United States Olympic Com21 mittee to ensure the integrity of athletic competition, 

22 the health of the athletes and the prevention of use of 

23 performance-enhancing drugs by United States ama24 teur athletes. 


ccoleman on PROD1PC71 with BILLS
146 

•S 2560 RS

1 SEC. 702. RECORDS, AUDIT, AND REPORT. 

2 (a) RECORDS.—The United States Anti-Doping Agen3 cy shall keep correct and complete records of account. 

4 (b) REPORT.—The United States Anti-Doping Agency 

5 shall submit an annual report to Congress which shall in6 clude— 

7 (1) an audit conducted and submitted in accord8 ance with section 10101 of title 36, United States 

9 Code; and 

10 (2) a description of the activities of the agency. 

11 SEC. 703. AUTHORIZATION OF APPROPRIATIONS. 

12 There are authorized to be appropriated to the United 

13 States Anti-Doping Agency— 

14 (1) for fiscal year 2007, $9,700,000; 

15 (2) for fiscal year 2008, $10,300,000; 

16 (3) for fiscal year 2009, $10,600,000; 

17 (4) for fiscal year 2010, $11,000,000; and 

18 (5) for fiscal year 2011, $11,500,000. 

19 TITLE VIII—DRUG-FREE 

20 COMMUNITIES 

21 SEC. 801. REAUTHORIZATION. 

22 Section 1024(a) of the Drug-Free Communities Act of 

23 1997 (21 U.S.C. 1524(a)) is amended— 

24 (1) in paragraph (9), by striking ‘‘and’’ after the 

25 semicolon; 


ccoleman on PROD1PC71 with BILLS
147 

•S 2560 RS

1 (2) in paragraph (10), by striking the period 

2 and inserting a semicolon; and 

3 (3) by adding at the end the following: 

4 ‘‘(11) $109,000,000 for fiscal year 2008; 

5 ‘‘(12) $119,000,000 for fiscal year 2009; 

6 ‘‘(13) $129,000,000 for fiscal year 2010; 

7 ‘‘(14) $139,000,000 for fiscal year 2011; and 

8 ‘‘(15) $149,000,000 for fiscal year 2012.’’. 

9 SEC. 802. SUSPENSION OF GRANTS. 

10 (a) IN GENERAL.—Section 1032(b) of the Drug-Free 

11 Communities Act of 1997 (21 U.S.C. 1532(b)) is amended 

12 by adding at the end the following: 

13 ‘‘(4) PROCESS FOR SUSPENSION.—A grantee 

14 shall not be suspended or terminated under para15 graph (1)(A)(ii), (2)(A)(iii), or (3)(E) unless that 

16 grantee is afforded a fair, timely, and independent 

17 appeal prior to such suspension or termination.’’. 

18 (b) REPORT TO CONGRESS.—Not later than 60 days 

19 after the date of enactment of this Act, the Director of the 

20 Office of National Drug Control Policy shall submit to Con21 gress a report detailing the appeals process required by sec22 tion 1032 (b)(4) of the Drug-Free Communities Act of 1997, 

23 as added by subsection (a). 


ccoleman on PROD1PC71 with BILLS
148 

•S 2560 RS

1 SEC. 803. GRANT AWARD INCREASE. 

2 Subsections (b)(1)(A)(iv), (b)(2)(C)(i), and (b)(3)(F) 

3 of section 1032 of the Drug-Free Communities Act of 1997 

4 (21 U.S.C. 1532) are amended by striking ‘‘$100,000’’ and 

5 inserting ‘‘$125,000’’. 

6 SEC. 804. PROHIBITION ON ADDITIONAL ELIGIBILITY CRI7 TERIA. 

8 Section 1032(a) of the Drug-Free Communities Act of 

9 1997 (21 U.S.C. 1532(a)) is amended by adding at the end 

10 the following: 

11 ‘‘(7) ADDITIONAL CRITERIA.—The Director shall 

12 not impose any eligibility criteria on new applicants 

13 or renewal grantees not provided in this chapter.’’. 

14 SEC. 805. SUPPLEMENTAL GRANTS FOR COALITIONS. 

15 The Drug-Free Communities Act of 1997 (21 U.S.C. 

16 1521 et seq.) is amended by inserting after section 1035 

17 the following: 

18 ‘‘SEC. 1036. SUPPLEMENTAL GRANTS FOR COALITIONS 

19 WITH A MAJOR LOCAL DRUG CRISIS. 

20 ‘‘(a) AUTHORITY TO MAKE GRANTS.—As part of the 

21 program established under section 1031, the Director may 

22 award an initial grant under this subsection, and renewal 

23 grants under subsection (f), to any coalition awarded a 

24 grant under section 1032 that meets the criteria specified 

25 in subsection (d) in order to fund a coalition dealing with 

26 a major local drug crisis. 


ccoleman on PROD1PC71 with BILLS
149 

•S 2560 RS

1 ‘‘(b) TREATMENT WITH OTHER GRANTS.— 

2 ‘‘(1) SUPPLEMENT.—A grant awarded to a coali3 tion under this section is in addition to any grant 

4 awarded to the coalition under section 1032. 

5 ‘‘(2) REQUIREMENT FOR BASIC GRANT.—A coali6 tion may not be awarded a grant under this section 

7 for a fiscal year unless the coalition was awarded a 

8 grant or renewal grant under section 1032(b) for that 

9 fiscal year. 

10 ‘‘(c) APPLICATION.—A coalition seeking a grant under 

11 this section shall submit to the Administrator an applica12 tion for the grant in such form and manner as the Adminis13 trator may require. 

14 ‘‘(d) CRITERIA.—A coalition meets the criteria speci15 fied in this subsection if the coalition— 

16 ‘‘(1) has achieved by or through it’s own efforts 

17 measurable results in the prevention and reduction of 

18 substance use among youth generally; 

19 ‘‘(2) has documented a highly, statistically sig20 nificant increase in a specific drug, from a baseline 

21 determined by locally collected data, that can be de22 fined as a local drug crisis; and 

23 ‘‘(3) submits to the Administrator a detailed 

24 plan for addressing the specific local drug crisis. 


ccoleman on PROD1PC71 with BILLS
150 

•S 2560 RS

1 ‘‘(e) USE OF GRANT FUNDS.—A coalition awarded a 

2 grant under this section shall use the grant amount for im3 plementing comprehensive, community-wide strategies that 

4 address their local drug crises in accordance with the de5 tailed plan submitted to the Administrator under subsection 

6 (d)(3). 

7 ‘‘(f) RENEWAL GRANTS.—The Administrator may 

8 make a renewal grant to any coalition awarded a grant 

9 under subsection (a), or a previous renewal grant under 

10 this subsection, if the coalition at the time of the application 

11 for such renewal grant— 

12 ‘‘(1) continues to meet the criteria specified in 

13 subsection (d); and 

14 ‘‘(2) has made demonstrable progress in address15 ing the specific local drug crisis. 

16 ‘‘(g) GRANT AMOUNTS.— 

17 ‘‘(1) IN GENERAL.—Subject to paragraphs (2) 

18 and (3) the total amount of grants awarded to a coa19 lition under this section for a fiscal year may not ex20 ceed the amount of non-Federal funds raised by the 

21 coalition, including in kind contributions, for that 

22 fiscal year. 

23 ‘‘(2) INITIAL GRANTS.—The amount of the ini24 tial grant awarded to a coalition under subsection (a) 

25 may not exceed $50,000. 


ccoleman on PROD1PC71 with BILLS
151 

•S 2560 RS

1 ‘‘(3) RENEWAL GRANTS.—The total amount of 

2 renewal grants awarded to a coalition under sub3 section (f) for any fiscal year may not exceed $50,000. 

4 ‘‘(h) FISCAL YEAR LIMITATION ON THE AMOUNT

5 AVAILABLE FOR GRANTS.—The total amount available for 

6 grants under this section, including renewal grants under 

7 subsection (f), in any fiscal year may not exceed the amount 

8 equal to 5 percent of the actual amount appropriated for 

9 that fiscal year.’’. 

10 SEC. 806. NATIONAL COMMUNITY ANTI-DRUG COALITION 

11 INSTITUTE. 

12 Section 4 of Public Law 107–82 (21 U.S.C. 1521 note), 

13 reauthorizing the Drug-Free Communities Support Pro14 gram, is amended— 

15 (1) by amending subsection (a) to read as fol16 lows: 

17 ‘‘(a) IN GENERAL.—The Director of the Office of Na18 tional Drug Control Policy shall, using amounts authorized 

19 to be appropriated by subsection (d), make a directed grant 

20 to Community Anti-Drug Coalitions of America to provide 

21 for the continuation of the National Community Antidrug 

22 Coalition Institute.’’; 

23 (2) by striking subsection (b) and redesignating 

24 subsections (c) and (d) as (b) and (c), respectively; 

25 and 


ccoleman on PROD1PC71 with BILLS
152 

•S 2560 RS

1 (3) in subsection (c), as redesignated by para2 graph (2), by adding at the end the following: 

3 ‘‘(4) For each of the fiscal years 2008 through 

4 2012, $2,000,000.’’. 

5 SEC. 807. CONTRACTING REQUIREMENT. 

6 Section 1031(d) of the Drug-Free Communities Act of 

7 1997 (21 U.S.C. 1531(d)) is amended by adding at the end 

8 the following: ‘‘The Director shall delegate all authority for 

9 grant eligibility determinations, review, selection, manage10 ment, and appeals to another qualified national drug con11 trol agency.’’. 

12 TITLE IX—NATIONAL GUARD 

13 COUNTERDRUG SCHOOLS 

14 SEC. 901. NATIONAL GUARD COUNTERDRUG SCHOOLS. 

15 (a) AUTHORITY TO OPERATE.—Under such regula16 tions as the Secretary of Defense may prescribe, the Chief 

17 of the National Guard Bureau may establish and operate, 

18 or provide financial assistance to the States to establish and 

19 operate, not more than five schools (to be known generally 

20 as ‘‘National Guard counterdrug schools’’). 

21 (b) PURPOSE.—The purpose of the National Guard 

22 counterdrug schools shall be the provision by the National 

23 Guard of training in drug interdiction and counterdrug ac24 tivities and drug demand reduction activities to personnel 

25 of the following: 


ccoleman on PROD1PC71 with BILLS
153 

•S 2560 RS

1 (1) Federal agencies. 

2 (2) State and local law enforcement agencies. 

3 (3) Community-based organizations engaged in 

4 such activities. 

5 (4) Other non-Federal governmental and private 

6 entities and organizations engaged in such activities. 

7 (c) COUNTERDRUG SCHOOLS SPECIFIED.—The Na8 tional Guard counterdrug schools operated under the au9 thority in subsection (a) are as follows: 

10 (1) The National Interagency Civil-Military In11 stitute (NICI), San Luis Obispo, California. 

12 (2) The Multi-Jurisdictional Counterdrug Task 

13 Force Training (MCTFT), St. Petersburg, Florida. 

14 (3) The Midwest Counterdrug Training Center 

15 (MCTC), Johnston, Iowa. 

16 (4) The Regional Counterdrug Training Acad17 emy (RCTA), Meridian, Mississippi. 

18 (5) The Northeast Regional Counterdrug Train19 ing Center (NCTC), Fort Indiantown Gap, Pennsyl20 vania. 

21 (d) USE OF NATIONAL GUARD PERSONNEL.— 

22 (1) IN GENERAL.—To the extent provided for in 

23 the State drug interdiction and counterdrug activities 

24 plan of a State in which a National Guard 

25 counterdrug school is located, personnel of the NaVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00153 Fmt 6652 Sfmt 6203 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
154 

•S 2560 RS

1 tional Guard of that State who are ordered to perform 

2 full-time National Guard duty authorized under sec3 tion 112(b) of that title 32, United States Code, may 

4 provide training referred to in subsection (b) at that 

5 school. 

6 (2) DEFINITION.—In this subsection, the term 

7 ‘‘State drug interdiction and counterdrug activities 

8 plan’’, in the case of a State, means the current plan 

9 submitted by the Governor of the State to the Sec10 retary of Defense under section 112 of title 32, United 

11 States Code. 

12 (e) TREATMENT UNDER AUTHORITY TO PROVIDE

13 COUNTERDRUG SUPPORT.—The provisions of section 1004 

14 of the National Defense Authorization Act for Fiscal Year 

15 1991 (Public Law 101–510; 10 U.S.C. 374 note) shall apply 

16 to any activities of a National Guard counterdrug school 

17 under this section that are for an agency referred to in sub18 section (a) of such section 1004 and for a purpose set forth 

19 in subsection (b) of such section 1004. 

20 (f) ANNUAL REPORTS ON ACTIVITIES.— 

21 (1) IN GENERAL.—Not later than February 1 

22 each year, the Secretary of Defense shall submit to 

23 Congress a report on the activities of the National 

24 Guard counterdrug schools during the preceding year. 


ccoleman on PROD1PC71 with BILLS
155 

•S 2560 RS

1 (2) CONTENTS.—Each report under paragraph 

2 (1) shall set forth the following: 

3 (A) FUNDING.—The amount made available 

4 for each National Guard counterdrug school dur5 ing the fiscal year ending in the year preceding 

6 the year in which such report is submitted. 

7 (B) ACTIVITIES.—A description of the ac8 tivities of each National Guard counterdrug 

9 school during the year preceding the year in 

10 which such report is submitted. 

11 (g) AUTHORIZATION OF APPROPRIATIONS.— 

12 (1) IN GENERAL.—There is hereby authorized to 

13 be appropriated for the Department of Defense for the 

14 National Guard for each of fiscal years 2006 through 

15 2010, $30,000,000 for purposes of the National Guard 

16 counterdrug schools in such fiscal year. 

17 (2) CONSTRUCTION.—The amount authorized to 

18 be appropriated by paragraph (1) for a fiscal year is 

19 in addition to any other amount authorized to be ap20 propriated for the Department of Defense for the Na21 tional Guard for such fiscal year. 


ccoleman on PROD1PC71 with BILLS
156 

•S 2560 RS

1 TITLE X—NATIONAL METH2 AMPHETAMINE INFORMATION 

3 CLEARINGHOUSE ACT OF 2006 

4 SEC. 1001. SHORT TITLE. 

5 This title may be cited as the ‘‘National Methamphet6 amine Information Clearinghouse Act of 2006’’. 

7 SEC. 1002. DEFINITIONS. 

8 In this title— 

9 (1) the term ‘‘Council’’ means the National 

10 Methamphetamine Advisory Council established under 

11 section 1003(b)(1); 

12 (2) the term ‘‘drug endangered children’’ means 

13 children whose physical, mental, or emotional health 

14 are at risk because of the production, use, or other ef15 fects of methamphetamine production or use by an16 other person; 

17 (3) the term ‘‘National Methamphetamine Infor18 mation Clearinghouse’’ or ‘‘NMIC’’ means the infor19 mation clearinghouse established under section 

20 1003(a); and 

21 (4) the term ‘‘qualified entity’’ means a State or 

22 local government, school board, or public health, law 

23 enforcement, nonprofit, community antidrug coali24 tion, or other nongovernmental organization pro25 viding services related to methamphetamines. 


ccoleman on PROD1PC71 with BILLS
157 

•S 2560 RS

1 SEC. 1003. ESTABLISHMENT OF CLEARINGHOUSE AND ADVI2 SORY COUNCIL. 

3 (a) CLEARINGHOUSE.—There is established, under the 

4 supervision of the Attorney General of the United States, 

5 an information clearinghouse to be known as the National 

6 Methamphetamine Information Clearinghouse. 

7 (b) ADVISORY COUNCIL.— 

8 (1) IN GENERAL.—There is established an advi9 sory council to be known as the National Meth10 amphetamine Advisory Council. 

11 (2) MEMBERSHIP.—The Council shall consist of 

12 10 members appointed by the Attorney General— 

13 (A) not fewer than 3 of whom shall be rep14 resentatives of law enforcement agencies; 

15 (B) not fewer than 4 of whom shall be rep16 resentatives of nongovernmental and nonprofit 

17 organizations providing services or training and 

18 implementing programs or strategies related to 

19 methamphetamines; and 

20 (C) 1 of whom shall be a representative of 

21 the Department of Health and Human Services. 

22 (3) PERIOD OF APPOINTMENT; VACANCIES.— 

23 Members shall be appointed for 3 years. Any vacancy 

24 in the Council shall not affect its powers, but shall be 

25 filled in the same manner as the original appoint26 ment. 


ccoleman on PROD1PC71 with BILLS
158 

•S 2560 RS

1 (4) PERSONNEL MATTERS.— 

2 (A) TRAVEL EXPENSES.—The members of 

3 the Council shall be allowed travel expenses, in4 cluding per diem in lieu of subsistence, at rates 

5 authorized for employees of agencies under sub6 chapter I of chapter 57 of title 5, United States 

7 Code, while away from their homes or regular 

8 places of business in the performance of services 

9 for the Council. 

10 (B) NO COMPENSATION.—The members of 

11 the Council shall not receive compensation for 

12 the performance of the duties of a member of the 

13 Council. 

14 SEC. 1004. NMIC REQUIREMENTS AND REVIEW. 

15 (a) IN GENERAL.—The NMIC shall promote sharing 

16 information regarding successful law enforcement, treat17 ment, environmental, prevention, social services, and other 

18 programs related to the production, use, or effects of meth19 amphetamine and grants available for such programs. 

20 (b) COMPONENTS.—The NMIC shall include— 

21 (1) a toll-free number; and 

22 (2) a website that provides a searchable database, 

23 which— 

24 (A) provides information on the short-term 

25 and long-term effects of methamphetamine use; 


ccoleman on PROD1PC71 with BILLS
159 

•S 2560 RS

1 (B) provides information regarding meth2 amphetamine treatment and prevention pro3 grams and strategies and programs for drug en4 dangered children, including descriptions of suc5 cessful programs and strategies and contact in6 formation for such programs and strategies; 

7 (C) provides information regarding grants 

8 for methamphetamine-related programs, includ9 ing contact information and links to websites; 

10 (D) allows a qualified entity to submit 

11 items to be posted on the website regarding suc12 cessful public or private programs or other useful 

13 information related to the production, use, or ef14 fects of methamphetamine; 

15 (E) includes a restricted section that may 

16 only be accessed by a law enforcement organiza17 tion that contains successful strategies, training 

18 techniques, and other information that the Coun19 cil determines helpful to law enforcement agency 

20 efforts to identify or combat the production, use 

21 or effects of methamphetamine; 

22 (F) allows public access to all information 

23 not in a restricted section; and 

24 (G) contains any additional information 

25 the Council determines may be useful in identiVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00159 Fmt 6652 Sfmt 6203 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
160 

•S 2560 RS

1 fying or combating the production, use, or effects 

2 of methamphetamine. 

3 (c) REVIEW OF POSTED INFORMATION.— 

4 (1) IN GENERAL.—Not later than 30 days after 

5 the date of submission of an item by a qualified enti6 ty, the Council shall review an item submitted for 

7 posting on the website described in subsection (b)(2)— 

8 (A) to evaluate and determine whether the 

9 item, as submitted or as modified, meets the re10 quirements for posting; and 

11 (B) in consultation with the Attorney Gen12 eral, to determine whether the item should be 

13 posted in a restricted section of the website. 

14 (2) DETERMINATION.—Not later than 45 days 

15 after the date of submission of an item, the Council 

16 shall— 

17 (A) post the item on the website described in 

18 subsection (b)(2); or 

19 (B) notify the qualified entity that sub20 mitted the item regarding the reason such item 

21 shall not be posted and modifications, if any, 

22 that the qualified entity may make to allow the 

23 item to be posted. 

24 SEC. 1005. AUTHORIZATION OF APPROPRIATIONS. 

25 There are authorized to be appropriated— 


ccoleman on PROD1PC71 with BILLS
161 

•S 2560 RS

1 (1) for fiscal year 2006— 

2 (A) $2,000,000 to establish the NMIC and 

3 Council; and 

4 (B) such sums as are necessary for the oper5 ation of the NMIC and Council; and 

6 (2) for each of fiscal years 2007 through 2010, 

7 such sums as are necessary for the operation of the 

8 NMIC and Council. 

9 TITLE XI—MISCELLANEOUS 

10 PROVISIONS 

11 SEC. 1101. REPEALS. 

12 (a) ACT.—Sections 709, 710, and 711 are repealed. 

13 (b) FORFEITURE ASSETS.—Section 6073 of the Assets 

14 Forfeiture Amendments Act of 1988 (21 U.S.C. 1509) is re15 pealed. 

16 SEC. 1102. CONTROLLED SUBSTANCES ACT AMENDMENTS. 

17 Section 303(g)(2)(B)(iii) of the Controlled Substances 

18 Act (21 U.S.C. 823(g)(2)(B)(iii)) is amended by striking 

19 ‘‘except that the Secretary’’ and inserting the following: 

20 ‘‘unless, not sooner than 1 year after the date on which the 

21 practitioner submitted the initial notification, the practi22 tioner submits a second notification to the Secretary of the 

23 need and intent of the practitioner to treat more than such 

24 applicable number of patients. A second notification under 


ccoleman on PROD1PC71 with BILLS
162 

•S 2560 RS

1 this clause shall contain the certifications required by 

2 clauses (i) and (ii) of this subparagraph. The Secretary’’. 

3 SEC. 1103. REPORT ON INTELLIGENCE SHARING. 

4 Not later than 180 days after the date of enactment 

5 of this Act, the Director shall submit to Congress a report— 

6 (1) evaluating existing and planned intelligence 

7 systems used by Federal, State, and local law enforce8 ment agencies responsible for drug trafficking and 

9 drug production enforcement; and 

10 (2) addressing— 

11 (A) the current intelligence systems used by 

12 Federal, State, and local law enforcement agen13 cies; 

14 (B) the compatibility of such systems in en15 suring access and availability of intelligence to 

16 Federal, State, and local law enforcement; 

17 (C) the extent to which Federal, State, and 

18 local law enforcement are sharing intelligence in19 formation to assess current threats and design 

20 appropriate enforcement strategies; and 

21 (D) the measures needed to ensure and to 

22 promote effective information sharing among in23 telligence systems operated by Federal, State, 

24 and local law enforcement agencies responsible 


ccoleman on PROD1PC71 with BILLS
163 

•S 2560 RS

1 for drug trafficking and drug production enforce2 ment. 

3 SEC. 1104. REQUIREMENT FOR SOUTH AMERICAN HEROIN 

4 STRATEGY. 

5 (a) IN GENERAL.—Not later than 90 days after the 

6 date of enactment of this Act, the Director shall submit to 

7 Congress a comprehensive strategy that addresses the in8 creased threat from South American heroin, and in par9 ticular Colombian heroin, and the emerging threat from 

10 opium poppy grown in Peru and often intended for transit 

11 to Columbia for processing into heroin. 

12 (b) CONTENTS.—The strategy submitted under sub13 section (a) shall include— 

14 (1) opium eradication efforts to eliminate the 

15 problem at the source to prevent heroin from entering 

16 the stream of commerce; 

17 (2) interdiction and precursor chemical controls; 

18 (3) demand reduction and treatment; 

19 (4) alternative development programs, including 

20 direct assistance to regional governments to demobi21 lize and provide alternative livelihoods to former 

22 members of insurgent or other groups engaged in her23 oin, cocoa, or other illicit drug production or traf24 ficking; 


ccoleman on PROD1PC71 with BILLS
164 

•S 2560 RS

1 (5) efforts to inform and involve local citizens in 

2 the programs described in paragraphs (1) through 

3 (4), such as through leaflets advertising rewards for 

4 information; 

5 (6) provisions that ensure the maintenance at 

6 current levels of efforts to eradicate coca in Colombia; 

7 and 

8 (7) an assessment of the specific level of funding 

9 and resources necessary to simultaneously address the 

10 threat from South American heroin and the threat 

11 from Colombian and Peruvian coca. 

12 (c) TREATMENT OF CLASSIFIED OR LAW ENFORCE13 MENT SENSITIVE INFORMATION.—Any content of the strat14 egy submitted under subsection (a) that involves informa15 tion classified under criteria established by an Executive 

16 order, or whose public disclosure, as determined by the Di17 rector or the head of any relevant Federal agency, would 

18 be detrimental to the law enforcement of national security 

19 activities of any Federal, foreign, or international agency, 

20 shall be presented to Congress separately from the rest of 

21 the strategy. 

22 SEC. 1105. MODEL ACTS. 

23 (a) IN GENERAL.—The Director shall enter into an 

24 agreement with a nonprofit corporation that works with 

25 States on laws and policies to address alcohol and other 


ccoleman on PROD1PC71 with BILLS
165 

•S 2560 RS

1 drug issues, under which the corporation shall revise the 

2 model State drug laws developed by the President’s Com3 mission on Model State Drug Laws and draft supple4 mentary model acts to meet changes in States’ substance 

5 abuse issues. 

6 (b) AUTHORIZATION OF APPROPRIATIONS.—There are 

7 authorized to be appropriated $1,500,000 to carry out this 

8 section. 

9 SEC. 1106. STUDY ON IATROGENIC ADDICTION ASSOCIATED 

10 WITH PRESCRIPTION OPIOID ANALGESIC 

11 DRUGS. 

12 (a) IN GENERAL.— 

13 (1) STUDY.—The Director of the Office of Na14 tional Drug Control Policy shall request the Institute 

15 of Medicine of the National Academy of Sciences to 

16 enter into an agreement under which the Institute 

17 agrees to study certain aspects of iatrogenic addiction 

18 to prescription opioid analgesics included in schedules 

19 II and III of the Controlled Substances Act (21 

20 U.S.C. 812). 

21 (2) IATROGENIC ADDICTION.—In this section, the 

22 term ‘‘iatrogenic addiction’’ means an addiction de23 veloped from the use of an opioid analgesic by an in24 dividual with no previous history of any addiction, 

25 who has lawfully obtained and used the drug for a leVerDate Aug 31 2005 08:22 May 26, 2006 Jkt 049196 PO 00000 Frm 00165 Fmt 6652 Sfmt 6203 E:\BILLS\S2560.RS S2560

ccoleman on PROD1PC71 with BILLS
166 

•S 2560 RS

1 gitimate medical purpose by administration from, or 

2 pursuant to the prescription or order of, an indi3 vidual practitioner acting in the usual course of pro4 fessional practice. 

5 (b) REQUIREMENTS.—The study conducted pursuant 

6 to this section shall assess the current scientific literature 

7 to determine, if possible— 

8 (1) the rate of iatrogenic addiction associated 

9 with the appropriate use of prescription drugs de10 scribed in subsection (a); 

11 (2) the impact of iatrogenic addiction associated 

12 with the appropriate use of prescription drugs de13 scribed in subsection (a) on the individual, the pre14 scriber, other patients, and society in general; 

15 (3) the comparative abuse liability of prescrip16 tion drugs described in subsection (a) when used 

17 properly by the ultimate user for a legitimate medical 

18 purpose; and 

19 (4)(A) what types of prospective or retrospective 

20 studies should be undertaken to determine the rate of 

21 iatrogenic addiction associated with the appropriate 

22 use of the prescription drugs described in subsection 

23 (a); and 

24 (B) a feasible timeline for conducting and re25 porting such studies, should the current state of the 


ccoleman on PROD1PC71 with BILLS
167 

•S 2560 RS

1 scientific literature be insufficient to determine the 

2 rate, impact, and comparative abuse liability of pre3 scription drugs described in subsection (a). 

4 (c) REPORT.—Not later than 1 year after the date of 

5 enactment of this Act, the Director of the Office of National 

6 Drug Control Policy shall ensure that the agreement under 

7 subsection (a) provides for the submission of a report to 

8 the Congress on the status of the study conducted pursuant 

9 to this section. 

10 SEC. 1107. REQUIREMENT FOR STRATEGY TO STOP INTER11 NET ADVERTISING OF PRESCRIPTION MEDI12 CINES WITHOUT A PRESCRIPTION. 

13 Not later than 120 days after the date of the enactment 

14 of this Act, the Director of the Office of National Drug Con15 trol Policy shall submit to Congress a strategy to stop ad16 vertisements that provide information about obtaining over 

17 the Internet drugs (as defined in section 702(3) of the Office 

18 of National Drug Control Policy Reauthorization Act of 

19 1998) for which a prescription is required without the use 

20 of such a lawful prescription. 

21 SEC. 1108. REQUIREMENT FOR STUDY ON DIVERSION AND 

22 INAPPROPRIATE USES OF PRESCRIPTION 

23 DRUGS. 

24 Not later than 90 days after the date of enactment of 

25 this Act, the Director of the Office of National Drug Control 


ccoleman on PROD1PC71 with BILLS
168 

•S 2560 RS

1 Policy, in consultation with the Secretary of Health and 

2 Human Services, shall submit to Congress a report that in3 cludes a plan to conduct a study on the illegal diversion 

4 and inappropriate uses of prescription drugs, including the 

5 following: 

6 (1) Methods to utilize both public use surveys 

7 that are in existence as of the date of enactment of 

8 this Act and other surveys to provide appropriate 

9 baseline data on the natural history of diversion and 

10 abuse of prescription drugs that are included in 

11 schedules under the Controlled Substances Act to 

12 evaluate the extent and nature of potential problems 

13 with such use to guide corrective actions which may 

14 reduce such problems without unintentionally hin15 dering access to these drugs for legitimate medical 

16 purposes. Specifically, other surveys to be considered 

17 are those that address the abuse of these substances on 

18 a regional or national basis, and those that address 

19 the diversion of these substances on a regional or na20 tional basis. 

21 (2) A scientifically based analysis of the relative 

22 contribution of both innate and acquired genetic fac23 tors, environmental factors, psychological factors and 

24 drug characteristics that contribute to addiction to 

25 prescription drugs. 


ccoleman on PROD1PC71 with BILLS

ccoleman on PROD1PC71 with BILLS
Calendar No. 452 

109TH CONGRESS 

2D SESSION S. 2560 

A BILL 

To reauthorize the Office of National Drug Control 

Policy. 

MAY 25, 2006 

Reported with an amendment 


ccoleman on PROD1PC71 with BILLS